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Summary 
Deregulation of factors involved in the epigenetic regulation of gene expression is a 
hallmark of cancer. In this dissertation, DNA methylation and microRNA (miRNA) 
expression, as two components implicated in epigenetic regulation, were studied in breast 
cancer. 
In the first study, the establishment of a DNA methylation signature for breast cancer was 
aimed at, based on the early occurrence and stability of abnormal DNA methylation 
patterns in tumors. Specialized oligonucleotide microarrays were developed and optimized 
to screen DNA methylation patterns of the candidate loci associated with breast cancer. The 
assay was applied to analyze DNA methylation patterns of breast cancer and control 
samples. The profiling data was subjected to multiple bioinformatic analyses in order to 
identify a DNA methylation signature with appropriately high potential for diagnosis. 
Methylation patterns of CpG sites associated with two genes, SFRP2 and GHSR, were 
identified as promising markers. 
Up-regulation and activation of estrogen receptor α (ERα) signaling is a common feature of 
almost 70% of breast cancers. However, our understanding of the molecular mechanisms 
underlying deregulation of this signaling pathway is scarce. In the second study, based on 
miRNA profiling data of human mammary cell lines, miR-375 was identified as an 
overexpressed miRNA in ERα-positive cells. Analysis of the miRNA locus revealed that 
miR-375 overexpression is mainly caused by the loss of epigenetic marks, such as 
H3K9me2 and local DNA hypomethylation, which, in turn, triggers the dissociation of the 
transcriptional repressor CCCTC-binding factor (CTCF) from the promoter and enables 
interactions of ERα with regulatory regions of miR-375. Inhibition of miR-375 in ERα-
positive MCF7 cells resulted in reduced ERα activation and cell proliferation. In addition, 
RASD1, an estrogen inducible gene, was identified as a miR-375 target mediating miR-375 
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effect on ERα. These data indicate the existence of a positive feedback regulation between 
ERα and miR-375. 
The methylation signature identified shows a promising potential to be applicable for 
diagnosis/risk assessment of breast cancer. Furthermore, our findings from miRNA study 
provide significant insight into the deregulation of ERα pathway, which may open new 
therapeutic strategies for breast cancer. 
Zusammenfassung  
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Zusammenfassung 
Krebserkrankungen weisen meist eine veränderte epigenetische Regulation der 
Genexpression auf. In dieser Dissertation werden sowohl DNA-Methylierung als auch die 
Expression von microRNA (miRNA) als zwei Komponenten der epigenetischen Regulation 
in Brustkrebs untersucht. 
Veränderte DNA-Methylierungsmuster tauchen in Tumoren gewöhnlich früh auf und haben 
eine hohe Stabilität. Daher hatte die erste Studie das Ziel, eine für Brustkrebs spezifische 
Signatur der DNA-Methylierung zu identifizieren. Hierzu wurden spezifische 
Oligonukleotidarrays entwickelt und optimiert, um DNA-Methylierungsmuster 
ausgewählter Kandidaten-Loci zu untersuchen, die mit Brustkrebs assoziert werden. Um 
derartige Muster mit einem ausreichend hohen Potential für eine Diagnose auszuwählen, 
wurden Tumorproben mit gesunden Kontrollen verglichen und einer Vielzahl von 
bioinformatischen Analysen unterzogen. Hierbei wurden Methylierungsprofile in zwei 
CpG-Bereichen identifiziert, die mit den Genen SFRP2 und GHSR assoziiert sind und ein 
Potenzial für eine Diagnosestellung besitzen. 
Eine erhöhte Expression und Aktivierung der Estrogenrezeptor α (ERα)-Signalkaskade ist 
ein gemeinsames Merkmal von fast 70% aller Tumore der Brust. Die zugrunde liegenden 
molekularen Mechanismen dieser Signalkaskade sind bislang wenig verstanden. Daher 
wurden in einer zweiten Studie humane Mammakarzinomzelllinien mittels eines miRNA-
Profilings untersucht. Hierbei wurde eine deutliche Überexpression von miR-375 in Erα-
positiven Zellen entdeckt. Eine Analyse des miRNA-Lokus zeigte, dass die Überexpression 
hauptsächlich durch den Verlust von epigenetischen Markierungen, wie beispielsweise 
H3K9me2, sowie eine lokale DNA-Hypomethylierung verursacht werden. Die 
Hypomethylierung löst eine Dissoziation des Transkriptionsrepressors CTCF vom 
Zusammenfassung  
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Promotor aus und ermöglicht Interaktionen von Erα mit den regulatorischen Reg ionen von 
miR-375. Eine Inhibierung von miR-375 in ERα-positiven MCF7 Zellen resultierte in einer 
reduzierten ERα-Aktivierung und Zellproliferation. Zusätzlich wurde festgestellt, dass das 
estrogeninduzierbare Gen RASD1 als ein Ziel-Gen von miR-375 den Effekt auf Erα 
vermittelt. Diese Daten dokumentieren eine vorhandene positive Rückkopplung zwischen 
ERα und miR-375.  
Das in dieser Arbeit identifizierte spezifische Methylierungs-Muster zeigt ein 
vielversprechendes Potenzial für die Anwendung im Rahmen von Brustkrebs-Diagnose und 
–Prognose. Die Ergebnisse der miRNA-Studie ermöglichen neue Einblicke in die 
Regulation der ERα-Signalkaskade und könnten neue Möglichkeiten in der Entwicklung 
theapeutischer Strategien zur Brustkrebsbehandlung eröffnen. 
Introduction  
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1 Introduction 
1.1 Cancer 
Cancer is a highly complex and heterogeneous disease. Currently, it is the second leading 
cause of death after cardiovascular diseases (1). Different types of cancers are named based 
on the part of the body from which they originate. Although, different cancer types are 
clinically distinct, they all develop from uncontrolled cell growth resulting in the formation 
of an unstructured tissue mass, called tumor. Tumors are classified into two categories 
based on their degree of aggressive growth. Those that grow locally without invading 
adjacent tissues are classified as benign. Others that invade nearby tissues are malignant 
tumors. Malignant tumors are able to infiltrate into the blood stream, migrate to the areas 
distant from their place of origin and seed tumor colonies in other tissues. This behavior is 
known as metastatic potential and describes the aggressiveness of the corresponding cancer. 
The metastatic cancers are responsible for 90% of cancer related deaths (2).  
The comparatively disorganized tissue architecture of tumors points towards the fact that 
cancer is a disease of malfunctioning cells. Tumor formation can be originated from 
transformation of a single cell within the organism. The transformation process can be 
facilitated by cancerous agents (carcinogens; like toxins, free radicals, UV exposure and 
some viruses such as human papilloma virus (HPV)) that cause functional mutations in 
DNA (2). Mutations can also happen spontaneously at an estimated rate of about 10-6 
mutations per gene per cell division. However, human body has been endowed with various 
safeguard mechanisms to protect itself from serious mutations and cellular defects. For 
example, the DNA repair system repairs mutations that might happen during replication. 
Likewise, the cell division process is highly controlled and can be arrested when necessary. 
Furthermore, in case of a fundamental damage to DNA -which could not be repaired- or a 
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pivotal cellular malfunction, the cell undergoes the programmed cell death (apoptosis) 
process (3).  
Many cancers arise when the above mentioned self-protecting mechanisms of the cell do 
not work properly, mostly due to dysregulation of key genes involved in such processes. 
Based on their function, these genes are categorized into two classes: oncogenes and tumor 
suppressor genes. Oncogenes are usually growth-promoting genes that can contribute to the 
development of cancer by helping cells to escape several growth controlling mechanisms. 
Unlike oncogenes, tumor suppressor genes are necessary for cells to maintain important 
control barriers, and balance between cell proliferation and death (2).  
1.1.1 Breast Cancer 
Breast cancer is the most common malignant tumor in women worldwide. According to 
estimations by the World Health Organization (WHO), breast cancer leads to about 519,000 
deaths per year in the world, and belongs to the top ten mortal diseases (4). Besides the 
large number of cases, breast carcinoma is a very heterogeneous cancer in terms of 
histopathological and clinical classification, genetic and genomic background of the tumor 
mass and clinical outcomes (5).  
1.1.1.1 Estrogen Receptor α and breast cancer 
Although it is a heterogeneous disease, two-thirds of breast cancers share the common 
feature of being dependent on the presence and interaction of estrogen with its nuclear 
receptor, the Estrogen Receptor-α (ERα), for their growth (5, 6). Approximately 70% of 
invasive breast cancers express ERα in their actively proliferating cells. It has become 
evident that ERα is up-regulated in luminal mammary epithelial cells during early steps of 
tumorigenesis process and its overexpression is an important stimulatory factor for 
proliferation of mammary cells, leading to an un-controlled cell division and eventually to 
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tumor development (6, 7). ERα functions as a ligand-dependent transcription factor. It acts 
mainly by regulating the expression of target genes whose promoters contain a specific 
sequence known as estrogen-responsive element (ERE) (8). The obvious role of ERα 
signaling in orchestrating the expression of genes involved in growth-related pathways has 
established ERα as an important therapeutic target breast cancer treatment (6). However, 
there is a lack of knowledge about the molecular mechanisms underlying the up-regulation 
of ERα in breast cancer. 
1.1.1.2 Breast cancer types 
Almost all invasive breast tumors are adenocarcinoma (arisen from secretory epithelia) 
(96.9%). Among the adenocarcinoma, the largest subgroup is comprised of the invasive or 
infiltrating ductal carcinoma (IDC) with about 80% of all breast carcinoma, followed by the 
infiltrating lobular carcinoma (ILC) (Fig. 1). Less common types of breast cancer include 
mucinous, tubular, papillary, medullary or those not otherwise specified (NOS) that arise 
only to very low percentages (2.6%, 1.6%, 0.4%, 0.7%, and 1.1%, respectively). Non-
invasive breast cancers include the ductal carcinoma in situ (DCIS) and lobular carcinoma 
in situ (LCIS). In these types, cancer cells are inside the ducts or lobules and have not 
invaded the surrounding tissues. These types may develop to invasive forms or predispose 
the affected person to develop an invasive breast cancer (9). 
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Figure 1. Anatomy of the breast. IDC originates from cells of ducts (milk passage), whereas ILC 
starts in milk- producing glands in the lobules (Website of National Cancer Institute; 
www.cancer.gov). 
 
1.2 Epigenetics 
Epigenetics was first defined by Conrad Hal Waddington as "the causal interactions 
between genes and their products, which bring the phenotype into being" (10). This 
definition initially referred to understanding chromatin structure and its impact on gene 
function. The current definition of epigenetics is "the study of heritable changes in gene 
expression that occur independent of changes in the primary DNA sequence". Epigenetic 
mechanisms that govern these expression patterns have been divided into four main 
categories: DNA methylation, covalent histone modifications, nucleosome remodeling 
factors and non-coding RNAs including microRNAs (miRNAs) (11). 
Introduction  
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1.2.1 DNA methylation  
DNA methylation is the most-studied epigenetic factor referring to the modification of 
cytosine residues by methylation at their carbon-5 position. In mammalian genomes, this 
modification is primarily occurs on cytosine residues that are located 5' to guanine- i.e. 
CpG dinucleotides (12). DNA methylation is catalyzed by DNA methyltransferases 
(DNMTs). In human, at least, three DNMTs are involved in establishment and maintenance 
of DNA methylation patterns; de novo DNA methyltransferases DNMT3A and DNMT3B 
and maintenance DNA methyltransferase DNMT1 (13, 14). CpG dinucleotides are not 
equally distributed across the human genome but are concentrated in distinct CpG-rich 
regions called “CpG islands” (CGIs) and in regions of large repetitive sequences. CGIs are 
mainly found at the 5' regulatory regions of genes. About 60% of human gene promoters 
are embedded in CGIs. CGIs are also found in first exon and even first intron of several 
protein coding genes (15).  
While most of the non-CGI CpG dinucleotides in the genome are methylated, majority of 
the CGIs remain unmethylated in normal conditions (16). However, it is known that some 
CGIs undergo methylation during development resulting in long-term transcriptional 
silencing of the associate genes. Such a natural silencing mechanism plays a crucial 
repressing role in X-chromosome inactivation, genomic imprinting, and transcriptional 
repression of repetitive and centromeric regions. DNA methylation exerts its silencing role 
in conjunction with histone modifications and nucleosome remodeling (17, 18). 
1.2.2 Covalent histone modifications   
Histone proteins are building blocks of nucleosomes that can be post-translationally 
modified by methylation or acetylation, for example. The methylation and acetylation of 
histones regulate variety of nuclear processes including organization of chromatin structure 
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and gene expression (19). Generally, it has been observed that regions silenced by DNA 
methylation show hypoacetylation and hypermethylation of specific histone lysine residues 
including lysine 9 or 27 in histone H3 (H3K9 or H3K27). Inversely, promoters of actively 
transcribed genes show hyperacetylation of histones H3 and H4, and methylation of lysine 
4 of histone H3 (H3K4). The interactions between DNA methylation and histone 
modifications mediate gene silencing through recruitment of repressive complexes and 
methylated DNA binding proteins (20) (Fig. 2).  
Silencing
 
Figure 2. DNA methylation and histone modifications contribute to gene silencing. The 
promoter region of a transcriptionally active gene is hypomethylated and acetylated in the lysine 
residues on histone tails. These marks lead to the formation of euchromatin (Upper part). A silenced 
gene, is characterized by DNA hypermethylation in the promoter region, which attracts methyl-
binding proteins such as MBD. Additionally, increased activity of histone deacetylases and histone 
methylases leads to loss of active markers such as H3K4 and H4K16 acetylation, and 
establishment of repressive markers such as H3K9 methylation (Lower part). DNMT, DNA 
methyltransferase; HAT, histone acetyltransferase; HDAC, histone deacetylase; HMT, histone 
methyltransferase (21). 
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1.2.3 microRNAs (miRNAs) 
MicroRNAs (miRNAs) are endogenous small non-coding RNAs of 20-23 nucleotides in 
size which are involved in post-transcriptional control of gene expression (22). miRNA 
transcripts are generated either by RNA polymerase II (23) or III (24) as long primary 
transcripts (pri-miRNA) carrying the mature miRNA sequence in a stem loop structure. In 
the nucleus, cleavage of the pri-RNA stem loop by the RNase III endonuclease Drosha 
releases a 60-70 nucleotide long precursor RNA (25), called pre-RNA, which is 
subsequently transported into the cytoplasm and is further processed by Argonaute2 and 
Dicer (26, 27). One strand of the Dicer cleavage product - an RNA duplex with 3' 
overhangs and 5' phosphate ends – carrying the mature miRNA sequence is further 
incorporated into the RNA-induced silencing complex (RISC) (28). Due to the 
complementarities of miRNAs to the 3’UTR of mRNAs, the active RISC recognizes target 
transcripts and promotes translation inhibition or mRNA destabilization (29-32), both 
resulting in the reduction of target protein level (Fig. 3).  
1.3 Epi-Genetics of Cancer 
The inactivation of tumor suppressor genes has been widely observed in almost all cancers. 
A well-accepted model defining the genetic background of this inactivation is Knudsen’s 
"two-hit" model. Originally, his hypothesis suggested that a germline mutation in one allele 
of a tumor suppressor gene can lead to an inherited predisposition to retinoblastoma; 
however, tumorigenesis requires a somatic mutation of the second copy of the respective 
gene. Non-hereditary cancer of the same type requires the same two hits, but both are 
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Figure 3. Pathway of miRNA processing. Following different processing and cleavage steps of 
miRNA transcripts in the nucleus and cytoplasm, the mature form of the miRNA is produced. The 
functional strand (red) of the mature miRNA is loaded together with Argonaute (Ago2) proteins into 
the RISC, where it guides RISC to silence target mRNAs through mRNA cleavage, translational 
repression or deadenylation, whereas the passenger strand (black) is degraded (33). 
somatic (34, 35). This very specific finding has been generalized to other cancers and 
related tumor suppressor genes and has become a key concept in tumor genetics. This 
model has also been broadly used to find and characterize the genetic defects responsible 
for hereditary cancers.  
In 1993, Bert Vogelstein and Kenneth Kinzler proposed that tumor formation is a multistep 
process which involves sequential mutations in certain genes associated with the disruption 
or over-activation of certain pathways that consequently lead to the transformation of 
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normal cells to cancerous cells (36). This model was originally described for colon 
carcinoma which shows clear morphological stages during development. Subsequent 
studies on involvement of genetic defects in cancer, especially in hereditary cancers, 
provided more evidences on dysregulation of tumor suppressor genes and oncogenes in 
tumors. Nevertheless, subsequent data revealed that dysregulation of cancer related genes is 
not always accompanied by causative genetic defects, supporting the possible involvement 
of “epigenetic” factors in aberrant regulation of genes and pathways involved in 
tumorigensis (e.g.12, 37). 
1.3.1 Abnormal DNA methylation patterns in cancer 
Epigenetic patterns of the genome are dramatically different between normal and cancerous 
cells. Abnormal changes in methylation patterns found in human cancers include global 
demethylation of DNA with simultaneous hypermethylation of CGIs. Hypomethylation at 
DNA repetitive elements leads to genomic instability and might also induce overexpression 
of oncogenes, whereas, hypermethylation of CGIs located at promoter or in the vicinity of 
transcription start site (TSS) of tumor suppressor genes results in silencing of cognate genes 
(12, 38) (Fig. 4). 
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Figure 4. Epigenetic landscapes of normal and cancer cells. (A) DNA methylation. In normal 
cells, almost all of the CpGs are methylated while CGIs are unmethylated. In cancer cells, many 
CGIs become hypermethylated leading to silencing of their cognate genes, while global 
hypomethylation, mostly at repetitive elements, occurs. (B) Chromatin and histone modification. 
Active genes are associated with acetylation of histone tails, methylation of H3K4 and absence of 
nucleosome at their promoters. The promoters of silenced genes become associated with 
nucleosomes, lose acetylation and H3K4 methylation marks, and gain repressive methylation marks 
such as H3K9 or H3K27, which recruit repressive complexes (18).  
The first tumor suppressor gene shown to harbor promoter CGI hypermethylation in cancer 
was Rb (Retinoblastoma) gene (39). This discovery was followed by other reports on 
promoter hypermethylation and silencing of other tumor suppressor genes in different 
cancers (40-42) confirming the existence of abnormal DNA methylation patterns in cancer. 
In 1995, Peter Laird showed that induction of hypomethylation in a mouse model for 
development of intestinal adenomas (early stage of colon cancer) reduces the number of 
intestinal adenomas (43). This study advanced the field of cancer epigenetics by providing 
evidence on a direct casual role for DNA methylation in cancer development. This study 
accompanied by other reports on hypermethylation and silencing of genes with causative 
roles in different tumors- such as Rb in retinoblastoma or MLH1 in colorectal carcinoma 
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(44-46) – led to recognition of DNA methylation as an alternative “hit” to DNA sequence-
based defects in Knudson’s two-hit model (Fig. 5). 
 
Figure 5. DNA methylation in Knudson’s two-hit model. The active alleles of a tumor suppressor 
gene (green boxes) can become inactivated in the first or second hit or in both by a genetic defect 
disrupting DNA sequence or DNA methylation (epigenetic effect) resulting in transcriptional 
inactivation. LOH: loss of heterozygosity (47). 
Subsequent studies on individuals affected by hereditary cancer but lacking any causative 
genetic mutations revealed that, indeed, epimutations (abnormal DNA hypermethylation) 
affect the responsible genes (48, 49).  
1.3.1.1 DNA methylation as a biomarker 
Aberrant DNA methylation events are abundant in tumors and also happen in the early 
stages of tumourigenesis. Also, this modification occurs on DNA molecule (which is more 
stable than RNA and protein molecules) through a covalent stable modification which can 
be detected in body fluids e.g. serum. In addition, hypermethylation of DNA occurs mainly 
at specific CGIs associated with tumor suppressor gene promoters, whereas point mutations 
often appear at different sites within a given gene in individual tumors. These facts have 
nominated the DNA methylation as a promising marker for clinical applications in cancer 
management (50, 51). To date, promoter DNA hypermethylation has been identified for a 
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large number of tumor suppressor genes (20, 52), among which some are suggested as 
potential clinical markers for cancer early diagnosis (GSTP1; prostate cancer), prognosis 
(MGMT; response to temozolomide treatment in glioma patients) or patient follow-up (p15; 
acute myeloid leukemia) (12). 
1.3.1.2 Detection of DNA methylation 
DNA methylation patterns are removed by classical molecular biology techniques, such as 
cloning in bacteria and PCR. Moreover, as the methyl group is located in the major groove 
of DNA, it is not detected by hybridization methods. Therefore, methylation-dependent pre-
treatment of DNA have been developed to uncover the presence of the methyl group at 
cytosine residues. There are three main approaches used in this pre-treatment step; 
endonuclease digestion (using methylation sensitive/dependent enzymes), affinity 
enrichment (using antibodies against 5-methyl cytosine or methyl-binding proteins) and 
bisulfite conversion. Following the pre-treatment step, variety of molecular biology 
methods can be applied to analyze DNA methylation patterns, such as sequencing or 
microarray hybridization (53). 
1.3.1.3 Oligonucleotide microarrays for DNA methylation analysis 
Microarray-based technologies provide an opportunity for a high-throughput analysis of 
methylation patterns with a locus-specific resolution (54). Specialized microarrays have 
been developed to determine methylation patterns, following all the above mentioned pre-
treatment steps (55). 
Based on the bisulfite conversion of  unmethylated cytosine to uracil and, following PCR-
amplification, eventually to thymine, methylation patterns represent chemically introduced 
mutations that can be analyzed using different approaches (56). Therefore, when followed 
by an appropriate genotyping approach, bisulfite conversion of DNA provides a single-
base-pair resolution for DNA methylation analysis (57). This concept has been used, by 
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different investigators, for the determination of DNA methylation patterns of tumor 
suppressor genes by oligonucleotide microarrays (58-62). In this microarray platform, 
methylation status of each CpG site is interrogated by two oligonucleotide probes; one 
detecting the methylated C and another one detecting unmethylated cytosine (Fig. 6). 
Despite high resolution in CGI mapping, the previous studies using these assays have been 
limited to individual genes. Recently, a genome-wide platform using the same principle has 
been developed by Illumina (63, 64). The current version of this array technology (called 
Infinium) has the coverage of more than 27,000 CpGs, associated with 14,495 protein 
coding genes and 110 miRNA gene promoters across the human genome. Nevertheless, the 
assay resolution is restricted to two CpG dinuclotides per locus, in the optimum condition.  
 
Figure 6. Analysis of DNA methylation by oligonucleotide microarrays following bisulfite 
conversion. Two oligonucleotide probes are used to interrogate methylation patterns of a CpG site; 
one detecting unmethylated target and another one detecting the methylated target. The signal 
intensity ratio of these probes reflect the methylation of the CpG site (62).  
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1.3.2 miRNAs and cancer  
miRNAs are abundantly present in human cells (65). Due to their diversity and target 
variety - each miRNA can regulate the expression of numerous genes - they are assumed to 
directly control the expression of a large portion of all human protein-coding transcripts 
and, thus, are involved in several distinct cellular activities such as metabolism, 
differentiation, proliferation and apoptosis (reviewed in 66, 67). The observations that all 
these processes are altered in cancer (reviewed in 68) and that miRNA expression is 
deregulated in a variety of cancer types (69) suggests that miRNAs expression has 
profound influence on carcinogenesis (reviewed in 70). Actually, microarray-based 
expression profiling shows distinct miRNA profiles for different tumor entities (69). 
Moreover, based on function of their target mRNAs or pathways, several miRNAs have 
been characterized as tumor suppressors or oncogenes (71). Whereas differential expression 
patterns of miRNAs between normal and cancer cells are intensively investigated, the 
cellular function of the majority of miRNAs is still unknown.  
The expression of miRNAs can be regulated by various mechanisms including genetic and 
epigenetic factors. DNA copy number abnormalities of miRNA genes loci, aberrant 
expression of transcription factors involved in transcription of miRNAs and abnormal 
epigenetic patterns of miRNA gene loci have been identified in cancer cells. (72-78) 
1.3.3 Epi-Genetics of breast cancer 
It is known that mutations in two major susceptibility genes, BRCA1 and BRCA2, are 
directly associated with the development of the disease (79). Screening of these genes has 
been considered in clinical management of breast cancer patients with a family history (80). 
In addition, mutations of other genes, involved in different molecular pathways, have also 
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been reported in familial or sporadic forms of breast cancers (e.g. TP53, PTEN, ATM and 
CHEK2) (81).  
1.3.3.1 DNA methylation and breast cancer 
The most commonly mutated gene in familial breast cancer, BRCA1, is rarely found 
mutated in sporadic cases of the disease, though it is inactivated in the patients. Esteller and 
colleagues showed that the BRCA1 inactivation in sporadic breast cancer was directly due 
to changes in the methylation level of BRCA1 promoter (37), indicating the involvement of 
epigenetic factors on deregulation of key genes in breast cancer. This finding was further 
supported by identification of aberrant methylation on promoter of different genes 
associated with breast cancer, such as steroid receptor genes family members (ER, RARβ2), 
mismatch repair genes (hMLH1), cell cycle regulators (p16), cell adhesion (CDH1) and 
inhibitors of proteases (TIMP-3) (82, 83). 
Today, perturbations of epigenetic patterns are recognized as early events in breast 
 
Figure 7 Epi-genetic alterations contribute to development of breast cancer. Deregulation of 
epigenetic patterns occurs in the early steps of tumorigenesis. The normal breast terminal ductal 
lobular unit (TDLU) contains lobules and ducts. Atypical ductal hyperplasia (ADH) is a premalignant 
lesion characterized by abnormal cell layers within the duct or lobule. ADH is thought to be the 
precursor of ductal carcinoma in situ (DCIS). With each stage, the risk of developing malignant or 
invasive breast cancer (IBC) increases. DCIS may give rise to IBC (indicated by a blue star 
adjacent to a DCIS lesion). Once cells have invaded, the risk for developing metastasis significantly 
increases. The lymph nodes are the primary site for breast cancer metastasis (MET; indicated by a 
blue star) (5).  
cancer development (5) (Fig. 7) with a potential value to be used for early diagnosis. In 
addition, detection of cancerous cells by identification of abnormal DNA methylation has 
been successfully carried out in fluids obtained by nipple aspiration and ductal lavage (84, 
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85). Thus, screening for abnormal methylation patterns seems to provide a non-invasive 
approach for early cancer diagnosis. To this aim, identification of genomic loci whose 
methylation patterns represent an early diagnostic marker has been a focus of research in 
recent years.     
1.3.3.2 miRNAs and breast cancer 
In breast cancer, specific down-regulated and up-regulated miRNA subsets have been 
identified (86). A key role for de-regualted miRNAs in breast cancer development has 
recently been established through the identification of target proteins involved in breast 
cancer establishment and metastasis (87); miR-21 was shown to inhibit the expression of 
programmed cell death 4 (PDCD4) (88) and tropomyosin 1 (TPM1) (89) promoting cellular 
proliferation. miR-27a regulates the expression of zinc finger and BTB domain containing 
10 (ZBTB10) leading to increased levels of SP proteins (90). miR-125a and miR-125b were 
shown to regulate the oncogenes ERBB2 and ERB3 in SKBR3 cells (91). miR-206 and 
miR-222/221 were reported to target estrogen receptor alpha (ERα) (92, 93). Whereas, 
miR-10b targets homeobox D10 (HOXD10) and initiates metastasis and tumor invasion 
(94), miR-31 is able to inhibit breast cancer metastasis by regulating a cohort of 
prometastatic genes (95). 
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1.3.4 Aim 
In this dissertation, two mechanisms involved in epigenetic control of gene expression were 
studied in breast cancer; DNA methylation and miRNAs. 
Microarray based analysis of DNA methylation patterns 
The aim of this study was to assess the potential of establishment of a DNA methylation 
signature, based on available literature data, for diagnosis of female breast cancer. For this 
purpose, loci with methylation patterns associated with breast cancer had to be identified by 
literature review, and oligonucleotide microarrays dedicated to these loci had to be 
developed and optimized to obtain reliable data for each locus. Then, DNA methylation 
patterns in breast tissue samples were analyzed using the microarrays. After validation in 
independent sets of samples, the identified methylation signature would be helpful for the 
diagnosis of breast cancer and/or for the assessment of risk to develop breast cancer.  
Identification of miRNAs involved in ERα activation  
This study was aimed at evaluation of possible involvement of miRNAs in up-regulation of 
ERα in breast cancer cells. In the first part of the study, a microarray-based profiling for 
miRNAs in ERα -positive and -negative mammary cell lines was the method of choice to 
identify miRNAs with a potential role in ERα signaling. A regulative role on ERα pathway 
for the candidate miRNA had to be demonstrated functionally. Elucidation of mechanism 
through which the candidate miRNA exerts its regulative role would help to improve our 
understanding of mechanisms underlying ERα activation in breast cancer. As ERα has a 
crucial role in proliferation and survival of vast majority of breast tumors, identified 
miRNA(s) might serve in possible new strategies for treatment of breast cancer. 
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2 Material and Methods 
2.1 Materials 
2.1.1 Instruments 
Instrument Supplier 
7900 HT Fast Real Time PCR Systems  Applied Biosystems, Forster city, USA 
ABI PRISM 7900 Sequence Detection System  Applied Biosystems, Forster city, USA 
Automatic developing machine  Amersham, Freiburg, Germany  
Beckman GS-6KR centrifuge Beckmann, Wiesloch, Germany  
Biofuge 13R, Biofuge Fresco, Biofuge pico Heraeus, Kendro, Hanau, Germany  
Centrifuge 5810 R  Eppendorf, Hamburg, Germany  
Cell culture incubator Köttermann, Hänigsen, Germany 
Cell culture microscope Carl Zeiss, Jena, Germany 
Centrifuge 580R Eppendorf, Hamburg, Germany 
Cell viability analyzer Beckmann, Wiesloch, Germany 
Dismembrator B.Braun Biotech, Melsungen, Germany 
EL800 Universal Microplate Reader BIO-TEK, VT, USA 
External Hybridization holder febit biomed GmbH, Heidelberg, Germany 
Electrophoresis power supply E-C Apparatus Corporation, USA  
GSA- and SS34- Rotor DuPont, Boston, USA 
Geniom One microarray  febit biomed GmbH, Heidelberg, Germany 
Geniom RT analyzer febit biomed GmbH, Heidelberg, Germany 
Heat Block QBT2 Grant Instruments/CLF, Emersacker  
LB-940 Mithras Multilabel Reader  Berthold Technologies, Bad Wildbach, 
  Micro-centrifuge NeoLab Laborbedarf, Heidelberg, Germany  
Mini-Protein 3 gel and electrophoresis system  Bio-Rad Laboratories, Munich, Germany  
Multifuge 3SR Heraeus, Kendro, Hanau, Germany 
NanoDrop ND-100 Spectrophotometer NanoDrop Technologies, San Diego, USA 
QuadriPERM plates  Vivascience, Hannover, Germany  
Speedvac concentrator apparatus  Eppendorf, Cologne, Germany  
Thermomixer compact  Eppendorf, Cologne, Germany  
Thermal Cycler MJ Research, California, USA 
Unimax 1010 Shaker  Heidolph Instruments, Schwabach, Germany  
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Vortex Scientific Industries Genie-2, New York, USA 
Water bath SW22 Julabo Labortechnik, Seelbach, Germany  
2.1.2 Chemical reagents, enzymes and general materials 
Reagent Supplier 
2-Mercaptoethanol Roche Diagnostics, Mannheim, Germany 
Acrylamide (30%w/v)/Bisacrylamide 
(29/10.8%) 
Bio-Rad Laboratories, Munich, Germany 
Agarose Sigma-Aldrich, Munich, Germany 
Ammonium peroxydisulfate (APS) Sigma-Aldrich, Munich, Germany 
Ampicillin Sigma-Aldrich, Munich, Germany 
Bacto-agar Difco Laboratories, Detroit, USA 
Bovine serum albumin (BSA) Sigma-Aldrich, Munich, Germany 
Bacto-trypton Difco Laboratories, Detroit, USA 
Bacto-yeast -extract Difco Laboratories, Detroit, USA 
Biotinylated-dUTP Roche Diagnostics, Mannheim, Germany 
Bromphenol blue Sigma-Aldrich, Munich, Germany 
Blocking-Reagent Roche Diagnostics, Mannheim, Germany 
BstUI New England Biolabs, Frankfurt, Germany 
Chloroform Merk, Darmstadt, Germany 
Chloramphenicol Sigma-Aldrich, Munich, Germany 
DEPC water, molecular biology grade Roth, Karlsruhe, Germany 
Desoxynucleotide–Set  Fermentas, St. Leon-Rot, Germany 
Dithiothreitol (DTT) Invitrogen, Karlsruhe, Germany 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, Munich, Germany 
DNA loading buffer Fermentas, St. Leon-Rot, Germany 
DNase I, amplification grade Invitrogen, Karlsruhe, Germany 
ECL Hyperfilm GE Healthcare Europe, Freiburg, Germany  
EDTA Merk, Darmstadt, Germany 
EpiTect PCR control DNA set Qiagen, Hilden, Germany 
Estradiol (E2) Sigma-Aldrich, Munich, Germany 
Ethanol Merk, Darmstadt, Germany 
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Ethidiumbromide Sigma-Aldrich, Munich, Germany 
GeneRuller 1kb and 50 bp DNA size markers Fermentas, St. Leon-Rot, Germany 
Glycerin Roth, Karlsruhe, Germany 
Halt™ protease and phosphatase inhibitor 
single-use cocktail, EDTA-free 
Thermo Scientific, Rockford, USA 
Hind III New England Biolabs, Frankfurt, Germany 
Human Universal Reference RNA Agilent Technologies, Waldbronn, Germany 
Kanamycin Roche Diagnostic, Mannheim, Germany 
Klenow fragment New England Biolabs, Frankfurt, Germany 
M-PER mammalian protein extraction reagent Thermo Scientific, Rockford, USA 
Magnesiumchloride Merk, Darmstadt, Germany 
Methanol Merk, Darmstadt, Germany 
Milk powder Sigma-Aldrich, Munich, Germany 
Na2HPO4 Merk, Darmstadt, Germany 
NaH2PO4 Merk, Darmstadt, Germany 
NaOH Merk, Darmstadt, Germany 
Natriumacetat Merk, Darmstadt, Germany 
Natriumchloride Merk, Darmstadt, Germany 
Natriumcitrate Merk, Darmstadt, Germany 
Methanol Merk, Darmstadt, Germany 
Nuclease free water Ambion, Austin, USA 
Random primer oligonucleotides Invitrogen, Karlsruhe, Germany 
QIAzol Qiagen, Hilden, Germany 
Rainbow Molecular Weight Marker Amersham, Freiburg, Germany 
SAM  New England Biolabs, Frankfurt, Germany 
SDS Sigma-Aldrich, Munich, Germany 
SAPE  Invitrogen, Karlsruhe, Germany 
SpeI New England Biolabs, Frankfurt, Germany 
SssI methyltransferase New England Biolabs, Frankfurt, Germany 
T4 Gene 32 protein Roche Diagnostic, Mannheim, Germany 
TEMED Bio-Rad Laboratories, Munich, Germany 
Tris-(hydroxymethyl)-aminomethane (Tris) Sigma-Aldrich, Munich, Germany 
Tris-Base Sigma-Aldrich, Munich, Germany 
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Triton-X100 Sigma-Aldrich, Munich, Germany 
Tween 20 (Polyoxy-ethylen-sorbitan-
monolaurate) 
Sigma-Aldrich, Munich, Germany 
2.1.3 Cell culture  
Item Supplier 
Charcoal-stripped FBS Gibco/ Invitrogen Karlsruhe, Germany 
DMEM Gibco/Invitrogen, Karlsruhe, Germany 
Mammary Epithelial Cell Growth medium Provitro, Berlin, Germany 
Foetal bovine serum (FBS) Biochrom, Berlin, Germany 
Phosphate buffered saline (PBS) Gibco/ Invitrogen Karlsruhe, Germany 
Penicillin 1000u/ml-Streptomycin100µg/ml Gibco/ Invitrogen Karlsruhe, Germany 
Trypsin/EDTA solution Gibco/ Invitrogen Karlsruhe, Germany 
2.1.4 Kits 
Item Supplier 
Absolute qPCR Green Mixes ABgene, Epsom, UK 
CellTiter Glo Luminescent Cell viability assay Promega, Mannheim Germany 
Caspase-Glo3/7 assay Promega, Mannheim Germany 
DNeasy blood and tissue kit Qiagen, Hilden, Germany 
Effectene Transfection Reagent Qiagen, Hilden, Germany 
ECL + Western Blot Detection Kit GE Healthcare Europe, Freiburg, Germany 
Epitect Bisulfite Kit Qiagen, Hilden, Germany 
miRNAeasy Kit Qiagen, Hilden, Germany 
HotStar Taq DNA polymerase Kit Qiagen, Hilden, Germany 
QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany 
QIAquick PCR purification Kit Qiagen, Hilden, Germany 
Dual-Luciferase Assay Reporter System Promega, Karlsruhe, Germany 
siPORT™ NeoFX™ Reverse Transfection Kit Ambion, Austin, USA 
SuperScript III reverse transcription Kit Invitrogen, Karlsruhe, Germany 
Pierce BCA Protein Assay Kit − Reducing Thermo Scientific, Rockford, USA 
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Agent Compatible Kit. 
Taq DNA polymerase Kit Qiagen, Hilden, Germany 
TaqMan MicroRNA Reverse Transcription Kit Applied Biosystems, Darmstadt, Germany 
TaqMan Universal PCR Master Mix Applied Biosystems, Darmstadt, Germany 
T4 DNA ligase Invitrogen, Karlsruhe, Germany 
TOPO TA cloning Kit for sequencing Invitrogen, Karlsruhe, Germany 
2.1.5 Media, solutions and buffers 
Media, Solutions and Buffers Components 
APS 10% APS w/v in ddH20 
LB Medium 1 % (W/V) Bacto-Trypton 
0.5 % (W/V) Bacto-Yeast –Extract 
1 % (W/V) NaCl 
In H2O, pH = 7.5 
Autoclave at 121°C and 1000hPa for 20 min 
S.O.C. Medium 
 
2% trypton 
0.5% yeast extract 
10 mM NaCl 
2.5 mM KCL 
10 mM MgCL2 
10 mM MgSO4 
20 mM glucose 
10x PBS 
 
137 mM NaCl 
27 mM KCl 
100 mM NaH2PO4 
17 mM KH2PO2 
dissolved in ddH2O 
1x TBS-T 
 
20 mM Tris-Base 
137 mM NaCl 
3.8 ml 1M HCl 
0.1% (v/v) Tween 20 
dissolve in 1l ddH20 
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5x Loading buffer 
 
100 mM EDTA 
30% (v/v) glycerine 
0.25% (w/v) bromophenolblue 
dissolved in ddH2O 
20% SDS 20% SDS (w/v) dissolve in ddH20 
2x Laemmli buffer 
 
50 mM Tris/HCl pH=8.0 
2.4% w/v SDS 
8% glycine 
0.2% w/v bromphenol blue 
2.5% v/v β-mercaptoethanol 
5x SDS-PAGE running buffer 
 
25 mM Tris-Base 
200 mM glycine 
10% (w/v) SDS 
ddH20 
10x Western blot buffer 
 
25 mM Tris-Base 
192 mM Glycine 
20% v/v methanol (added when preparing 1× 
buffer) 
ddH20 
BSA- blocking buffer 3% BSA in PBS 
Resolving gel buffer 1.5M Tris-Base 
10% (w/v) SDS 
ddH20 
PH= 8.8 
Stacking gel buffer 0,5M Tris-Base 
10% (w/v) SDS 
ddH20 
PH=6.8 
Milk-blocking buffer 5% Milk powder in TBS-Tween (0.1%)  
Stripping buffer 
 
100 nM β-Mercaptoethanol 
2% SDS 
62.5 nM Tris-HCl, pH=6.7 
ddH20 
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SSPE, 6× 0.9M NaCl 
60mM NaH2PO4, (pH=7.4) 
6 mM Na2EDTA 
TAE buffer, 50× 0.4M Tris base 
0.4M acetic acid 
20mM EDTA (pH=8) 
 
2.1.6 Antibodies 
Antibodies Supplier Dilutions 
Anti-rabbit IgG, HRP-linked Antibody  Cell Signaling Inc, Danvers, 
  
1:5000 
Anti-mouse IgG, HRP-linked Antibody  Cell Signaling Inc, Danvers, 
 
1:5000 
Actin Sigma-Aldrich, Munich, 
 
1:1000 
ERα Cell Signaling Inc, Danvers, 
 
1:1000 
GAPDH Sigma-Aldrich, Munich, 
 
1:25000 
2.1.7 Plasmids and synthetic RNAs 
Plasmid/synthetic RNAs Source 
Actin-RL renilla luciferase construct Dorothee Nickles & Michael Boutros, DKFZ 
pc-myc-CMV-D12 expression vector Core Facility of DKFZ 
pMIR-REPORT firefly luciferase construct Ambion, Austin, USA 
RASD1 siRNA-2 Qiagen, Hilden, Germany (SI00113197) 
RASD1 siRNA-4 Qiagen, Hilden, Germany (SI00113211) 
RASD1 siRNA-5 Qiagen, Hilden, Germany (SI03080483) 
RASD1 siRNA-6 Qiagen, Hilden, Germany (SI03104115) 
ERα siRNA-01 Dharmacon, Rockford, USA (D-003401-01) 
ERα siRNA-02 Dharmacon, Rockford, USA (D-003401-02) 
ERα siRNA-03 Dharmacon, Rockford, USA (D-003401-03) 
ERα siRNA-09 Dharmacon, Rockford, USA (D-003401-09) 
Negative control siRNA #1 Ambion, Austin, USA (AM4611) 
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Pre-miR-375 Ambion, Austin, USA (PM10327) 
Pre-miR-Control Ambion, Austin, USA (AM17110) 
Anti-miR-375 Ambion, Austin, USA (AM10327) 
Anti-miR-Control Ambion, Austin, USA (AM 17010) 
2.1.8 qRT-PCR primers 
Primer Name Sequence or Cat. number 
LAMINB1 forward 5'-CTGGAAATGTTT GCATCGAAGA-3' 
LAMINB1 reverse 5'-GCCTCCCATTGGTTGATCC-3' 
GHSR reverse 5'-CCGACCTGGACTGGGATG-3' 
GHSR reverse 5'-GCGATACCCACCACGAAG-3' 
pS2 forward 5'-ATACCATCGACGTCCCTCCA-3' 
pS2 reverse 5'-AAGCGTGTCTGAGGTGTCCG-3' 
RASD1 QT00201390 (Qiagen, Hilden, Germany) 
SFRP1 QT00031927 (Qiagen, Hilden, Germany) 
SFRP2 QT00073220 (Qiagen, Hilden, Germany) 
SFRP3 QT02238551 (Qiagen, Hilden, Germany) 
SFRP4 QT02238537 (Qiagen, Hilden, Germany) 
HDPR1 QT01891071 (Qiagen, Hilden, Germany) 
 
miR-375 000564 (Applied Biosystems, Darmstadt, Germany) 
RNU6B 001093 (Applied Biosystems, Darmstadt, Germany) 
RNU66 001002 (Applied Biosystems, Darmstadt, Germany) 
2.1.9 Genomic primers for the amplification of CGIs 
from genomic DNA 
CGI Forward primer (5'→3')  Reverse primer (5'→3') 
APCA1 ACTGCCATCAACTTCCTTGC GCAGCACCTCCATTCTGTCT 
BRCA1.A GGAAGTGAAATATGATCCCTATCCT GTAGAGACGGGGTTTCACCA 
BRCA1.B TCTCCCTCCCACAAAATCCT GCAGGCACTTTATGGCAAAC 
BRCA1.C GTGCGCGCTTGTACTTGTC ACGAAGGGCTCTCTCATCCT 
Materials and Methods  
26 
 
C/EBPα CAGCAGCTCAAGACCAAGACT GACTCCATGGGGGAGTTAGAG 
CCND2 GTGAAGAAACGCCACCAGAT GCAGAGTGTGTGCAGAGGAA 
CDH1 CAGGTCCCATAACCCACCTA AATGCGTCCCTCGCAAGT 
CDH13 GCCAGAGTGGGAGCCTGTGT CACCCTGAGGCACTCCCTGT 
CST6 GCTGCGGTTGGTAGTTCATT GGTTGTCCATCGTGGAGTTT 
DAPK CAGGCTGGAGAGAGATTGCTCCCAGTG TGTTGTCACAGAAGGGCAAG 
DKK-3 ACAGGACAGAGGTTGGCTTG AAGCCTCTCTCAGCCCCTAC 
ER GCACACCCCATTCTATCTGC CCTCGGGGTAGTTGTACACG 
GSTP1.A AGAATTGCTTGAACCCGAGA ACTCACTGGTGGCGAAGACT 
GSTP1.B ACCTACTCGGGAGGCTGAAG GGGAAGCCTTTCCCTCTTT 
HDPR1 GGTGCAGTAAACCCGAAAAG CAGCAAGATGTTCTCCTCCA  
HIC1 GTGGGGCATCGGCTAAGAG GAGAAGGAGCAGGAGGTGAGC 
HIN-1.A TGTGCTTTGCTCTCCATCTG CGCCTGCCAAGAGGAAGT 
HIN-1.B CGAGCCCACTAAGAAAGCAG CGAGCCCACTAAGAAAGCAG  
HOXA5 TCCCCGAAGGTGATATCTGTAT TAGCGACCGCAAAATGAGTTTA 
HPGD TGCTCCGCTCTCCTTCTATC TGGCAATTAGGTTTGGGTTC 
MLH1 CAAATAACGCTGGGTCCACT TCTGTTCACATCCAAAGGCA 
OGDHL GCATTCCCATTTTACAGACGA AAGGTCAGAGCCAAGGTCAC 
P53 ATCCGACGCAGAGCTAAAGA CCCTAACGTTTTCTCCCAGA   
PAK3 ATGTTCCCTCCCCTTCAGTT GGCTGACGTAGCTTTCAAGG 
PGR.A CCCTAGAGGAGGAGGCGTTG CGGGAATATAGGGGCAGAGG 
PGR.B CAGCGGACTGCTGGACAGTG GGAGGACGCAGACGAGACTGA 
PTEN CGAGGCTTAGCTCGTTATCCT CTCTCATCTCCCTCGCCTGAG 
RARB TGCTGGGAGTTTTTAAGCTCTG ACAGGCTTTTAGCTGGCTTG 
RASSF1A GTGTGAGGAGGGGACGAA GATGAAGTCGCCACAGAGGT 
SFRP1 CCCTTCTTTTTCTCCCCTTG GCAAACTTCCAGGGACCTC 
SFRP2.A GCAAAACCAGACCCAGAAAG GAAGAGCGAGCACAGGAACT 
SFRP2.B GAGATTCGAGGGAAAACGAA GGCACAGCCAGAGTTTTCTT 
SFRP3 AGCTCTTAGCCCACACAGGA CTGGAAGTCAATGGTGCAGA 
SFRP4 TCTAAGGCAGAGGGAGCAAA ACCAGCTCCTCGTACTGCTC 
SFRP5 TGTGGCGGAGAGAGATAAGG GCCTGCCAGCCATAGTAGTC 
SOCS1 GGAGGAGGGAGGGGAGTC CGAACGGAATGTGCGGAAGT 
Stratifin GAGACACAGAGTCCGGCATT TGATGAGGGTGCTGTCTTTG 
TCF4 TCAAAACAGCTCCTCCGATT CCCTTAAAGAGCCCTCCATC 
TWIST.A CCCCTCTGGCTCTGCTGCCTTT CCCGCGAGGTGTCTGGGAGT 
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TWIST.B  CGGGGGAGGGGGACTGGAA  GCCGCCAGCTTGAGGGTCT 
TWIST.C CAGCGCACCCAGTCGCTGAA TGGCGCTGACAAAACGGTCCT 
WIF1 TCACCATCACCATCACCATC AGGTACAGGCTCTCCTCCTG 
2.1.10 SoBi primers for the amplification of CGIs from 
deaminated DNA 
CGI Forward primer (5'→3')  Reverse primer (5'→3') 
APCA1 AGGGTTAGGTAGGTTGTG ACCAATACAACCACATATC 
ARHI GTTGGGTTAGTTTTTTATAGTTGGTT AACCAAACAACCTAAAAAACAAATAC 
BRCA1.A GTTTAGGTTGGAGTGTAATGG ATTTCTCAAATAACTAAACCCCTAC 
BRCA1.B AGTAGAGGGTGAAGGTTTTTTGAG AAACAAACTAAATAACCAATCCAAAAC 
BRCA1.C TTTGTATTTGTTAATAGTTATGGATTGGA TTCTTTACAAAATTCCTCCCTTAAAC 
C/EBPalp
 
TAGGTAGGAGGAGGGGGTTT TCCATAAAAAAATTAAAATTCTCCC 
CCND2 GTAAAGATAGTTTTGATTTAAGTATG TCTAAAAAAATAAAATATAATCCTC 
CDH1 ATTTAGTGGAATTAGAATAGTGTAGGTTTT CTACAACTCCAAAAACCCATAACTAAC  
CDH13 ATTTTTTGGAAAAGTGGAATTAGTT AAAAATACCTAAAATCTCTAAACTC 
CST6 TTTTTGTATTGGTATTTGTTGTTGG CCTATAACCTCCCCCATCTAAAC 
DAPK GGTTGGAGAGAGATTGTTTTTAGTG ACCCTAAACTACTACCTCTCCTCCA 
DKK-3 GTAGGTAGTGAAGGAGATGGTTGTT TCCACCAAAAAAAACTAAACTCAAC 
ER AGTGTAGTTTTTTTTAGGGTTATTTTATGT AACCTCCAACTTTAAATACTAATCTCC 
GHSR.A ATTGTTTGTGAAAGGTAAGTATAAA ACACTAACAAAATAACCCTCTAAAc 
GHSR.B GATTTGGATTGGGATGTTTTTT CCCTTAATAACCACCACCTTAAC 
GSTP1.A GGAAAGAGGGAAAGGTTTTTT CCATACTAAAAACTCTAAACCCCATC 
GSTP1.B TGGGGTTTAGAGTTTTTAGTAT ACTACAACCCCAACCCCTAC 
HDPR1 TTGATAGAGGAGGGGAAGTTTG  CCCCTAACCAACAACTCTTAAC 
HIC1 GGGTAGGGGAGTTTAGGGTT ATTACCCCAATTAAAAAAAATAATAC 
HIN-1.A ATTTGTTATATTTTTGTAGGTGATAGA ATACCCTAACCAACTTCCTACTAC 
HIN-1.B GTAGTAGGAAGTTGGTTAGGGTA AAACTAAAAAAACCTAAAATCCAC 
HOXA5 TATAAAAATAAGAGGGGTTGTAAAA CCTACCTAATAACCTCTAAAAATAAACTC 
HPGD GGTTTTTAGGGTATTGAAGGAAATT ATACTCACAACCTCAACTTCAACAA 
MLH1 TTTTTTTTAGGAGTGAAGGAGGTTA TTTAATTAATAAAAATAAAAATATT 
OGDHL GGTTTTAGAGAGGAGTTTTTTTT CAAAACCAAAATCACAATCTATTC 
P53 TTTTGAAAGTATTGTGTTTTTTAGTAT TCTTATTCATTATTATATTCCTAAATACCT 
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PAK3 TTTGATTGGTTTAGGTAAGGTGTAGA AAAAACAAAACATCTACCCAACAAC 
PGR.A TGTTAGAAAGTTGTTTGGTTAGTTTATAGT CTAATCAACTCCTACCCTTAACCTC 
PGR.B GGATTGTTGGATAGTGTTTTGG AAACTATCTCCAACCTTACACCC 
PTEN TTATATTGGGTATGTTTAGTAGAGTTTG AACTTCCATCATAACTACAACTTCC 
RARB TTTGGGAGTTGGTGATGTTAGA ATTTACCATTTTCCAAACTTACTC 
RASSF1A GGAGGGAAGGAAGGGTAAGG  CAACTCAATAAACTCAAACTCCC 
SFRP1 TTTTTAAGGGGTGTTGAGT CAAACTTCCAAAAACCTCC 
SFRP2.A AAAAGGTTAAGAAAATTTTGGTTGT CTACTCCAACACCTCCTTCATAATC 
SFRP2.B ATGTTTGGTAATTTAGTAGAAATTT CAACCAAAATTTTCTTAACCTTTTT  
SFRP3 GTGATTTAGGGGAGGAGATATTTTAGA TTCCAAAACAAAAACTTACACAAAA 
SFRP4 AAAGTAGGTTTTTAGTTTTGGGTTG AAAAAAAACATAACACTACCCTCTC 
SFRP5 TAGGGAGTTTTGGGGAGAAA CCCAAATAAATAACAACCTAC 
SOCS1 AGGGGAGTTTAGGGTAGTTAGGAG CTACCATCCTACAAAAAAAACCAAC 
Stratifin TTTGTGTGTTTTTAGAGTTATGGAGAG  TCTTAACCAAAAAAATAACCTCCTC 
TCF4 TTTTATTTGTTTTTTGGGTTTGGTA AAAAAACCCTCCATCTTACCTCTTA 
TWIST.A GTTGTTTTTTTTATGGATTGGGTT ACAACAATAACAACAACTTCTACACAATAA 
TWIST.B  ATGAGATATTATTTATTGTGTAGAAGTTGT TTAAAAACAACAATATCATTAACCTAAC 
TWIST.C TTGAGTAAGATTTAGATTTTTAAGTTGG ATATCTCTATCTCCCCTCCTATCAC 
WIF1 GATGTTTTAGGGGTTTTTGAGTGT CTACAACTCCCTCAACCAAAACTAT 
miR-375 Bisulfite sequencing primers  
Bs1 GTTTTATAGTGTAGTGGATGAGGGG AAAAAACAAAAAATCCCAAATAAAC 
Bs2 GGGGATTGAATAGGTAGTATAAGAGTATA TAAAACCTAACAACCCAAAAACTAC 
 
 
2.1.11 Primers used for ChIP analysis of miR-375 locus 
Primer Forward primer (5'→3')  Reverse primer (5'→3') 
CHIP-1 GGATGAGGGGAGTCGAATG 
 
CAAAAAGTCCCAGGTAGGCG 
 
CHIP-2 TCTTCCAGGAGTCTGACCC AGTGTGGGCGGAGAGGTG 
CHIP-3 TGGACAGGTGTGAGTGTGTG GTCGCCCTCGGTGATCTC 
CHIP-4 GCCCTCCGCTCCCGCC GGTTTCCACCTCCAGAAGG 
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2.1.12 Primers used for isolation of miR-375 target sites 
Primer Sequence (5'→3')  
RASD1_forward CACACTAGTGGACCTTTTTGTTAAGTC
 RASD1_reverse CACAAGCTTTTAAAGACCTCAGACAC
 EBF3_forward CACACTAGTGCTTTTCCCACCTTTTCC
 EBF3_reverse CACAAGCTTTTTAGGCCTCTGAATTTT
 
2.1.13 Cell lines 
Cell lines Cellular origin Tumorigenic ERα Source 
HEK293T  Embryonic kidney Yes N/A ATCC (CRL-1573) 
MCF7 Breast Yes + ATCC (HTB-22) 
T47D Breast Yes + Prof. Peter Altevogt, DKFZ 
SK-BR3 Breast Yes - Prof. Peter Altevogt, DKFZ 
MDA-MB-435 Breast Yes - Prof. Peter Altevogt, DKFZ 
MDA-MB-231 Breast Yes - Prof. Peter Altevogt, DKFZ 
HDQ-P1 Breast Yes - Prof. Peter Altevogt, DKFZ 
MCF-10A Breast No - Prof. Annemarie Poustka, DKFZ 
MCF-12A Breast No - Prof. Annemarie Poustka, DKFZ 
MELN Breast N/A + Prof. Doris Mayer, DKFZ 
2.2 Methods 
2.2.1 General molecular biology methods 
2.2.1.1 Transformation in competent bacteria  
One Shot® TOP10 chemically competent E.coli DH10B (Invitrogen) were used to amplify 
plasmid DNA. 50μl of electro-competent E.coli were thawed on ice, mixed with the 
complete ligation reaction and incubated on ice for 30 minutes. Thereafter, the bacteria 
were shifted to 42°C for 30 seconds and briefly equilibrated on ice. 250-300μl of SOC 
medium was then added and cells were incubated for 1 h at 37°C with shaking (200 rpm). 
The suspension was plated onto LB-agar plates containing the respective antibiotic (100 
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mg/ml ) and incubated overnight at 37°C. In order to propagate the cultures, either single 
colonies were picked or frozen glycerol stocks were thawed and inoculated into 10ml LB 
medium with antibiotic, and shaken overnight at 37°C. For storage of bacteria, a bacterial 
culture was grown in culture medium to an OD of 0.8 (measured at 600nm). Thereafter, 
500µl of the bacterial culture was combined together with 500µl glycerol and subsequently 
frozen at –80°C. 
2.2.1.2 Mini-preparation of plasmid DNA 
E.coli containing the plasmid of interest was inoculated in 8ml LB medium, including the 
appropriate antibiotics (100 mg/ml) and grown overnight at 37°C in a shaking incubator 
(200 rpm). Plasmid DNA was extracted using the Qiagen Plasmid Mini Kit. First, the 
bacteria was  harvested by centrifugation for 15 minutes at 3500 rpm and re-suspended in 
250μl buffer P1 containing 0.1 mg/ml RNase A. Thereafter, 250μl of lysis buffer P2 was 
added and the tube inverted gently 4–6 times. 350μl neutralization buffer N3 was then 
added to the tube and mixed again by inversion. The resulting lysate was centrifuged for 10 
minutes at maximum speed in a tabletop microcentrifuge (13,000 rpm). The supernatant 
from this centrifugation was added to a QIAprep spin column placed in a 2ml collection 
tube and centrifuged for one minute at 13,000 rpm. The flow-through was discarded and the 
column bound plasmid DNA was washed using 500μl of buffer PB, followed by 
centrifuging for one minute (13,000 rpm). After discarding the flow-through, the column 
was washed with 750μl of PE-buffer, followed by centrifuging for 1 minute (13,000 rpm). 
Thereafter, the column was placed into a clean 1.5ml microcentrifuge tube, 50µl of water 
was added and incubated at room temperature for one minute. The DNA was then eluted by 
centrifugation for 1 minute (13,000 rpm). Quantification of the DNA samples were carried 
out on a Nanodrop spectrophotomer using the DNA measurement setting. 
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2.2.1.3 DNA isolation and quality assessment 
To isolate DNA from powdered tissue samples or cells, the DNeasy Blood & Tissue kit 
(Qiagen) was used according to the manufacture provided by company; 180µl ATL buffer 
was added to an eppendorf tube containing 20mg of powdered tissue sample or cell pellet 
(cells had been harvested by trypsinization after washing with PBS). Then, 20µl of 
proteinase K was added to the tube and contents were mixed by vortexing. The mixture was 
incubated at 56°C overnight on a shacking thermomixer. Subsequently, 200µl of buffer AL 
was added to the sample and mixed by vortexing. Afterwards, 200µl of ethanol (100%) was 
added and mixed by vortexing. The mixture was transferred into a DNeasy Mini spin 
column placed in a 2ml collection tube and centrifuged for one minute at 13,000 rpm. The 
column was placed in a new collection tube and washed first with 500µl AW1 buffer and 
then with 500µl AW2 buffer. The column was dried by centrifugation at 13000 rpm for 2 
minutes. Finally DNA was eluted in 200µl of AE buffer. The isolated patient DNA was 
then checked for the quality by gel electrophoresis on a 1% agarose gel. The DNA with 
good quality was then subjected to bisulfite conversion. 
2.2.1.4 RNA isolation and quality assessment 
Total RNA was extracted from cultured cells or tissue samples using miRNesy kit 
(Qiagen). To isolate RNA from cultured cells, cells were washed with PBS, then 1ml 
QIAzol lysis reagent was added to each flask (appropriate amount of lysis solution was 
used when isolating RNA from wells of 6-well plates) and cells were scraped using a 
disposable cell scraper. For isolation RNA from tissue samples, 700µl of lysis reagent was 
added to 25mg powdered sample and mixture was homogenized by pumping using a sterile 
syringe. The lysate was incubated for 5 minutes at RT and was collected into 1.5ml 
eppendorf tube. Afterwards, 300μl chloroform was added. The mixture was mixed 
thoroughly and incubated for another 5 minutes at RT. Thereafter the cell lysate was 
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centrifuged for 15 minutes in a pre-cooled centrifuge at 4°C at 13,000 rpm. The aqueous 
phase was placed into a fresh tube and mixed with an equal volume of 70% ethanol, 
transferred to a RNeasy spin column and centrifuged for one minute at 13,000rpm. The 
flow-through was discarded and 700μl of wash buffer RW1 was added, and the 
centrifugation and flow through removal procedure repeated. The same procedure was 
repeated using 500μl RPE wash buffer. In the end, the RNeasy spin column was placed in a 
new collection tube and the RNA eluted in 50μl nuclease free water by centrifugation at 
13,000 rpm for one minute. Quantification of the RNA sample was carried out using the 
Nanodrop spectrophotomer using the RNA measurement settings (A260 / A280 ratio). 
2.2.1.5 Protein isolation  
For protein isolation, the M-PER mammalian lysis buffer (Pierce) was used. During the 
isolation, the cells/lysates were kept on ice. Medium was aspirated from the cells in one 
well of a 6-well plate. Cells were washed with 1ml ice-cold PBS containing 1mM Na4VO3 
and 10mM NaF. Then, 40µl of M-PER solution containing Complete Mini Protease 
Inhibitor Cocktail, PhosSTOP Phosphatase Inhibitor Cocktail, 1mM Na4VO3 and 10mM 
NaF was added to each well. Cells were detached in the presence of the lysis buffer using a 
cell scraper. Then, the plate was shacked gently for 10 min on ice. Lysates were then 
collected and transferred into to an eppendorf tube and were centrifuged for 5 minutes at 
13,000 rpm in a tabletop centrifuge at 4°C. The supernatant was collected in a new 
eppendorf tube and was stored at -80°C. 
2.2.1.6 Protein quantification (BCA Protein Quantification) 
Total protein concentration was measured using the Pierce BCA Protein Assay. The BCA 
assay is based on the reduction of Cu+2 to Cu+1 by protein in an alkaline medium followed 
by colorimetric detection of the cuprous cation using bicinchoninic acid (BCA).  
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BCA working reagent was prepared by mixing 50 parts of BCA Reagent A to 1 part of 
BCA Reagent B. 20μl of the BSA standards or samples were plated into single wells of a 
96 well microtiter plate well.  Thereafter, 100μl of BCA working reagent was added, the 
plate shaken for 30 seconds and then placed in a 37°C incubator for 30 minutes. The plate 
was then cooled to room temperature and the absorbance was read at 562nm. A standard 
curve of absorbance versus micrograms of standard protein was prepared, and the protein 
concentration of the samples was determined from this graph. 
2.2.1.7 Western blot analysis 
For 10% SDS-PAGE gel, 10% acrylamide/bisacrylamide in resolving buffer for the 
resolving part and 5% acrylamide in stacking buffer for the stacking part were prepared. 
0.06% (w/v) ammoniumpersulphate and 0.1% (v/v) N,N,N´,N´-tetramethylethylendiamine 
(TEMED) were added to the gel solution to induce polymerization. 5µg of the protein 
samples were boiled in Laemmli buffer (1:1) for 5 minutes and subsequently loaded onto 
the slots of the gel. In addition, a protein size maker was also included. Electrophoresis of 
the protein gel was applied for 45 minutes at 160V and 70mA. The electrophoretic transfer 
of polypeptides from the polyacrylamide (PAA) gel to a polyvinylidene floride (PVDF) 
membrane was performed by using a wet gel transfer apparatus. The PVDF membrane was 
briefly activated in 100% methanol and soaked for 5 minutes in Western blot buffer for 10 
minutes. The PAA gels were carefully removed from the electrophoresis chamber, the 
stacking gel was cut and the gel was soaked 3 minutes in Western blot buffer. The Western 
blot ‘sandwich’ was assembled and the transfer was carried out for 2h at 100V and 250mA 
in ice-cold Western blot buffer. For protein detection with antibodies, the membrane 
containing the separated polypeptides were placed in a tank and washed with washing 
buffer (15 minutes) followed by milk-blocking buffer for 1h at RT. After blocking, the 
membrane was incubated with diluted primary antibody over night at 4°C. After washing 
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(3×10 minutes), the membrane was incubated with the secondary antibody conjugated with 
horse radish peroxidase for 1h at RT. After a further set of membrane washings (3×10 
minutes), the blots were ready for enhanced chemiluminescence (ECL) protein detection 
(ECL Western Blot Detection Kit). The ECL substrate was prepared and the blot incubated 
with the solution for 1 minute in the dark at RT. The solution was then drained off, the 
membrane placed in a plastic foil to prevent drying, placed in an X-ray cassette and 
exposed to ECL film (Hyperfilm-ECL™). The exposure time of the film was between 10 
seconds and 5 minutes. 
2.2.1.8 DNA Sequencing  
An aliquot of 30µl containing 30-100ng/µl plasmid DNA was sent to GATC Biotech AG 
for DNA sequencing. 
2.2.1.9 cDNA synthesis 
Reverse transcription (RT) is the transcription of RNA into single strand complementary 
DNA (cDNA). For the RT reaction, in a final volume of 20μl, 1μg of total RNA (in 8μl 
RNase-free water) was used together with 2μl of 5× 1st strand buffer (250 mM Tris-HCl, 
pH 8.3, 375 mM KCl, 15 mM MgCl2) and 1μl (10 units) DNaseI, and incubated for 20 
minutes at RT to allow digestion of genomic DNA. Thereafter, 3μl of Master Mix1, which 
contained equal parts of 25 mM EDTA, dNTP mix (10 mM dNTPs each), and 300ng/μl 
random hexamer primers, was added to the mix and incubated in a thermocycler, first for 
10 minutes at 65°C and then for 10 minutes at 25°C. This step removed secondary 
structures; heat inactivated the DNaseI and allowed the annealing of primers to the RNA. 
5μl of Master Mix 2 containing 5× 1st strand buffer, 0.1 M DTT and nuclease free water at 
a ratio of 2:2:1 was then added. The mixture was incubated initially at 42°C for 2 minutes, 
then 1μl of reverse transcriptase and 0.2μl of T4 gene P32 protein were added to the 
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mixture and further incubated for 50 minutes at 42°C. Thereafter, the reaction was heat 
inactivated for 10 minutes at 95°C. 
2.2.1.10 Quantitative PCR primer design 
PCR primers for quantitative real-time (qRT)-PCR experiments were provided by Qiagen 
company as pre-designed primers or designed with the primer design tool from Roche 
Applied Science: ‘Universal probe library’ (https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000). Intron spanning primers were chosen in 
order to distinguish between contaminating genomic DNA amplicons, and those resulting 
from amplification of the correct cDNA template (primer information are provided in 
section 2.1.8). 
2.2.1.11 Real-time PCR analysis 
The PCR reaction mixture consisted of 6μl SYBR Green PCR mixture, 100nM forward and 
reverse primers and 2μl cDNA template in a reaction volume of 12μl. A standard curve 
consisting of a dilution series of the cDNA produced from Stratagene Universal Human 
Reference RNA (1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128) was used to determine the 
efficiency of the PCR reaction. To quantify cDNA templates obtained from RNA samples, 
real-time PCR was performed in a 7900 HT Fast Real-Time PCR System (Applied 
Biosystems) with the following settings: 2 minutes at 50°C, 95°C for 15 minutes , then 40 
cycles of 15 seconds at 95°C and 1 minute at 60°C. Final steps comprised 15 seconds at 
95°C, 15 seconds of 60°C and 15 seconds at 95°C. The heating ramp between the last two 
steps was increased to 20 minutes to obtain a melting curve of the final qRT-PCR products. 
This was necessary because SYBR Green fluorescence signals may also be derived from 
side products such as primer dimers. Calculation of efficiency and relative quantification 
was performed using the housekeeping genes lamin B1 (LMNB1) and Glyceraldehyde 3-
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phosphate dehydrogenase (GAPDH) as reference. Individual samples were measured in 
triplicate to ensure reliability. 
2.2.1.12 Quantitative real-time PCR for miR-375 
Quantification of mature miR-375 expression was performed using a miR-375 TaqMan 
MicroRNA Assay which provided specific primers for reverse transcription (RT) of 
miRNA and primers for real-time PCR (Applied Biosystems). 20ng and 50ng of total RNA 
isolated from cell lines and patient samples, respectively, were reverse transcribed with 
sequence specific primers by using a TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems). First, a master mix was prepared for each reaction including 
following materials; 0.15µl dNTPs (100mM), 1µl MultiScribe Reverse Transcriptase (50 
U/µl), 1.5µl 10×RT buffer, 0.19µl RNase Inhibitor (20U/µl ), 4.16µl Nuclease free water, 
3µl RT primer. Then the above mentioned RNA amount in volume of 5µl was added to the 
prepared mix. Then the reaction was inclubated in a thermalcycler at 16°C for 30 minutes, 
then 42°C for 30 minutes followed by 5 minutes at 85°C to complete the RT procedure.  
Real-time PCR was performed in triplicate in a 384-well plate on a 7900HT Fast Real-Time 
PCR System (Applied Biosystems). Reaction consisted of 10µl 2×Universal Master Mix 
(Applied Biosystems), 1µl miR-375 real-time primers, 7µl RNase-free water. 2µl of the 
cDNA prepared in the RT reaction was added to this master mix in each well. Instrument 
setting was as follow; 2 minutes at 50°C, 95°C for 15 minutes, then 45 cycles of 15 seconds 
at 95°C and 1 minute at 60°C. The average expression of RNU6B and RNU66 was used for 
normalization. 
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2.2.2 Processing of tissue samples for DNA/RNA 
isolation 
Frozen surgical breast tissue samples were obtained with informed consent of patients after 
approval of the Institutional Review Board at Tehran University of Medical Sciences, 
Shahid Beheshti University of Medical Sciences and University of Welfare Sciences and 
Rehabilitation, Tehran, Iran and Odessa State Medical University, Odessa Ukraine. 
Samples were stored in –80ºC freezer until processed. They included tumors, farthest 
available normal tissue from tumors for some of the patients, benign samples and normal 
breast tissue samples from healthy individuals. Clinical annotations of the samples are 
presented in Supplementary table S1. Tissue samples were powdered using a tissue 
dismembrator (Micro Dismembrator from B.Braun Biotech International). Each sample 
was taken each time in an eppendorf tube (from –80ºC freezer) kept on dry ice. Perior to 
powdering, eppendorf tube containing the tissue sample was floated in liquid nitrogen (-
170ºC). Frozen tissue was immediately transferred into a dry Teflon shaking flask (obtained 
from Sartorius stedim biotech, and always stored in 4% Sodium Hypochlorite) along with a 
tungsten ball (obtained from Sartorius stedim biotech, and always stored in 4% 
Formaldehyde). The Teflon container was then covered with its lid and fixed to a tissue 
dismembrator which was subsequently vibrated at 3000rpm for 20 seconds. Afterwards, the 
Teflon container was taken off the dismembrator and dipped in liquid nitrogen. The 
powdered tissue was immediately transferred from the Teflon container into eppendorf 
tubes such that each tube accommodated up to 30mg of the powder. The eppendorf tubes 
were then floated in liquid nitrogen and stored at –80ºC until used for DNA or RNA 
extraction.  
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2.2.3 Selection of CGIs and designing PCR primers to 
isolate them from deaminated DNA 
Selection of CGIs was based on available literature. To find CGIs whose methylation 
patterns might be useful for breast cancer diagnosis, a review of available literature was 
conducted. Following this review 44 CGIs –associated with 35 protein coding genes- were 
selected (Table 1). The criteria applied for selection of the genes was as following;  
• Genes reported to become silenced by DNA hypermethylation in breast cancer. 
Most of these genes had been already recognized with tumor suppressor activities. 
• Genes found to be hypermethylated in other cancers and involved in growth-related 
pathways.  
• Genes down-regulated in breast cancer and associated with a CGI in vicinity of their 
transcription start sites. 
Table 1 Genes included in DNA methylation analysis. BC: Breast cancer; Dw-reg.: Down-
regulated 
 
Gene 
Methylation/Down-
regulation 
Reference Gene 
Methylation/Down-
regulation 
Reference 
14-3-3 sigma Methylated in BC (96) SFRP2 Methylated in BC (97) 
APC Methylated in BC (98) SFRP3 Methylated in others (99) 
BRCA1 Methylated in BC (37) SFRP4 Methylated in others - (100) 
C/EBP alpha Dw-reg. in BC (101) SFRP5 Methylated in BC (102) 
CCND2 Methylated in BC (103) WIF-1 Methylated in BC (104) 
CST6 Methylated in BC (105) HDPR1 Methylated in others - (106) 
CDH1 Methylated in BC (107) TCF4 Dw-reg. in BC (108) 
CDH13 Methylated in BC (109) PAK3 Methylated in BC (110) 
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ER Methylated in BC (111) OGDHL Methylated in BC (110) 
HIN-1 Methylated in BC (112) hMLH1 Methylated in BC (113) 
HOXA5 Methylated in BC (114) SOCS1 Methylated in BC (115) 
HPGD Methylated in BC (116) PTEN Methylated in BC (117) 
GSTP1 Methylated in BC (118) DAPK1 Methylated in BC (119) 
P53 Methylated in BC (120) HIC Methylated in BC (121) 
PGR Methylated in BC (122) GHSR Methylated in BC (123) 
RAR-b2 Methylated in BC (124) ARHI Methylated in BC (125) 
RASSF1A Methylated in BC (126) TWIST Methylated in BC (127) 
SFRP1 Methylated in BC (128)    
 
We extracted DNA sequence of a region spanning 2kb upstream and 2kb downstream of 
transcription start site of each gene from human genomic DNA sequences using Ensembl 
database (www.ensembl.org). The putative CGIs harboured within these sequences were 
identified by using CGI searcher (http://cpgislands.usc.edu) (129) and Methprimer 
(http://www.urogene.org/methprimer) (130) softwares and crosschecking with respective 
previous studies.  
Following bisulfite treatment, all cytosines are converted to uracils unless they are located 
in CpG dinucleotides and had already been methylated. Therefore, the sequence 
composition of DNA is different before and after bisulfite treatment. To design primer pairs 
that can be used for PCR-amplification of the selected CGIs from deaminated human DNA 
(DNA that is subjected to bisulfite treatment) we used Methprimer (130). This software 
creates a deaminated version of a given DNA sequence and then uses this version as a 
template for designing PCR primers. The criterion “Pick primers for bisulfite sequencing 
PCR” was chosen for all loci. This criterion avoids inclusion of CpG dinucleotides in the 
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primer sequences, thus preventing bias in PCR amplification that might happen due to the 
methylation status of the binding sites of primers. These primers are hereafter called SoBi 
primers and are listed in section 2.1.10. 
2.2.4 Preparation of the control samples  
The principle of performance of oligonucleotide microarrays is based on hybridization of 
the immobilized oligonucleotides (probes) with their complementary sequences available in 
the target template (target). A common feature of CGIs is their high GC-content which 
makes significant similarities between their sequence compositions. These similarities can 
lead to unspecific hybridization of target DNA samples to the probes which, in turn, 
necessitate the calibration of microarrays by control samples before the main screen (61). 
To evaluate the microarray performance and calibrate probes, we produced fully 
methylated and unmethylated versions of all selected CGIs (targets) in vitro to serve as 
control samples in calibration process.  
2.2.4.1 Isolation of CGIs from human genomic DNA by PCR 
The initial step in producing control samples was isolation of CGIs from genomic DNA by 
PCR. PCR primers were designed by primer3 software (http://frodo.wi.mit.edu/primer3/) 
(131) using ‘General Primer Picking Conditions’ of the software and were ordered from a 
supplier (Invitorgen). These primers are referred to as genomic primers in this manuscript 
and can be found in section 2.1.9. Genomic primers of each CGI were designed such that 
their PCR product spanned the region amplified by SoBi primers of the respective CGI. To 
find the best annealing temperatures for primer pairs leading to amplification of the 
respective specific PCR products, a gradient of annealing temperatures between 50°C and 
62°C were applied in amplification process for each primer pair. The PCR products were 
checked on agarose gel and the appropriate annealing temperature was used for 
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amplification of each amplicon. In case of no amplification or non-specific PCR products in 
all annealing temperatures, a modified PCR protocol using Q-Solution reagent was used in 
gradient and final PCR procedures. Addition of Q-Solution to the PCR mixture was based 
on the fact that this reagent changes the melting behaviour of DNA and improves the PCR 
amplification of those regions that have a high degree of secondary structure or high GC-
content, which is the case for the majority of CGIs (15). The fully methylated and 
unmethylated versions of ARHI and GHSR CGIs were amplified from EpiTect control 
DNA set (Qiagen) using respective SoBi primers.  
2.2.4.2 Pools of control samples with different methylation levels 
At first step, fully methylated and completely unmethylated versions of all CGIs were 
prepared independently. After establishment of PCR conditions, CGIs were amplified by 
PCR from genomic DNA using genomic primers resulting in an unmethylated amplicon 
served as unmethylated control after purification. To produce 100% methylated controls, 
purified PCR products were treated with CpG Methyltransferase (M.SssI; New England 
Biolabs) in the presence of S-adenosylmethionine (SAM; New England Biolabs). M.SssI 
methylates all cytosine residues (C5) within the double-stranded dinucleotide recognition 
sequence 5'...CG...3'. (132). Methylation reactions were prepared according to the Table 2 
and were incubated at 37°C for 3 hours followed by 20 minutes incubation at 65°C 
(enzyme inactivation).  
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Table 2. Components of Methylation reaction 
Components Volume (µl)
DNA (1µg) #
SAM (3.2 mM) 12,5
Buffer 21 5
MSss12 2
ddH2O *
Final volume 50
#calculated for 1µg
1Buffer 2: 10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 
1 mM Dithiothreitol, pH 7.9 @ 25°C 
2Sss1 methylase (CpG methylase)
*added to final volume of 50µl
 
The methylation status of the prepared control samples was then examined by incubating 
them with BstUI restriction endonuclease (New England Biolabs) at 60°C for 2 hours 
(Table 3) and subsequent analysis of digestion results by gel electrophoresis. BstUI 
recognizes and cuts “CG/CG” sequence -which is frequently found in CGIs- only if the 
cytosines are not methylated. Therefore, we expect to observe an undigested DNA band and 
completely digested DNA fragments for unmethylated and fully methylated control 
samples, respectively.  
Table 3. Components of BstUI digestion reaction 
Components Volume (µl)
DNA (200ng) *
Buffer 2 2
Bst UI (10 units/µl) 2
ddH2O #
Final volume 20
#added to total volume of 20µl
*calculated for 200ng
 
After validation of expected methylation levels for in vitro prepared control samples (CGIs 
isolated from human genome using genomic primers), they were subjected to bisulfite 
treatment as will be described in 2.2.5.1-2 sections. Then, each locus was PCR-amplified 
Materials and Methods  
43 
 
from corresponding fully methylated and unmethylated control samples – that had been 
treated by bisulfite - using SoBi primers. Thereafter, these amplicons were column- purified 
using Qiagen PCR purification kit and were quantified by Nanodrop. Thus, we produced 
two control bisulfite-treated samples for each CGI representing its 100% and 0% 
methylation levels. A pool of 0% methylated amplicons was produced by mixing same 
amount of all unmethylated amplicons together. Same strategy was followed to create a 
100% methylation control by pooling fully methylated amplicons. In addition, using 
individual control samples, additional control pools corresponding to 33% methylation 
(33ng of each methylated amplicons + 66ng of each unmethylated amplicons) and 50% 
methylation (50 ng of each methylated amplicons + 50 ng of each unmethylated amplicons) 
and 66% methylation (66ng of each methylated amplicons + 33ng of each unmethylated 
amplicons) were prepared. These control pools were subsequently used for calibration and 
filtration of probes and monitoring the performance of microarrays. 
2.2.5 Sodium bisulfite treatment of DNA samples 
The control amplicons containing methylated and unmethylated CGIs as well as DNA 
samples isolated from the patient tissue specimens were subjected to bisulfite conversion. 
By treating DNA with sodium bisulfite, one can make use of selective conversion of 
unmethylated cytosines to uracils by this treatment. The bisulfite treated DNA when used 
as a template for PCR amplification, the uracils in the template will be subsequently 
replaced by thymine in the amplified product.  
2.2.5.1 Deamination of DNA by bisulfite 
The treatment of DNA samples was performed using EpiTect Bisulfite Kit (Qiagen) which 
provides a relatively fast 6-hour procedure for efficient DNA deamination and purification. 
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The reaction mixtures were prepared according to table 4 and were incubated in the 
thermocycler with thermal program presented in table 5.  
Table 4. Reaction contents in Bisulfite treatment of DNA 
Component Volume per reaction (µl)
DNA solution (1µg) Variable*
Rnase-free water Variable*
Bisulfite Mix 85
DNA Protect Buffer 35
Total Volume 140
*The combined volume of DNA and Rnase-free water must total 20µl  
Table 5. Incubation prolife of bisulfite treatment reaction 
Step Time Temperature
Denaturation 5 min 99°C
Incubation 25 min 60°C
Denaturation 5 min 99°C
Incubation 85 min 60°C
Denaturation 5 min 99°C
Incubation 175 min 60°C
Hold Indefinite* 20°C  
2.2.5.2 Purification of deaminated DNA 
The EpiTect kit provides necessary materials to clean up the DNA after bisulfite treatment. 
Briefly, 560µl freshly prepared buffer BL containing 10µg/ml carrier RNA was added to 
each converted sample and was mixed. The whole mixture was then transferred to an 
EpiTect spin column and was centrifuged at maximum speed for one minute. The flow-
through was removed and column (containing the DNA) was washed with 500µl buffer 
BW (wash buffer). After removing flow-through, 500µl buffer BD (desulfonation buffer) 
was added to the column and column was incubated for 15 minutes at room temperature, 
and then was centrifuged. Flow-through was discarded and column was washed twice with 
500µl buffer BW. Column was then placed into a new collection tube and was centrifuged 
for 2 minutes to remove any residual liquid. Subsequently, DNA was eluted from column in 
60µl of elution buffer (10mM Tris-HCL, pH: 8.5) and stored in -20°C. All centrifugation 
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steps were carried out at 13000 rpm and room temperature for 1 minute unless otherwise 
mentioned.  
2.2.6 Isolation of selected CGIs from patients DNA 
DNA isolated from each patient sample was bisulfite treated and was used as a template to 
PCR-amplify all the 44 CGIs (amplicons) pertaining to the 35 pre-selected genes using 
SoBi primers. Considering the variations between the annealing temperatures of primers 
related to different CGIs, a PCR program combined of touchdown and gradient PCR 
procedures was established such that all the 44 amplicons could be amplified at once. 
Amplification program included activation of Hotstar Taq DNA polymerase at 95ºC for 15 
minutes, denaturation at 95ºC for 1 minute, annealing at 65ºC for 2 minutes. This process is 
continued for 7 cycles going down with the annealing temperature by 1ºC in every cycle. 
This touchdown amplification was followed by a gradient PCR program consisting of 
denaturing at 95ºC for 40 seconds, annealing temperature ranging from 48ºC – 62ºC for 30 
seconds and 30 seconds with 72ºC elongation temperatures for 38 cycles. The reactions 
were carried out using a gradient thermocycler (MJ Research, PTC-200, Peltier thermal 
cycler) in 200µl PCR tubes (Thermo Scientific). All the reactions carried out were 50µl 
PCR reactions in 96 well plates. 2µl converted DNA was loaded in each well and PCR 
mastermix comprised of dNTPs (Fermentas Life Sciences), PCR water (Aqua ad 
iniectabilia, Braun), Hotstar Taq DNA polymerase and PCR buffer (Qiagen) was added to 
the wells. The primers were then added individually to each reaction. The amounts of 
material and reagents used in PCR amplification are summarized in table 6. PCR products 
were then examined on 1% agarose gel.  
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Table 6. Reaction contents used for PCR amplification of CGIs from patients’ samples 
10x PCR buffer
Components Volume (µl)
5
ddH2O 33.7
dNTPs (2.5 mM each) 4
Forward primer (10 µM) 2.5
Reverse primer (10 µM) 2.5
HotstarTaq Polymerase 0,3
Total 49  
Following evaluation of amplification of the selected CGIs, the amplicons were purified 
using 96 well format purification plates (Millipore 96 PCR purification plate) and vacuum 
manifold. The concentrations of the purified PCR products, was measured using a 
Nanodrop device (ND-1000 spectrophotometer, Peqlab, Biotechnologie GmbH). 
Approximately 10ng of each purified amplicon was pooled with other amplicons in a clean 
1.5ml eppendorf tube. The pool of all amplicons of each patient was used as a template for 
labeling. 
2.2.7 Labeling of DNA by random priming 
To label the DNA for microarray experiments, random priming in the presence of 
biotinylated uracil was used. The DNA that is to be labeled is denatured by heating and to 
this denatured DNA, hexamer mix (mixture of short oligonucleotide of 6 nucleotide long) is 
added. The hexamers bind randomly to the single stranded DNA and the region between 
two hexamers is then synthesized by the polymerase enzyme used. During this process, the 
biotinylated nucleotides will be incorporated into the newly synthesized DNA. Following 
hybridization, this DNA can be detected using fluorescently labeled molecules that have a 
high affinity for biotin, like Streptavidin. The polymerase used for this process was Klenow 
Fragment. This enzyme is an N-terminal truncation of DNA polymerase I which retains 
polymerase activity but has lost the exonuclease activites. 
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Before labeling, volume of the polled amplicons in the eppendorf tube was adjusted to 
26.4µl with DEPC water. The content from the 1.5ml eppendorf tube was transferred to a 
200µl PCR tube. The DNA was then incubated at 99ºC for 5 minutes in a thermocycler. In 
the mean time, a master mix consisting of Random Priming (RP) buffer (febit), dNTPs 
(Fermentas Life Sciences), biotinylated uracil (Biotin-16- dUTP, Roche Diagnostics 
GmbH), bovine serum albumin (BSA, Fermentas Life Sciences) and Klenow fragment 
(New England Biolabs) was prepared according to table 7. Following the denaturation of 
the pooled DNA, the tubes were immediately transferred onto ice. To this denatured DNA 
pool, 1.5µl of hexamers mix and 12.1µl of the previously prepared master mix were added. 
This mixture (40µl in volume) was then incubated at 37ºC for 3 hours in a thermocycler to 
facilitate the amplification of DNA template (mixture of all the amplicons). Reaction tubes 
were then incubated for 10 minutes in another thermocycler which was pre-heated to 75ºC 
to deactivate the polymerase (Klenow fragment).  
Table 7. Reaction contents used together with hexamers in random priming procedure 
Component Volume (µl)
RP buffer (5x) 8
dNTPs* 1
BSA solution (10 mg/ml) 1.6
Klenow fragment (5 U/µl) 1.5
Final volume 12.1
*dNTPs mixture consists of dATP, dCTP, dGTP (each 2 mM),
dTTP (1.3 mM) and biotinylated dUTP (0.7 mM).  
Afterwards, the reaction mixture was transferred to a 1.5ml eppendorf tube. To precipitate 
the DNA, 4µl of sodium acetate (3M, pH: 5.6) along with 100µl of 100% ethanol (pre-
cooled at -20ºC) were added to the mixture and the tube was stored at -20ºC overnight or 
until the sample was used for hybridization. 
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2.2.8 Microarrays for DNA methylation analysis 
The first step in this study was to establish oligonucleotide microarrays capable of 
screening DNA methylation patterns of the pre-selected CGIs with the highest possible 
resolution (as many as possible CpGs of a CGI). To this aim, the Geniom One microarray 
technology of febit Company was used. This technology enables the user to design and 
synthesis the customised microarrays on Biochips provided by the company. In addition to 
the chip synthesis, washing and detection procedures could also be performed within the 
same device.  
2.2.8.1 Designing microarrays 
Oligonucleotide probes were designed using MetPat software (febit). Probe sets were 
designed to analyze methylation status of all CpG dinucleotides within each CGI. 
Methylation of each CpG was assayed by two probes; one of which complementary to the 
unmethylated CpG (U; detecting TG) and the other one was matched to the methylated 
CpG (M; detecting CG). For chip evaluation experiments, probes were designed with 
different lengths of 17, 21 and 25 nucleotides. Each probe was designed such that the target 
C (of a CpG nucleotide) could be addressed by the nucleotide located at the central position 
of the probe. After probe design, list of probes for a given CGI was exported as a text file 
including the probes name and sequences and was stored for array design. The array design 
was performed by cumulating the probe sets of all CGIs (analysis probes) and addition of 
control probes. The control probes acted as positive controls for the occurrence of synthesis 
and hybridization or represented entirely independent sequences, which indicated the 
background signal of unspecific binding. Each array could accommodate 6676 probes 
including 280 probes as positive and 80 probes as negative controls, thus providing 
capacity for 6316 analysis probes. As analysis probe set was synthesized at least three times 
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(replicates) on each array, up to 2104 different analysis probes could be synthesized on 
each array. Array design was loaded into database of the Geniom One system. 
2.2.8.2 Generation of microarrays 
Oligonucleotide arrays were generated by photo-controlled in situ synthesis within the 
Geniom device on an activated three-dimensional reaction carrier consisting of a glass-
silicon-glass sandwich (biochip) provided by febit. The synthesis procedures and conditions 
had been already established in the device (133, 134). Each biochip consists of eight 
individually accessible micro-channels, each of which is referred to as array in this 
manuscript. The arrays are connected to the micro-fluidic system of the geniom device. 
Oligonucleotides can be synthesized in parallel in all eight arrays of one biochip. 
Prior to synthesis, the glass surface is activated by coating with a spacer. Then, arrays are 
filled with the four nucleoside phosphoramidite monomers dA, dT, dC and dG, 
sequentially. Phosphoramidite is a phosphite that has a NR2 group (R: isopropyl) instead of 
OH group. The phosphoramidites are protected by the photolabile 2-(2-nitrophenyl)-
propoxycarbonyl (NPPOC) group (Fig. 8). Due to the presence of this group, the binding of 
next phosphoramidite to the 5' end of previously added one is prevented. In each cycle, 
only distinct areas (spots) to which next phosphoramidite should be added are illuminated. 
Upon excitation, the photoprotecting groups of the already existing, partial oligonucleotide 
sequences at these locations, synthesized earlier during the process, are removed and the 
oligomers are extended by another phosphoramidite after adding the relevant monomer 
(Fig. 9). There is also another protective group, phenoxyacetyl (Pac), which protects amino 
groups of the bases with NH2 groups (Fig. 8). This group is removed at the end of synthesis.  
All materials and reagents necessary for synthesis were provided by febit in individual 
bottles and were loaded in special places within the Geniom instrument before starting the 
synthesis procedure (Fig. 10).  
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Figure 8 Photolabile protecting group attached to phosporamidite. NPPOC is highlighted with 
gray background (Adapted from Beier & Hoheisel (133)). 
 
 
Figure 9- Photo-controlled in situ synthesis within the Geniom device. According to the array 
design, micromirror system of the device directs light to activate the specific spots to which amidites 
should bind (Provided by febit). 
Upon loading the instrument with chemical sets, the synthesis module of the Geniom is 
activated through Geniom software and array design (already transferred to the Geniom 
database) is selected as the template for oligo synthesis. Geniom software controls oligo-
synthesis steps and dictates the movement of Digital Micromirror Device (DMD) according 
to the array design. The cyclic process of DNA synthesis steps (photo-activation, flow of 
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amidites and reagents to the arrays) continues until all oligos are produced. After 
completion of probe production, the synthesized chip can be stored at 4°C until hybridized. 
2.2.8.3 Array hybridization and post-processing 
The random primed DNA precipitated at -20ºC was taken out and centrifuged at 15300 rpm 
and 4ºC for 20 minutes. The supernatant was removed and the DNA pellet was air-dried. 
The pellet was then dissolved in 3.75µl DEPC-treated water and 11.25µl of hybridization 
mixture (provided by febit). All the CGIs amplified from one patient DNA were hybridized 
to one array of a biochip following pooling and labeling.  
Before hybridization, synthesized chip was imported into the machine and washed with 
water at 25°C for 15 minutes. This step is to take care that all the probes are straightened 
and not collapsed. Hybridization was carried out outside the geniom machine in an external 
hybridization holder (febit). Initially a 15µl pre-hybridisation buffer (provided by febit) was 
filled into each array and the chip was incubated for 15 minutes at room temperature. 
Meanwhile, the labeled DNA dissolved in hybridization mixture was incubated at 99ºC for 
5 minutes (for denaturation) and then was kept on ice until loaded into the arrays. Then, 
pre-hybridization buffer was removed from the arrays and the labeled DNA samples were 
filled into the arrays and the chip was incubated at 45ºC for 16 hours in a hybridization 
chamber (febit). Following the incubation, target DNA samples were removed from the 
chip and the chip was imported into the geniom machine where further washing of the chip 
and detection were carried out. 
To detect the hybridization, the high affinity of streptavidin for biotin (incorporated in the 
form of biotinylated uracil during random priming procedure) by using the fluorescently 
labeled streptavidin SAPE, was exploited. SAPE (streptavidin, R-phycoerythrin conjugate, 
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Figure 10. Geniom One instrument. (A) Front view. (B) Biochip consisting of 8 arrays. (C) Different 
parts of the Geniom machine. 
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molecular probes, invitrogen detection technologies) solution was prepared by mixing 44µl 
of SAPE (1mg/ml) with 9ml of 6× SSPE buffer and was loaded into the geniom instrument. 
Likewise, the machine was supplied with washing buffers (6× SSPE and 0.5× SSPE). The 
arrays were first washed with the stringent 0.5× SSPE buffer (prepared from the 20× SSPE 
buffer, Sigma) (four times; 5 seconds flow, 30 seconds hold) at 45ºC. Then the arrays were 
filled with SAPE solution and incubated for 15 minutes at 25ºC. Afterwards, washing with 
non-stringent 6× SSPE buffer was performed at 25ºC (four times; 5 seconds flow, 30 
seconds hold). Finally hybridization signals were detected by charge coupled device (CCD) 
camera system of the geniom using a Cy3 filter. The exposure time for signal detection was 
calculated automatically by the device based on strength of signals of all spot on the chip 
providing informative data for vast majority of the spots while avoiding the occurrence of 
saturation of strong signals (Maximum intensity = 65000). An image of the chip was 
created and saved by the detection system. This image was first inspected for successful 
occurrence of probe synthesis and hybridization by verifying the signals from analysis and 
control probes in different positions of all arrays (Fig. 11). The image was then analyzed by 
the detection system of the device for calculating signal intensities of all spots. The primary 
data consisting of intensity values of individual spots were generated by the detection 
module of the instrument and saved in the database of geniom.  
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Figure 11. Image taken from a biochip after detection. Controls and a pair of spots related to 
one CpG site, as an example, are shown.  
 
2.2.9 Data analysis 
The signal intensity values measured by the detection module of the geniom machine were 
used as raw data to analyze the DNA methylation patterns. The data were first exported 
from geniom database in format of text files consisting of all probe names and median 
signal intensity of each probe. This data were then process using Microsoft Excel. At the 
first step, 2% of the lowest signal intensities from each array were taken and their mean was 
considered as the background signal. This value was subtracted from all the signals of this 
array to avoid the false positive signals. Then a normalized local methylation index (MI) 
was defined for each CpG by dividing the signal intensity value of its methylated probe (M) 
to sum of intensity values of its methylated (M) and adjacent unmethylated (U) probes 
(MI=M/M+U). Since probe pairs (M and U of each CpG) had been synthesized in triplicate 
in different positions of each array, three local MIs were defined for each CpG. The MI of 
each CpG was calculated as the average of the its three local MIs and considered as 
methylation level of that CpG in the hybridized DNA sample. These normalized data were 
next used for evaluating array performance or identification of methylation signature. 
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Probe selection was carried out following calibration of probes based on hybridization of 
arrays with pools of control samples. Only the probes that could show an appropriate 
discriminative power between different methylation levels of control samples were 
considered for further analyses. The methylation indices shown by these probes from each 
of the patients sample were put together. This combined data set was then used for 
identification of diagnostic methylation signature. Data analysis towards the identification 
of the methylation signature was performed in collaboration with Amin Moghaddas 
Gholami from the Division of Functional Genome Analysis, DKFZ. To identify 
differentially methylated CpGs between tumors and control samples, datasets were 
analyzed with the M-CHiPS (Multi-Conditional Hybridization Intensity Processing System) 
software (135).  The data were used to compute p-values via the limma package (136). The 
limma package uses an approach called linear models to analyze designed microarray 
experiments. This approach allows very general experiments to be analyzed as a simple 
replicated experiment. It requires one or two matrices to be specified. The first is the design 
matrix which indicates which samples have been applied to each array. The second is the 
contrast matrix which specifies which comparisons of interest between the samples. For 
very simple experiments, there is no need to specify the contrast matrix. The approach 
starts by fitting a linear model data which fully models the systematic part of the data. The 
model is specified by the design matrix. Each row of the design matrix corresponds to an 
array in the experiment and each column corresponds to a coefficient which is used to 
describe the samples in the experiment. Consequently there would be as many coefficients 
as samples in the experiment, thus any set of independent coefficients will describe all 
treatments. The main purpose of this step is to estimate the variability in the data; hence the 
systematic part needs to be modeled so it can be distinguished from random variation. 
In limma, systematic methylation effect for each gene is described by a linear model using 
a design matrix and a gene-specific vector of regression coefficients. A complete pairwise-
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comparisons contrast matrix was set up to test differential methylation across all samples. 
In limma, the regression coefficients represent comparison of interest between samples in 
the experiment. These coefficients are estimated using a least squares linear model fitting 
procedure and tested for differential methylation with moderated Student’s t-statistic via the 
empirical Bayesian statistics described in the limma package. P-values computed for the F-
statistic (136) were adjusted for multiple testing to control the False Discovery Rate (FDR) 
at 5% (137). The adjusted p-values can serve to accept or reject the null-hypothesis based 
on a significance level. 
2.2.10 Bisulfite-sequencing  
Bisulfite sequencing was applied to verify the methylation patterns of interesting candidate 
genes in more details. This procedure included different steps of ligation of the PCR 
product to the vector, transformation of competent bacteria with the vector, bacteria culture, 
colony picking and finally the plasmid preparation and sequencing. 
2.2.10.1 Ligation of amplicons and transformation in competent bacteria 
The ligation reaction and transformation were done according to the protocol of TOPO TA 
Cloning Kit for Sequencing (Invitrogen). This kit provides a highly efficient, 5 minutes, 
one-step cloning strategy for direct insertion of Taq polymerase-amplified PCR products 
into a vector for sequencing. The plasmid vector is supplied linearized with single 
3´deoxythymidine overhangs and a Topoisomerase which is covalently bound to the vector. 
The Taq polymerase has a non-template-dependent terminal transferase activity which adds 
a single deoxyadenosine to the 3´end of PCR products. Together with the overhanging 
3´deoxythymidine residue of the vector the ligation of the PCR products is performed. 
The PCR product was ligated into the pCR4 TOPO vector (Invitrogen). For ligation 
reaction the components described in table 8 were mixed together in a 200µl PCR tube. 
Materials and Methods  
57 
 
Table 8. Contents of TOPO cloning reaction 
Component Volume (µl)
Fresh PCR product 4
Salt solution 1
TOPO vector 1
Final volume 6  
The reaction was mixed gently and incubated for 5 minutes at room temperature. 
Transformation of bacteria and purification of plasmid were performed as described in 
section 2.2.1.1.  
2.2.11 Cell culture  
2.2.11.1 Maintenance of cells 
Cell lines were maintained at 37°C and 5% CO2 in the following media: HEK293T, MCF7, 
T47D, SKBR3, MDA-MB 231, MDA-MB-435 and HDQ-P1 in DMEM with 4.5g/L D-
glucose (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 100 
units/mL penicillin (Invitrogen) and 100μg/mL streptomycin (Invitrogen). MCF-10A and 
MCF-12A in Mammary Epithelial Cell Growth medium (Provitro) supplemented with 
10ng/mL human recombinant Epithelial Growth Factor, 0.5μg/mL hydrocortisone, 5μg/mL 
insulin, 52μg/mL bovine pituitary extract (all supplements from Provitro), 100units/mL 
penicillin (Invitrogen) and 100μg/mL streptomycin (Invitrogen). All cells were passaged 
every 2-3 days cells and diluted 1:4 in fresh medium. Before experimental use, MCF7 and 
MELN (138) cells were grown for 96 h in phenol red-free DMEM with 4.5g/L D-glucose 
(Invitrogen) supplemented with 10% dextran-coated charcoal-treated (DCC)-FBS 
(Invitrogen). Before hormonal treatment with 10nM E2 (Sigma), serum-free medium was 
added to the cells for 24 hours and cells were kept in this medium until the end of the 
experiment. 
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2.2.11.2 Transfection of cells 
Chemical transient transfections using Effectene transfection reagent (Qiagen) for 
transfecting DNA molecules or siPORT™ NeoFX™ (Ambion) for transfecting RNA 
molecules were performed in 24 or 96 well plates. Effectene-based transfections were 
carried out in 24 well plates using 4×104 cells per well and 100ng/well plasmid DNA in a 
final volume of 400μl culture medium. Ectopic expression was performed for RASD1 using 
a pc-myc-CMV-D12 expression vector containing RASD1 open reading frame (ORF). 
Reverse transfection using siPORT™ NeoFX involves the simultaneous transfecting and 
plating of cells. siPORT™ NeoFX transfection agent and RNA molecules are mixed, 
incubated, distributed to culture wells, and overlaid with cells. Transfection complexes are 
active and stable in the presence of serum, therefore, in the absence of a cellular stress 
response, there is no need to remove or replace media after transfection. In the this study, 
siPORT™ NeoFX™-based transfections were carried out in either 96 well plate using 
6×103 cells per well in a final volume of 100μl culture medium or 24 well plate using 4×104 
cells per well in a final volume of 500μl culture medium and final concentration of 50nM 
RNA molecules. 
2.2.11.3 Decitabine treatment  
Decitabine is a compound that can induce hypomethylation by inhibiting DNMTs (21). One 
million cells were seeded in 75cm2 cell culture flask in appropriate medium. After 24 hours, 
medium was replaced with fresh medium alone or medium containing 0.5µM decitabine. 
Following 72 hours incubation, DNA and total RNA were isolated from cells as described 
previously. 
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2.2.12 Chromatin Immunoprecipitation (ChIP) assay 
ChIP-assays were performed by Achim Breiling from Division of Epigenetics as 
collaboration. All steps were carried out as described previously (139). In brief, cells were 
fixed in the cell culture dishes by adding fixation solution directly to the medium. Cells 
were fixed at room temperature for 10 minutes. Fixed cells were washed once with PBS, 
scratched of the plates and transferred into falcon tubes. Chromatin was then prepared and 
immunoprecipitated as described using antibodies specific for H3K9me2 (Abcam ab1220) 
and H3K4me2 (Upstate 07-030) acetylated H3 (Upstate 06-598) and H4 (Upstate 06-599), 
ZEB1 (Santa Cruz H-102, sc25388X), POLII (8WG16, Abcam ab817), CTCF (Abcam 
ab70303) and ERa (Santa Cruz HC-20, sc543X). Immunoprecipitates were eluted into 25µl 
of TE buffer (10 mM Tris-HCL pH 8, 1 mM EDTA) and one µl was analysed by real time 
PCR using ChIP primers (100nM final concentration, section 2.1.11) in a 10 µl PCR 
reaction consisting of 6µl Absolute QPCR SYBR Green Mix (Thermo Scientific) in Roche 
LightCycler 480. PCR conditions were similar to that explained before. Cycle threshold 
numbers for each amplification were measured with the LightCycler 480 software and 
enrichments were calculated as percentage of the input. 
2.2.13 Expression arrays 
2.2.13.1 Illumina mRNA expression array 
Three major expression profiling platforms (Affymetrix, Agilent, Illumina) are 
commercially available. In this study the Illumina platform for expression profiling has 
been used (service is available at core facility of DKFZ). Illumina’s BeadArray technology 
is based on 3µm silica beads that self assemble in microwells on either of two substrates: 
fiber optic bundles or planar silica slides. When randomly assembled on one of these two 
substrates, the beads have a uniform spacing of ~5.7µm. Each bead is covered with 
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hundreds of thousands of copies of a specific oligonucleotide representing one unique 
cDNA sequence that act as the capture sequences in the Illumina assay. Characteristics of 
the BeadArray technology are quality control of every single array and the high feature- 
redundancy (>20× average) providing high-confidence results. The BeadChip array format 
used by Illumina utilizes either 6, 8, or 12 different arrays on a glass slide, which are 
processed simultaneously. In the current study, we applied 6 arrays/chip, each representing 
> 48,000 probe sequences. 
2.2.13.1.1 cRNA synthesis, purification and labeling  
In this step, 250ng of total RNA was used for complementary DNA (cDNA) synthesis, 
followed by an amplification/labelling step (in vitro transcription) to synthesize biotin-
labeled cRNA according to the MessageAmp II aRNA Amplification kit (Ambion). Biotin-
16-UTP was purchased from Roche Applied Science. The cRNA was column-purified 
according to TotalPrep RNA Amplification Kit’s manual (Ambion) and eluted in 60μl of 
water. The quality of cRNA was controlled using the RNA Nano Chip Assay on an Agilent 
2100 Bioanalyzer and spectrophotometrically quantified using a NanoDrop 
spectrophotometer.  
2.2.13.1.2 Probe labeling and Illumina Sentrix BeadChip array hybridization 
Biotin-labelled cRNA samples for hybridization on Illumina Human Sentrix-6 BeadChip 
arrays (Illumina) were prepared according to the protocol of Illumina's recommended 
sample labeling procedure (140). Hybridization was performed at 58°C in GEX-HCB 
buffer (Illumina) at a concentration of 50ng cRNA/μl, unsealed in a wet chamber for 20 
hours. Spike-in controls for low, medium and highly abundant RNAs were added, as well 
as mismatch control and biotinylation control oligonucleotides. The microarrays were 
washed twice in E1BC buffer (Ambion) at room temperature for 5 minutes. After blocking 
Materials and Methods  
61 
 
for 5 minutes in 4ml of 1% (w/v) Blocker Casein in phosphate buffered saline Hammarsten 
grade (Pierce Biotechnology), array signals were developed by a 10-minutes incubation in 
2ml of 1μg/ml Cy3-streptavidin solution and 1% blocking solution. After a final wash in 
E1BC buffer, the arrays were dried and scanned. 
2.2.13.1.3 Scanning and data analysis 
Microarray scanning was done using a Beadstation array scanner, setting adjusted to a 
scaling factor of 1 and PMT settings at 430. Raw data extraction was performed using the 
Beadarray R package (svn release 1.7.0) from bioconductor (www.bioconductor.org). Then, 
outliers were removed when their expression value dropped below a threshold: the median 
+ *MAD (median absolute deviation) expression of all negative control beads. Individual 
bead types were also flagged as filtered when their bead replicate count dropped below 17. 
All data were then used for the mean expression value calculations within Beadarray. 
Finally, a bead type was discarded when the bead type’s filter flag was set across all 
samples. Data analysis was carried out by variance stabilizing and robust spline 
normalization of the remaining signals using the algorithms from the Lumi R package 
(release 1.1.0 from bioconductor). Subsequently, values of normal samples were subtracted 
from values of the tumors. Genes with positive and negative resulting values were 
considered as up- and down-regulated genes in tumors, respectively.  
2.2.13.2 Array-based miRNA profiling 
miRNA profiles were generated by using febit's Geniom Realtime Analyzer. The array 
contained 7 replicates of each human miRNA as annotated in the Sanger miRBase 11.0 
(141). Briefly, 3μg of total RNA containing small RNAs were labeled using the FlashTag 
RNA kit (Genisphere). Following overnight hybridization for 16 hours at 42°C, the biochip 
was washed automatically as indicated by the supplier and signal intensities were calculated 
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using the Geniom Wizard Software (febit). All further statistical analyses were provided by 
febit company using R. Following background correction, the seven replicate intensity 
values of each miRNA were summarized by their median value. To normalize the data of 
different arrays, the Variance Stabilizing Normalization (142) was applied by the R ‘vsn’ 
package, such that the miRNA profiles were homoscedastic. This normalization 
transformed the background subtracted raw data, ensuring that the variance was almost 
constant. Differentially expressed miRNAs between cell line models were identified by 
using the t test procedure within Significance Analysis of Microarrays (SAM) (143). 
2.2.14 Functional analysis 
2.2.14.1 Cell proliferation assay 
The CellTiter-Glo® Luminescent cell viability assay is a method of determining the number 
of viable cells in culture based on quantitation of the ATP present, an indicator of 
metabolically active cells representing the viability and proliferation of cells. The Cell Titer 
Glo Luminescent Cell Viability Assay was used to verify the viability of the transfected 
MCF7 cells in opaque-walled multiwell plates (Costar). 48 and 72 hours after transfection, 
100μl of CellTiter-Glo® Reagent (Promega) was added to each well of 96 well plates in 
order to measure the ATP content of the well. After 10 minutes incubation at RT, 
luminescent signals were measured using a luminometer. Each assay was performed in five 
replicates. An integration time of 0.25 second per read was applied. 
For cell counting, 72 hours post-transfection of cells in 6-well plates (3 × 105 cells per 
well), the cells were trypsinized and live cells were counted by a cell viability analyzer 
(Beckman Coulter). 
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2.2.14.2 Caspase activity measurement using the Caspase-Glo® 3/7assay  
The Caspase-Glo® 3/7 Assay (Promega) is a luminescent assay that measures caspase 
activity. The assay provides a proluminogenic caspase 3/7 substrate in a buffer system 
optimized for caspase activity, luciferase activity and cell lysis. Luminescence is 
proportional to the amount of active caspases. Caspase activity assays were performed in 96 
well opaque-walled multiwell plates. MCF7 cells were reverse transfected (6×103cells/well) 
with RNA molecules. After incubation for 48 or 72 hours, 100µl of Caspase-Glo reagents 
for caspases 3/7 were added to each well, incubated for 30 minutes, and the luminescent 
signal was measured using a luminometer. 
2.2.14.3 Luciferase reporter assays  
2.2.14.3.1 ERE-Firefly luciferase reporter gene assay in MELN cells 
Genetic reporter systems are widely used to study regulation of eukaryotic gene expression. 
In order to assess a possible role of miR-375 in ERα signaling, ERα protein as well as 
transcriptional activity levels were measured following ectopic expression of miR-375 in 
MELN cells. MELN are MCF7 cells which stably express an estrogen responsive element 
(ERE)-controlled firefly luciferase reporter gene. MELN cells (3×105 cells/well in 6-well 
plates) were reverse-transfected with Pre-miR-control or Pre-miR-375 and incubated for 48 
hours before stimulation. Cells were treated or not for 16 hours with 10nM estradiol, 
washed and lysed with 150µl/well (10 minutes at RT) of Luciferase Cell Culture Lysis 
Reagent (Promega). After centrifugation (13,000 rpm for 15 minutes), the supernatant was 
collected and luciferase activity was analyzed using the firefly luciferase assay system from 
Promega and a luminometer, in triplicates. Luciferase results were normalized to the 
corresponding protein concentration of cell lysates.  
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2.2.14.3.2 Dual-luciferase reporter assays in HEK293T and MCF7 cells 
The term ‘dual’ refers to the simultaneous expression and measurement of two individual 
reporter enzymes within a single system. The experimental reporter (firefly-luciferase) 
correlates with specific experimental conditions, while the activity of the co-transfected 
‘control’ (renilla-luciferase) provides an internal control that serves as a baseline for 
transfection efficiency. Normalizing the activity of firefly-luciferase to the activity of 
renilla- luciferase minimizes experimental variability caused by differences in cell viability 
or transfection efficiency. 
Estrogen receptor activity reporter assay 
For analyzing estrogen receptor transcriptional activity in MCF7 cell, cells were reverse 
transfected with RNAs at a density of 4×104 cells/well in 24-well plates. After 24 hours, 
cells were co-transfected with 50ng/well ERE-Firefly and 10ng/well Actin-Renilla 
luciferase reporters and 24 hours later reporter activities were assayed by Dual Luciferase 
Reporter Assay System (Promega). 
Reporter assay for miRNA target identification 
Segments of the 3' untranslated region (3' UTR) of RASD1 (600 bp) and EBF3 (495 bp) 
containing target sites for miR-375 were amplified from genomic DNA with primers listed 
inpresented in section 2.1.12. Each amplicon was cloned into the multiple cloning site 
(MCS) of a pMIR-REPORT Luciferase vector (Ambion) located at the 3'UTR of the firefly 
luciferase gene. To be able to clone the UTRs into the MCS of the vector, recognition sites 
of SpeI and HindIII endonucleases had been added to the 5' sites of forward and reverse 
primers, respectively. Following PCR amplification, amplicons and pMIR-REPORT vector 
were cut with above mentioned restriction enzymes. The digestion reactions were prepared 
as described in table 9. Reactions were incubated at 37°C for 2 hours and subsequently at 
65°C for 20 minutes. Digestion products were analyzed on 0.8% agarose gel and desired 
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bands were cut from the gel on a UV lamp. DNA was purified from gel using Qiagen gel 
purification kit. To ligate the cut PCR product to the cut vector, T4 DNA ligase kit 
(Invitrogen) was used. Ligation reaction was prepared according to the table 10 and was 
incubated at 22°C for 4 hours. 
Table 9. Reaction contents of DNA digestion with SpeI and HindIII. 
DNA (amplicon/vector)      
Components Volume (µl)
5µg
ddH2O Variable
NEB Buffer 2 5
BSA (2mg/ml) 5
SpeI (10 units/µl) 1
HindIII (20 units/µl) 1
Total 50
 
Table 10. Reaction contents of ligation of 3'UTRs into reporter vector 
Components Volume (µl)
5x ligation buffer
T4 ligase 1
Vector 1
Amplicon 10
ddH2O 4
Final volume 20
4
 
For miRNA target identification, lusiferase reporter assays were performed in HEK293T 
and MCF7 cells. MCF7 and HEK293 cells were transfected with Anti-miR-375 and Pre-
miR-375, respectively, in quadruplicate in a 24-well plate (4×104 cells/well). Reverse 
transfections with Pre-miR and Anti-miR negative controls were performed as well. One 
day later, cells were co-transfected with 50ng pMIR-REPORT constructs containing 
RASD1 or EBF3 3' UTRs and 10ng Actin-Renilla Luciferase expression vector. After 24 
hours, reporter activities were assayed by Dual Luciferase Reporter Assay System 
(Promega) as following; transfected cells grown in a 24-well plate were lysed with 100μl of 
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1× passive lysis buffer (Promega) for 15 minutes at RT on a shaker (310 rpm). 20μl of each 
lysate were pipetted into a reader plate of the luminator in triplicate. The firefly-luciferase 
activity was measured by adding 100μl of LAR II reagent (Promega) to generate a 
stabilized luminescent signal. After quantifying the firefly luminescence, this reaction was 
quenched and the renilla-luciferase reaction was initiated by adding 100μl of Stop- and Glo 
reagent to the same well. The Stop- and Glo reagent (Promega) produces a stabilized signal 
of the renilla-luciferase, which was measured in the luminometer (Mithras LB 940 
luminometer, Berthold Technologies). After normalizing the firefly-luciferase activity to the 
renilla-luciferase activity, a direct comparison of samples regarding firefly activity in 
different conditions was possible. 
2.2.15 Statistical analysis 
Data were presented as mean values ± SD from three to five independent experiments. 
Statistical significance was determined using student’s t-test to compare groups of data. P-
values <0.05 were considered as statistically significant. 
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3 Results 
3.1 Microarray based analysis of DNA methylation patterns 
In the present study, the discovery of a DNA methylation signature marker for breast cancer 
based on screening of DNA from breast tissue samples was investigated. As interrogating 
the methylation status of every CpG of several candidate loci was sought after, a 
specialized microarray that combines high throughput and high resolution had to be 
developed. Then, the microarray was used to analyze the methylation patterns of the 
candidate loci, which had been PCR-amplified from bisulfite-treated DNA samples of 
breast tissue specimens. Aiming at identification of a signature discriminating tumors from 
control samples, a stringent statistical analysis was conducted. Investigation of genomic 
sequences spanning the signature CpGs, revealed potential involvement of these CpGs in 
binding behaviour of transcription factors to the regulatory regions of cognate genes, 
indicating biological relevance of the signature. 
3.1.1 Developing microarrays for DNA methylation 
analysis 
3.1.1.1 Control samples representing different levels of DNA methylation 
One critical step in production of control samples was the amplification of CGIs from 
genomic DNA. The high GC content of these regions can strongly influence the denaturing 
and annealing behaviour of DNA which subsequently affect the PCR performance. Indeed, 
it was not possible to amplify some of these loci using normal PCR conditions and 
amplification was only achieved in modified conditions when Q-Solution was used. The 
best annealing temperature for PCR amplification of each locus was obtained by using a 
gradient of annealing temperatures in the presence or absence of Q-Solution and analyzing 
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the PCR products on agarose gel. As an example the agarose gel electrophoresis results for 
gradient PCR of GSTP1 CGI is shown in figure 12.  
 
Figure 12. PCR-amplification of GSTP1 CGI. To isolate the selected GCIs from genomic DNA, a 
gradient of annealing temperatures (shown in white lettering in upper part of the figure) was applied 
in the presence or absence of Q-Solution, in PCR amplification process. M: DNA Marker; NC: 
Negative Control.  
 
As mentioned in Methods (2.2.4.2), fully-methylated and -unmethylated versions of the 
CGIs, representing 100% and 0% DNA methylation statuses of all CGIs, were produced. 
The methylation status of these control samples was confirmed by gel electrophoresis 
analysis of the product of their digestion with methylation-sensitive restriction 
endonuclease BstUI. Digestion patterns are shown in figure 13 for PGR and CDH13 genes, 
as an example. 
After validation of expected methylation levels for in vitro prepared control samples (CGIs 
isolated from human genome using genomic primers, each locus was PCR-amplified from 
corresponding fully methylated and unmethylated control samples using SoBi primers 
following treatment of the samples by bisulfite and control pools were prepared as 
described. 
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Figure 13. Examining the methylation status of control samples. Following incubation of control 
samples with BstUI enzyme, the digestion mixtures were analyzed by gel electrophoresis. Digestion 
patterns are shown for three CGI (indicated in white lettering in upper part of the figure). MA: DNA 
Marker; UC: Uncut (CGI without digestion use as control); U: Unmethylated version of the CGI; M: 
Methylated version of the CGI. 
3.1.2 Optimization of probe length for reliable array 
performance 
The specific and strong hybridization of target to probe is the basis for accurate and reliable 
performance of oligonucleotide microarrays. The binding between target and probe can be 
affected by many factors including their sequence composition. For example, high GC 
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content of probe and target can lead to stronger hybridization. On the other hand, GC-rich 
targets and probes are prone to form secondary structures that disturb hybridization process. 
In addition, the specificity of binding of target to the probe can be influenced substantially 
by probe length. As the length of probe increases the number of mismatches between the 
probe and non-specific targets increases, leading to a weaker hybridization (in comparison 
to the specific binding) that can be washed away during washing steps. Nevertheless, long 
length of probes with high GC content can facilitate the formation of secondary structures. 
Consideration of above-mentioned facts in array-based DNA methylation analysis is 
crucial, because vast majority of the targets and probes are GC-rich. This feature can result 
in production of unreliable data by some probes. Likewise, as probes and targets share 
similar sequence composition, the probability of occurrence of non-specific hybridization 
(cross-hybridization) is high. Therefore, it is necessary to find the optimal probe length to 
achieve the reliable data.  
We evaluated the effect of probe length on behaviour and accuracy of array functioning by  
hybridizing the control targets to their probes, which were synthesized in different lengths. 
All arrays were synthesized with the same array design consisting of probes with 17, 21 and 
25 nucleotides long against control targets. Three control target pools representing 0, 50 
and 100% methylation levels of amplicons were used such that each control pool was 
hybridized to one array. The hybridization and post processing were carried out as 
described in Methods section. As initial examination, the reproducibility of the data created 
by microarrays was verified for different probe lengths. For this purpose, pairwise 
comparisons of the MIs produced by the same oligonucleotide pairs (M and U probes) in 
two independent hybridizations were performed and R-squared value (R2) was calculated 
for each comparison- the higher R2 value corresponds to more reproducibility. Results of 
these comparisons are presented in figure 14. The R2 value obtained from pairwise 
comparisons when using 21 and 25-mer probes were similar together but higher when  
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Figure 15. The effect of probe length on 
reproducibility of array performance. Probes 
with length of 21 and 25 nucleotides provide 
higher reproducibility as compared to 17-mer 
probes. 
 
 
 
 
Figure 14. Effect of array composition on 
performance of probes negatively correlates 
with probe length. Data show that 25-mer 
probes provide the highest reproducibility of 
methylation data in different array contexts. 
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compared to the R2 value of comparisons performed with 17-mer probes. These 
experiments showed that oligonucleotides with lengths of 21 and 25-mer are able to 
analyze DNA methylation patterns with higher reproducibility than those with length of 17-
mer.  
To address the effect of probe length on reproducibility of array performance in more 
detail, another experiment was designed. The aim of this experiment was to assess the 
possible effect of probe length on the production of reproducible data with same sets of 
probes in different array designs (array compositions). For this experiment, two different 
array designs (array designs 1 and 2) were prepared such that array design 1 included 
probes against amplicons ER-a, ER-b, HIN1-a, HIN1-b and HIN-c, and array design 2 
consisted of probes detecting amplicons ER-b, TWIST-a, TWIST-b, TWIST-d. Probes 
directed against ER-b amplicon were included in both array designs. Three arrays of one 
biochip were synthesized with each array design to be hybridized with corresponding 
control sample pools representing 0, 50 and 100% methylation each. After hybridization, 
detection and data processing, the MIs shown by probe sets against ER-b amplicon (shared 
target) in two array designs were compared together (Fig. 15). The R2 values calculated 
following pairwise comparisons increased with length of probes showing that longer probes 
are able to produce methylation data with higher reproducibility in different array contexts. 
The high R2 value (0.92) observed for 25-mer probes indicated that the functionality of 
these probes is very slightly influenced by array composition and the most reproducible 
data can be obtained using these probes.  
In another experiment, we examined the effect of probe length on cross-hybridization of 
probes to non-specific targets. For this purpose, two conditions were defined; in condition 
1, one array was hybridized with pool of all control targets whose probes were present on 
the array (BRCA1-a, BRCA1-b, BRCA-c, ER-a, ER-b, HIN1-a and HIN1-b targets); in 
condition 2, another array with same design was hybridized with the same pool of targets 
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but only one target (ER-b) out of this pool had been labelled and the other ones had 
undergone a mock labelling. Thus, in condition 2, all signal intensities detected should be 
specifically referred to ER-b target. The methylation indices produced by the probes against 
the shared target (ER-b) were obtained from both arrays. The obtained values representing 
the methylation levels of the CpGs belonging to the shared target (ER-b) were compared 
between the two conditions for each probe length. This experiment was performed with 
control samples of 0, 50 and 100% DNA methylation such that both conditions were tested 
for each control sample. 17 and 25-mer probes were examined. The parwise comparisons of 
MIs produced by ER-b related probes resulted in R2 value of 0.53 and 0.85 for 17 and 25-
mer probes, respectively. These data demonstrated that the performance of 25-mer probes is 
less influenced by target mixture composition and they are less subjected to cross-
hybridization with non-specific targets (Fig. 16). 
 
 
It is known that the performance of oligonucleotide probes is different from one probe to 
another one (61). They also differ in terms of sensitivity to cross-hybridization. Therefore, 
 
Figure 16. Effect of probe length on cross-hybridization. Two probe lengths of 17 and 25-mer 
were examined in conditions 1 and 2 as explained in the text. Pairwise comparison clearly shows 
that methylation data produced by 25-mer probes are similar in both conditions. Thus, cross-
hybridization is very low in case of 25-mer probes. 
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it is possible that not all of the probes work accurately and thus, a pre-selection of 
functioning probes using control samples before patients screen is indispensable. As the last 
step to find the optimal probe length, the effect of probe length on frequency of selected 
discriminative probes was verified. Arrays containing probes with different lengths were 
hybridized with fully methylated (100% methylation) and completely unmethylated (0% 
methylation) control samples. Following data analysis, those probes that could produce a 
MI < 0.2 for 0% methylated control and > 0.8 for 100% methylated control samples were 
selected. Then, the percentage of the selected probes (number of selected probes / number 
of total probes used × 100) for each gene was compared between different probe lengths.  
This analysis proved that 25 mer probes possess the highest discriminative power for DNA 
methylation screening. In addition, it showed that using 25 mer probes, it is possible to 
investigate the methylation state of more CpGs of a given CGI, providing higher resolution 
for the analysis (Fig. 17). These experiments proved that 25-mer is the optimal length for 
probes to be used in our study. 
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Figure 17. Evaluation of effect of probe length on frequency of selected probes after 
calibration. Probes targeting CGIs of three genes were examined. For all genes, the highest 
frequency of selected probes was achieved when using 25-mer long probes. 
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3.1.3 Selection of highly discriminative probes 
The preceding experiments demonstrated that probes with length of 25 nucleotides can 
create the most reproducible and accurate data in different experimental conditions. It was 
also observed that the performance of oligonucleotide probes is different from one probe to 
another one. Although some probes showed MIs compatible with methylation levels of 
control samples, others could not show the correct methylation indices corresponding to the 
methylation level of control samples used. This observation necessitated the selection of 
probes that can discriminate between methylated and unmethylated DNA. To select highly 
discriminative probes, a calibration was carried out for each probe based on hybridization 
with control DNA pools designating 0, 33, 66, 100% methylation levels. Only probes that 
showed a MI of less than 0.2 for 0% methylated control targets, more than 0.8 for 100% 
methylated targets and an increasing gradient of MI from 0% to 33% to 66% to 100% 
methylated targets were selected. The final array design included the probes that met the 
selection criteria and was used for analysing the methylation patterns of patient samples. 
This array design included 2136 analysis probes interrogating methylation levels of 1068 
CpGs in the genome.   
3.2 Screening DNA methylation patterns in tissue samples 
3.2.1 Isolation of DNA from tissue samples 
Following the isolation of DNA from tissue samples, concentration of DNA samples was 
measured by Nanodrop. Quality of extracted DNA samples was then tested by gel 
electrophoresis (Fig. 18). 
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Figure 18. The DNA samples extracted from tissue specimens were loaded on 1% agarose 
gel to analyze the quality of the extracted DNA.   
 
3.2.2 PCR-amplification of CGIs from DNA samples 
All the 44 different CGIs were amplified form the bisulfate-treated DNA template with a 
single PCR program as described in Methods. Subsequently, PCR products were checked 
by gel electrophoresis. Gel electrophoresis data for PCR products of one sample is shown 
in figure 19, as an example. 
 
Figure 19. All fourty four amplicons from each patient sample was examined by gel 
electrophoresis. Electrophoresis data of patient IR-14N are presented as an example. Amplicon 
number 12 (marked with a red box) which refers to a CGI from the promoter region of the gene 
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DKK3 could not be amplified from many patient samples. Hence this CGI was excluded from 
microarray analysis. 
3.2.3 Microarray-based analysis of methylation patterns 
in tissue samples 
The last array design prepared following the calibration of probes related to all CGIs was 
used to produce microarrays for patient screening. This array consisted of 1068 pairs of 
probes detecting the methylated and unmethylated versions of 1068 CpGs site pertaining to 
the selected 44 loci. In addition, 280 probes as positive and 80 probes as negative controls 
were accommodated on each array to ensure the correct occurrence of synthesize and 
hybridization. The pool of all amplicons of each patient was hybridized to one array 
subsequent to labelling. The four control DNA samples representing different levels of 
methylation (0, 33, 66 and 100%) were also included in the analysis. After obtaining signal 
intensities and calculating MI for each CpG, the hybridization data related to control 
samples were analyzed carefully. Final filtration - same as filtration explained for probe 
selection- was performed to select the probes showing reliable data in the very same 
experiment in which patients samples had been analyzed. By this filtration, 717 probe pairs 
that passed the selection criteria were selected. The MIs calculated by these probes from 
each tissue sample were put together. This combined datasets (Supplementary Table S2) 
were then used for further analyses. 
3.2.3.1 DNA methylation signature for diagnosis of breast cancer 
To identify differentially methylated CpGs between tumors and control samples, datasets 
were analyzed with the M-CHiPS and the statistical significance was computed via the 
limma package as described in the Methods. In order to identify the CpGs whose 
methylation levels significantly differentiated between all tumor and control samples, 
different cut-off p-values were tested. As a result, by selection of CpGs that exhibit 
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adjusted p-values smaller than 0.01 (93 CpGs), all tumors were distinguished from control 
samples. Heat-map hierarchical clustering of patients’ methylation data for these CpGs is 
shown in figure 20. As shown in this figure, based on the methylation levels of these CpGs, 
tumor and normal samples are clustered into two separate main clusters indicating a 
significant divergence of methylation levels between these groups. In addition, this analysis 
revealed that based on DNA methylation patterns, tumors can be clustered into four sub-
groups (shown with A, B, C and D in figure 20). The selected 93 CpGs belonged to 
eighteen CGIs associated with sixteen genes. These genes and their cellular functions are 
listed in the table 11. 
Although these 93 CpGs were identified as significantly differential methylated sites 
between tumor and control samples, a heterogeneous pattern of methylation for many of the 
identified CpGs could be observed among the tumors. Since the aim of this screen was to 
identify potential DNA methylation markers for diagnosis of breast cancer, we sought to 
find the most differentiating CpGs sites among these 93 CpGs to reduce this heterogeneity. 
This also helps to minimize the number of CpG sites necessary for discriminating tumors 
from normal samples. For this purpose, we applied a filtering on the pre-selected CpGs 
based on the reducing the p-value cut-off to select the CpGs exhibiting the lowest p-values. 
To monitor the effect of filtering on sample clustering, correspondence analysis (CA) was 
used.  
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Figure 20. Clustering of samples by DNA methylation levels of the identified 93 CpGs. Green 
and red colors represent low and high methylation levels, respectively. Tumors and normal samples 
are clustered into two main groups. Healthy samples are highlighted with “H” among the Normal 
population. Four sub-groups among tumors identified by DNA methylation patterns are shown with 
A, B, C and D. 
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Correspondence analysis is a computational method to investigate associations between 
variables, such as genes and patient samples in a low-dimensional space. Similar to 
principle component analysis, it displays the data in 2 or 3D projection plot. The data 
analysis and projection are performed simultaneously for two (or more) variables, thus 
Table 11. Genes whose CGIs accommodate the 93 identified CpGs. 
Gene Function (cellular signaling involved) 
SFRP1 Modulator of Wnt signaling 
SFRP2 (2 CGIs) Modulator of Wnt signaling 
SFRP3 Modulator of Wnt signaling 
SFRP4 Modulator of Wnt signaling 
SFRP5 Modulator of Wnt signaling 
HDPR-1 (DACT1) Modulator of Wnt signaling 
WIF-1 Modulator of Wnt signaling 
TCF4 Modulator of Wnt signaling 
CST6 Inhibitor of cysteine proteases 
C/EBPα Transcription factor 
HIC1 Transcription factor 
PAK3 Protein kinase 
PTEN Negative regulator of AKT/PKB signaling  
RASSF1A Cell cycle arrest 
GSTP1 Detoxification  
GHSR (2 CGIs) Growth hormone release 
 
Results 
81 
 
revealing associations between them. One major advantage of this process is its ability to 
represent the associations between samples and genes at the same time in a single biplot 
(Fig. 21). Not only the genes or CpGs (black dots) but also divergence of the individual 
samples (colored squares) is presented. Co-localization of genes or CpGs is indicative of a 
strong association between them; the closer they are the stronger the association is. 
Likewise, the genes or CpGs that are closer to one cluster, have higher level of expression 
or methylation in members of that cluster than members of farther clusters. Following this 
analysis, a DNA methylation signature composed of methylation patterns of fourteen CpG 
sites was identified, which differentiated between the tumors and the normal breast tissue 
samples. CA plot depicting the cluster analysis is shown in figure 21. We also added the 
data of benign samples to this plot for comparison purposes. Clustering of samples based 
on methylation levels of these CpGs by CA suggested that tumors (green squares) and 
control samples from healthy people (blue squares) exhibited markedly different 
methylation profiles and form distinct clusters (Fig. 21). Furthermore, this analysis showed 
that the principle difference (distance between clusters along the horizental axis) in 
methylation levels between the two groups exhibits correlation with the malignancy 
(cancer) phenotype in the analyzed samples. It is also clear that control samples from 
cancer patients (red squares) are clustered together and are separated from tumors. 
Interestingly, these samples are located between tumor samples and normal samples from 
healthy individuals along the horizontal axis on the plot, indicating that the same factor 
discriminating tumors from healthy samples, distinguishes patient-matched control samples 
from tumors as well as from healthy samples. It is worth noting that the cluster containing 
benign samples (pink squares) has a similar position as that of patient-matched control 
samples along the horizontal axis.  
Of significance, all CpGs included in this signature are close to the tumors and far from 
healthy samples. This suggests that signature CpGs have higher level of methylation in 
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tumors as compared to control samples. From this plot, it can be predicted that healthy 
samples have the least amount of DNA methylation among all sample types and DNA 
methylation level in patient-matched normal and benign samples is higher than those of 
healthy samples but less than those of tumors.    
 
Figure 21. Clustering of samples by DNA methylation signature identified in this study. This 
figure is the projection of the processed microarray data in Correspondence Analysis plot. The black 
dots in the figure represent the CpG dinucleotides whose methylation status can differentiate 
between tumor, paired normal and healthy samples. The green, pink, red and blue squares 
correspond to tumor, benign, paired normal breast tissue from cancer patients and normal breast 
tissue from healthy individuals samples, respectively. 
3.2.3.2 Signature CpGs are hypermethylated in tumors 
The correspondence analysis identified fourteen CpGs significantly differentiating tumors 
from control sample. These CpGs belong to the CGIs located at either the promoter or the 
first exon of SFRP2 and GHSR genes, respectively. Data from CA analysis suggested that 
signature CpGs have higher level of methylation in tumor samples in comparison to other 
samples. Indeed, by querying the methylation levels of individuals CpGs of this signature, 
we found that the signature CpGs are hypermethylated in tumors when compared to normal 
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samples from patients and healthy individuals (Fig. 22). In addition, we observed that 
majority of these CpG dinucletides showed a relatively higher level of methylation in 
tumor-matched normal tissue specimens as compared to normal tissue samples from 
healthy individuals (Fig. 22). The methylation levels of these CpGs sites were also 
compared between normal, tumor and benign samples. The methylation loads of these sites 
in benign specimens were lower as compared to those of tumors but higher when compared 
to their loads in samples from health persons (Fig. 23).  
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Figure 22. Methylation levels of signature CpGs in different sample types. Levels of 
methylation on the Y-axis are plotted against the sample types on the X-axis. (A) Six signature 
CpGs are located at the promoter region of SFRP2 gene. (B) Eight signature CpGs belong to a CGI 
located at the first exon of GHSR gene. 
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Figure 23. Comparison of DNA methylation of signature CpGs between healthy, benign and 
tumor samples. DNA methylation levels of benign samples are between those of healthy and 
tumor samples for the signature CpG dinucleotides. 
3.2.4 Bisulfite sequencing data 
The signature CpGs were located at CGIs related to GHSR and SFRP2 genes. To obtain a 
detailed view of DNA methylation patterns of these CGIs, we subjected them to bisulfite 
sequencing. We compared the DNA methylation maps of these loci between tumors, 
matched-normal and normal samples from healthy individuals. For this comparison, eight 
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tumors, their eight matched normal samples and five normal tissue samples from healthy 
individuals were used. Overall, GHSR CGI showed 44.5% methylation in tumors, 11.5% in 
patient-matched normal and 10% in healthy breast tissue samples (Fig. 24), whereas SFRP2 
CGI methylation levels were 44%, 4.3% and 5% in these samples, respectively (Fig. 25). 
This observation supports our array results on hypermethylation of these genes in tumors. 
Additionally, overall methylation levels of these loci were similar in normal samples from 
patients and cancer-free individuals. Bisulfite sequencing data were then analyzed at single 
CpG resolution. This analysis revealed several CpGs (in both CGIs) that represent a pattern 
of increasing gradient in methylation load from healthy people to the normal and then to the 
tumor samples of cancer patients (represented by red boxes in figures 24 and 25). 
Interestingly, most of these CpG dinucleotides exist at the regions where signature CpGs 
were located (signature CpGs are highlighted by blue arrows in figures 24 and 25). These 
data further support the ability of the signature CpGs to classify the tissue samples into 
distinct clusters.  
The detailed analysis of bisulfate sequencing data showed a selective pattern of 
hypermethylation for certain CpGs along GHSR and SFRP2 CGIs. To verify whether these 
CpGs might play an important role in regulation of the cognate genes, genomic sequences 
of these CGIs were analyzed. In silico analysis of the loci using MatInspector software 
(144) uncovered the consensus binding sites for several transcription factors in these CGIs 
(Figs. 24 and 25). The binding sites for CCCTC-binding factor (CTCF) protein and PAX 
family members were found in both CGIs. Strikingly, we found that majority of the CpGs 
exhibiting the gradient pattern of methylation are located in the annotated binding sites of 
CTCF. Moreover, a few of them settle in the binding sites of PAX family members (Figs. 
24 and 25). 
Results 
87 
 
 
Figure 24. (A) Methylation patterns of the CGI located at the first exon of GHSR in tumors and 
control samples from patients and healthy individuals. Each row is a clone and each column 
represents one of the 33 CpG dinucleotides in the CGI. The CpGs which are marked in red boxes 
show differential methylation between the tumors, paired normal and the healthy breast tissue 
samples, whereas those marked with a blue arrow are constituents of the methylation signature. 
The panel above is a miniature of the sequence with all the 33 CpGs highlighted with red and blue 
colored lines. Those belonging to the signature are shown in blue. The transcription factors whose 
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binding sites are found in the CGI are depicted. (B) Methylation levels of differentiating CpGs (in red 
boxes) from bisulfite sequencing data in different samples. 
 
 
Figure 25. (A) Methylation patterns of the CGI located upstream of the TSS of SFRP2 in tumors 
and control samples from patients and healthy individuals. Each row is a clone and each column 
represents one of the 30 CpG dinucleotides in the CGI. The CpGs which are marked in red boxes 
show differential methylation between the tumors, paired normal and the healthy breast tissue 
samples. Those CpG sites marked with a blue arrow are constituents of the signature CpGs. The 
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panel above is a miniature of the sequence with all the 30 CpGs highlighted with red and blue 
colored lines. Those belonging to the signature are highlighted in blue. The transcription factors 
whose binding sites are found in the CGI are depicted. (B) Methylation levels of differentiating CpGs 
(in red boxes) from bisulfite sequencing data in different samples. 
3.2.5 Re-activation of methylated genes following 
decitabine treatment 
To verify whether inhibitaion of DNA methylation can affect the expression of signature 
genes in breast cancer cells, cells were treated or not with decitabine and the mRNA levels 
of the candidate genes were compared between treated and untreated cells. This analysis 
was performed for other Wnt pathway-related gene listed in table 11. Figure 26 shows the 
mRNA levels of these genes in decitabine treated cells relative to their levels in untreated 
cells.  
 
Figure 26. Re-activation of methylated genes in MDA-MB-231 breast cancer cells following 
decitabine treatment. qRT-PCR data for the indicated genes. mRNA levels of genes were 
normalized to the level of GAPDH mRNA in treated and untreated cells. The values are represented 
as ratio of the normalized expression of each mRNA in treated cells versus untreated cells.   
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3.3 Identification of miRNAs involved in ERα activation 
3.3.1 miR-375 expression is increased in ERα-positive 
breast cancer cell lines 
In an initial attempt to identify miRNAs that might be involved in the regulation of ERα 
pathway and in the development of breast cancer, we performed miRNA profiling of 8 
human mammary cell lines, which included non-tumorigenic immortalized cells (MCF-10A 
and MCF-12A), ERα-positive (MCF7 and T47D) and ERα-negative (SK-BR3, MDA-MB-
231 and MDA-MB-435) cancer cell lines using microarray technology. Microarray raw 
data was processed, controlled for quality and subjected to normalization as described 
previously in methods. Normalized data are available in supplementary table S3. miRNA 
expression profiles of ERα-positive cells were compared to ERα-negative cancer cell lines 
as well as to non-cancer cells and differentially expressed miRNAs were shortlisted (Table 
12). Aiming at identification of miRNAs which might positively regulate ERα activity, we 
sought for up-regulated miRNAs in ERα-positive cell lines. Interestingly, we identified 
miR-375 as the second most significantly up-regulated miRNA in ERα-positive cells when 
compared to both ERα-negative and non-tumorigenic cell lines. Quantitative real-time PCR 
(qRT-PCR) confirmed that the expression level of mature miR-375 was higher in MCF7 
and T47D (ERα-positive) cancer cell lines when compared to ERα-negative cancer and the 
non-tumorigenic breast cell lines (Fig. 27). These results confirmed our miRNA profiling 
data and indicated that miR-375 is overexpressed specifically in ERα- positive breast 
cancer cell lines. 
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Table 12. Differentially expressed miRNAs in cell lines 
ERα+ compared to ERα- Cancer cells ERα+ compared to non-cancer cells 
miRNA Fold-change miRNA Fold-change 
5% most up-regulated 5% most up-regulated 
hsa-miR-203 7,4 hsa-miR-200a 7,7 
hsa-miR-375 5,4 hsa-miR-375 6,9 
hsa-miR-205 4,6 hsa-miR-200b 5,4 
hsa-miR-148a 4,3 hsa-miR-203 4,9 
hsa-miR-615-3p 4,0 hsa-miR-200b* 4,3 
hsa-miR-196a 3,9 hsa-miR-196a 4,2 
hsa-miR-200c 2,9 hsa-miR-615-3p 3,5 
hsa-miR-421 2,8 hsa-miR-429 3,5 
5% most down-regulated 5% most down-regulated 
hsa-miR-146b-5p -3,0 hsa-miR-34c-5p -3,7 
hsa-miR-29a -3,3 hsa-miR-29a -3,9 
hsa-miR-31* -4,0 hsa-miR-146b-5p -4,5 
hsa-miR-146a -4,9 hsa-miR-224 -5,3 
hsa-miR-155 -6,4 hsa-miR-31* -6,5 
hsa-miR-31 -6,7 hsa-miR-221 -8,6 
hsa-miR-221 -8,2 hsa-miR-31 -9,3 
hsa-miR-222 -9,7 hsa-miR-222 -10,3 
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Figure 27. Correlation between miR-375 expression and ERα in mammary cell 
lines. miR-375 levels were measured by qRT-PCR and ERα presence was verified by 
western blot. 
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3.3.2 Reciprocal regulation between miR-375 and ERα 
 Given the positive correlation between miR-375 and ERα expression in cell lines, we 
sought to examine the possible regulatory connection between these molecules. In order to 
assess a possible role of miR-375 in ERα signaling, ERα protein as well as transcriptional 
activity levels were measured following ectopic expression of miR-375 in MELN cells. 
MELN are MCF7 cells which stably express an estrogen responsive element (ERE)-
controlled firefly luciferase reporter gene (138). Overexpression of miR-375 in MELN cells 
resulted in a 2-fold induction of luciferase activity as compared to the control, following 
stimulation of cells with estradiol (E2) (Fig. 28 left). In agreement with this data, an almost 
2-fold increase of ERα protein levels was observed following transfection of cells with pre-
miR-375 (Fig. 28 right). This effect was reproducible in MCF7 cells transiently transfected 
with an ERE-controlled Firefly luciferase vector (Fig. 29A). In addition, blockade of miR-
375 resulted in decreased ERα levels in MCF7 cells (Fig. 29B). These findings provide 
evidence that miR-375 positively regulates ERα both at the protein and transcriptional 
activity levels. 
According to the correlation observed between miR-375 and ERα levels in different cell 
lines, it is conceivable that ERα presence is a determinant for miR-375 overexpression. To 
 
Figure 28. miR-375 positively regulates 
ERα activity and expression in MELN 
cells. The effect of miR-375 expression on 
ERα activity and expression was measured 
after modulation of miR-375 expression in 
MELN cells. Before measuring ERE-driven 
luciferase activity cells were treated or not 
with 10 nM E2 for 16h (left). ERα expression 
assayed by immunoblotting in cells with no 
E2 treatment (right). 
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investigate a potential role for ERα in the regulation of miR-375, miR-375 levels were 
quantified in MCF7 cells 48 hours after transfection with siRNAs against ERα. Quantitative 
real-time PCR analysis showed that miR-375 levels decreased by 50% (as compared to 
negative controls) after transfection with ERα specific siRNAs (Fig. 29C). These data 
indicate that miR-375 expression in MCF7 cells is partially dependent on ERα.  
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Figure 29. Reciprocal regulation between miR-375 and ERα in MCF7 cells. (A) MCF7 cells 
were co-transfected with an ERE-controlled firefly luciferase reporter vector and with pre-, anti-miR-
375 or the control RNAs. A co-transfected renilla luciferase vector was used for transfection 
normalization. siERα was used as positive control. (B) The effect of transfection of MCF7 cells with 
pre- and anti-miR-375 on ERα expression was measured by western blot. (C) miR-375 expression 
in MCF7 cells was measured by qRT-PCR 48h after transfection with siERα or control siRNAs. 
3.3.3 miR-375 inhibition reduces the proliferation rate 
of breast cancer cells  
Since ERα signaling is an important factor in the growth and proliferation of ERα-positive 
cancer cells, the potential contribution of miR-375 to the proliferation of these cells was 
evaluated through blocking miR-375 activity with anti-miR-375 in MCF7 cells. Compared 
to the control experiments (transfection with anti-miR-control), cell proliferation decreased 
in miR-375 inhibited cells to almost 50%, 72 hours after transfection (Fig. 30A-B). 
However, inhibition of miR-375 did not result in an induction of caspase activation (Fig. 
30C), suggesting that the antiproliferative activity of miR-375 inhibition is not due to 
apoptosis induction. These observations, together with the positive regulatory effect of 
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miR-375 on ERα activity, indicated that the positive effect of miR-375 on cell proliferation 
could be mediated by the positive modulation of ERα activity in cancer cells. 
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Figure 30. The effect of anti-miR-375 transfection on proliferation of MCF7 cells. Inhibition of 
miR-375 decreases proliferation of MCF7 cells. Proliferation of MCF7 cells transfected with anti-
miR-375 or anti-miR-control was measured 72h after transfection using (A) the Celltiter Glo assay 
or (B) by cell counting. (C) miR-375 inhibition does not induce apoptosis. Induction of apoptosis was 
assayed by measuring Caspase 3/7 activity in MCF7 cells after miR-375 inhibition using Caspase 
3/7 Glo assay. 
 
3.3.4 Epigenetic marks determine the transcriptional 
state of the miR-375 locus 
To further explore the regulatory mechanisms governing miR-375 expression, the genomic 
region upstream and spanning the miR-375 gene was analyzed in silico. The coding region 
of the miR-375 gene is located in a large CGI (CGI 2) of around 850 bp which contains at 
its most distal part a region homologous to the miR-375 promoter identified in mouse (145) 
(Fig. 31A). Another CGI (CGI 1) resides 550 bp upstream this region. As several miRNAs 
have been reported to be regulated by DNA methylation and histone modifications (78), we 
analyzed the epigenetic modification pattern of the miR-375 locus in MCF7, T47D (cells 
with high miR-375 expression) and MCF-10A, MCF-12A and MDA-MB-231 (cells with 
low miR-375 expression) cell lines by bisulfate sequencing and chromatin 
immunoprecipitation (ChIP). Bisulfite sequencing results showed that CGI 1 is methylated 
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in the cell lines with high expression of miR-375, whereas MCF-10A, MCF-12A and 
MDA-MB-231 cells showed specific hypomethylation in the distal part of this region (Fig. 
31B). In contrast, CGI 2 was mostly unmethylated in MCF7, T47D and MDA-MB-231 
cells, while MCF-10A and MCF-12A showed strong DNA methylation in the proximal part 
of the region (Fig. 31A).  
To characterize the chromatin state of the miR-375 locus, we employed four different 
antibodies recognizing distinct covalent histone modifications in a ChIP experiment. ChIP 
analysis revealed a peak of histone H3 dimethylated at lysine 4 (H3K4me2), a marker of 
active transcription, in the CGI 1 in all cell lines analyzed (Fig. 31C). Repressive histone 
H3 lysine 9 dimethylation (H3K9me2) was found throughout the locus in the three cell 
lines with low miR-375 expression, whereas H3K9me2 levels were found to be low in both 
CGIs in MCF7 and T47D. H3 and H4 acetylation, a marker of active transcription, was 
generally low and was only slightly enriched in CGI 1 in T47D cells (Fig. 31A). 
Together, these findings led us to conclude that an active miR-375 epiallele is characterized 
by a fully methylated CGI 1, an unmethylated CGI 2 spanning the gene body, H3K4me2 
enrichment in the CGI 1 and low overall H3K9me2 levels. The repressed epiallele is 
characterized by local hypomethylation around CpG 18 of the CGI 1 (see box in Fig. 31B), 
a methylated gene body (with the exception of the MDA-MB-231 cell line), H3K4me2 
enrichment in the CGI 1 and overall high levels of H3K9me2. These data suggest that 
H3K9 methylation is a major repressive mark of the miR-375 locus.  
3.3.5 Transcriptional repressors bind to the miR-375 
locus 
The bisulfite sequencing data indicated that one feature of the repressed epiallele of miR-
375 is local hypomethylation around CpG 18 of CGI 1, which in the case of MCF-12A and 
MDA-MB-231 cells also became detectable throughout the CGI (Fig. 31B). Analysis of the 
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miR-375 locus with MatInspector software (144) revealed the presence of consensus 
binding sites for the CCCTC-binding factor (CTCF) protein in this locus and especially in 
the hypomethylated region. CTCF is a highly conserved multifunctional zinc finger protein 
involved in transcriptional repression and activation, insulation, imprinting and X-
inactivation that binds preferentially to unmethylated DNA (146, 147). CTCF is a very 
widely expressed factor that is expressed in many breast cancer cell lines including MDA-
MB-231 and MCF7, but also in non-tumorigenic breast cell lines like MCF-12A (148). 
Moreover, we identified several Z- and E-boxes that are potential binding sites for the 
ZEB1, a transcriptional repressor that has been found to be involved in the regulation of 
several cancer-associated genes (149, 150). ZEB1 has been described to be expressed in 
MCF-10A and MDA-MB-231 cells; however, almost no expression was reported in MCF7 
and T47D cell lines (149). We therefore performed ChIP with antibodies against CTCF and 
ZEB1 in MCF7, MCF-12A and MDA-MB-231 cells. ChIP was also performed with 
antibodies against ERα and the largest subunit of RNA polymerase II to obtain information 
about ERα-binding and active or paused transcription events. We confirmed the binding of 
CTCF not only to the predicted binding site around CpG 18 (ChIP-1) in MCF12A cells but 
also to sites in the proximal region of CGI 1 (ChIP-2) and in CGI 2 (ChIP-3 and 4) (Fig. 
32). In MDA-MB-231 cells, a similar pattern was found, though peak binding was observed 
in all but the region amplified by the ChIP-1 primers. In contrast, MCF7 cells showed a 
weak enrichment for CTCF-immunoprecipitated DNA only in the proximal region of CGI-
1. These data suggest that CTCF regulates the miR-375 locus by interacting with several 
hypomethylated binding sites and creating a higher order chromatin structure that prevents 
active transcription. 
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Figure 31. Epigenetic marks determine the transcriptional state of the miR-375 locus. (A) 
Comparison of the miR-375 locus in human and mouse. CGIs (CGI 1 and 2) are shown. The 
Results 
98 
 
transcription start site (TSS) of miR-375 is indicated by arrows. The locations of two primer pairs 
used for bisulfite sequencing (bs-1 and bs-2) and the four primer pairs employed for the ChIP 
analysis (ChIP-1, ChIP-2, ChIP-3, ChIP-4) are depicted. (B) Bisulfite sequencing of the CGIs in five 
breast cell lines. Black and open circles represent methylated and unmethylated CpGs, 
respectively. The region with specific hypermethylation in MCF7 and T47D cells is shown in 
quadrangle. (C) ChIP analysis of the miR-375 locus in cell lines. Crosslinked chromatin of each cell 
line was immunoprecipitated with antibodies specific for acetylated histone H3 (3ac), acetylated 
histone H4 (4ac), dimethylated lysine 4 of histone H3 (3d4) and dimethylated lysine 9 of histone H3 
(3d9). Purified DNA was amplified with the four ChIP primer pairs (see A) 
 
RNA POLII was detected in most regions with CTCF enrichment, presumably representing 
paused polymerase molecules interacting with CTCF (Fig. 32). Consistently, low levels of 
RNA POLII were detected in the miR-375 coding region (ChIP-4) in MCF-12A and MDA-
MB-231 cells. ZEB1 binding was restricted to CGI 2 in the cell lines with low miR-375 
levels, which correlates well with the presence of E-boxes in the ChIP-3 region (Fig. 32). 
We found no ZEB1 binding in MCF7 cells, but very prominent peaks of ERα and RNA 
POLII in the miR-375 coding region (ChIP-4), adjacent to the putative miRNA promoter 
(Fig. 32). Collectively, these findings support a role of CTCF and ZEB1 in the repression 
and ERα in the activation of miR-375 expression. The binding of ERα to the putative 
miRNA promoter further supports our preceding findings on a key role of ERα in miR-375 
overexpression in MCF7 cells and indicates the existence of a positive feedback regulation 
between these molecules. 
Results 
99 
 
MCF-7 MCF-12A MDA-MB-231
0.00
0.25
0.50
0.75
1.00
1.25
1.50
0.00
0.25
0.50
0.75
1.00
1.25
1.50
0.00
0.25
0.50
0.75
1.00
1.25
1.50
0.00
0.25
0.50
0.75
1.00
1.25
1.50
ChIP-1 ChIP-2
ChIP-3 ChIP-4
Co
ntr
ol
ER
α
CT
CF
ZE
B1
PO
LII
%
of
in
pu
t
%
of
in
pu
t
Co
ntr
ol
ER
α
CT
CF
ZE
B1
PO
LII
 
Figure 32. Transcriptional repressors bind to the miR-375 locus. Crosslinked chromatin derived 
from MCF7, MCF-12A and MDA-MB-231 cells was immunoprecipitated with antibodies specific for 
ERα, CTCF, ZEB1 and DNA polymerase II (POLII). Purified DNA was amplified with the four ChIP 
primer pairs (see figure 31A). Results are shown as percentage of the input (normalized against 
input). 
 
3.3.6 RASD1 is a functional target of miR-375 
We expanded our functional analyses by measuring the expression of miR-375 in nine pairs 
of primary breast carcinomas and adjacent normal tissues from breast cancer patients using 
quantitative real-time PCR. Although not specific to ERα-positive tumors (Supplementary 
Table S4), miR-375 was up-regulated in seven of nine analyzed tumors (Fig. 33A). To 
identify miR-375 targets, mRNA expression profiles of tumor and normal breast tissue 
specimens of 4 patients (patients 1, 2, 6, 7) showing differential miR-375 expression were 
analyzed by Illumina microarrays. We identified 125 genes commonly down-regulated in 
tumors over-expressing miR-375 (Supplementary Table S5). In parallel, 144 potential miR-
375 targets were predicted using the TargetScan algorithm (151). Combining microarray 
profiling and target prediction data, we identified two genes, Ras dexamethasone-induced 1 
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(RASD1) and early B-cell factor 3 (EBF3), as potential miR-375 targets (Fig. 33B). We 
cloned segments of the 3’UTRs of both genes into luciferase reporter vectors and 
performed luciferase assays upon overexpressing miR-375 in HEK293T cells (that do not 
express endogenous miR-375) or blocking its activity in MCF7 cells. The EBF3 luciferase 
construct showed no sensitivity to miR-375. In contrast, reporter assays for RASD1 showed 
significant changes in luciferase activity (Fig. 33C). The observation that modulation of 
miR-375 caused consistent expression changes in RASD1-luciferase construct in both cell 
lines strongly suggests that RASD1 is a functional target of miR-375. Because of the lack 
of appropriate antibodies, the effect of miR-375 on RASD1 protein levels could not be 
evaluated. However, inhibition of miR-375 in MCF7 cells in more than 2.5 fold-induction 
in RASD1 mRNA levels, as measured by quantitative RT-PCR (Fig. 33D). 
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Figure 33. RASD1 is a target of miR-375. (A) miR-375 expression in breast cancer patients 
measured by qRT-PCR. Values are represented as the ratio of miR-375 expression in tumors 
versus matched normal tissues. (B) Comparison between 125 genes commonly down-regulated in 
patients showing overexpression of miR-375 and 144 predicted targets identified EBF3 and RASD1 
as potential miR-375 targets. (C) Luciferase assays in HEK293T and MCF7 cells transfected with 
the RASD1 3’ UTR reporter construct (middle). The respective miR-375 expression is indicated 
(lower part). (D) RASD1 mRNA expression in MCF7 cells after transfection with anti-miR-375 
measured by qRT-PCR. 
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3.3.7 Regulatory connection between ERα and RASD1 
It has been reported that RASD1 is able to suppress cell growth of breast cancer cells and to 
inhibit clonogenic growth of MCF7 cells (152). This report, combined with our findings, 
led us to hypothesize that RASD1 could function as a negative regulator of ERα. The effect 
o f RASD1  o n  ERα was tested  by lo ss- and gain-of-function experiments in MCF7 cells. 
While silencing of RASD1 by specific siRNAs gave rise to an increase in ERα levels, 
overexpression of RASD1 had the opposite effect and led to downregulation of ERα (Fig. 
34A). These findings support a negative regulatory effect of RASD1 on ERα expression. 
It has been shown that steroid hormones can positively modulate RASD1 expression in 
AtT-20 corticotrope cells (153). Therefore, we asked whether RASD1 could be regulated 
by estrogen in MCF7 cells. To address this question, MCF7 cells were treated with 
estradiol (E2) and RASD1 mRNA levels were monitored over time. Interestingly, RASD1 
was induced more than 10-fold 3 hours after treatment (Fig. 34B), whereas mRNA of pS2 
(TFF1), a well-known classical estrogen responsive gene, became elevated after 16 hours 
(Fig. 34B). The reduction of RASD1 transcript levels after 3 hours may be explained by the 
finding that ligand activation of ERα (e.g. activation by estrogens) is followed by its 
destabilization through degradation by the proteasome pathway (154). To investigate an 
association between E2-dependent RASD1 induction and ERα downregulation, we analyzed 
ERα protein levels in different time points after treatment with E2. We observed that 
substantial reduction of ERα protein levels occurred simultaneous to the E2-dependent up-
regulation of RASD1 mRNA (Fig. 34C). Together, our data show that; i) E2 induces 
RASD1 mRNA levels in a rapid and effective manner, ii) the level of ERα protein, which is 
the main mediator of E2, is reduced simultaneously with RASD1 up-regulation and iii) 
ERα is negatively regulated by RASD1 (as shown by the silencing and overexpression 
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experiments). These observations suggest a negative feedback regulation of ERα signaling 
which is mediated by RASD1.  
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Figure 34. Regulatory connection between ERα and RASD1. (A) RASD1 negatively regulates 
ERα. Immunoblots for ERα in MCF7 cells 48h after silencing or overexpression of RASD1. (B) qRT-
PCR data for RASD1 and pS2 transcripts in E2-treated MCF7 cells. (C) Immunoblots for ERα in 
MCF7 cells following E2 treatment. 
 
Discussion 
104 
 
4 Discussion 
4.1 DNA methylation analysis 
4.1.1 Development of microarrays 
Although the first technique used for broad DNA methylation profiling was based on two- 
dimensional gel electrophoresis (155), microarray technology soon found its way into the 
field. The adaptation of microarrays to the output of all major DNA pre-treatment 
procedures (mentioned in the Introduction) has resulted in diverse array-based techniques 
for determining DNA methylation profiles (53). Microarray formats that are used for 
methylation analysis are mainly based on either “CpG island arrays” (CGI arrays) or 
“oligonucleotide arrays”. CGI arrays have enabled the examination of the methylation 
patterns of multiple CGIs- following treatment of DNA with an endonuclease or affinity 
enrichment- in order to find the CGIs which show hypermethylation in tumors. However, 
these arrays provide low resolution about the methylation patters within a CGI. On the 
other hand, in addition to endonuclease treated- or affinity enriched-DNA, oligonucleotide 
arrays have also been adapted to bisulfite-treated DNA, providing an opportunity for high 
resolution analyses (54).  
The first step of this study was aimed at the development of a dedicated oligonucleotide 
microarray to screen DNA methylation patterns of multiple candidate loci on bisulfite-
treated DNA. The ultimate goal of the project was the establishment of a DNA methylation 
signature potentially useful for diagnosis of breast cancer. As it has been reported that CpG 
sites within a CGI can differ in their methylation statuses, a high resolution analysis of each 
locus was required. Oligonucleotides can be designed against any DNA sequence of 
interest, thus oligonucleotide arrays would be theoretically capable of dissecting the 
methylome at single-CpG-resolution. However, indeed, array hybridization methods are not 
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easily adapted to bisulfite-converted DNA. This is due to the fact that following bisulfite-
conversion, DNA sequence consists of essentially three different bases instead of four, with 
most cytosines being converted into thymines after PCR, resulting in reduced complexity of 
the genomic sequence. This feature of treated-DNA results in much sequence redundancy 
and, thus, decreased hybridization specificity. This problem has been reflected in the 
previous studies that applied bisulfite-treated DNA to oligonucleotide arrays. In these 
reports, either despite the high resolution of analyses, the coverage of assays was limited to 
a single gene (59, 156), or when several genes were analyzed, the assay resolution was low 
(58, 62).  
Considering the above mentioned facts, the specificity of array performance was assessed 
through different approaches in the initial step of microarray development process. Owing 
to its flexibility and fast performance- which is a valuable advantage in the process of 
technical optimization of customized arrays- the Geniom One technology (febit) was 
selected for this analysis. Several parameters related to the labeling of samples, duration 
and temperature applied in array hybridization and washing procedures had already been 
optimized (61). However, the effect of probe length- which directly influences the 
specificity of probe hybridization- had not been addressed systematically. Therefore the 
evaluation process was focused on the length of probes. According to the suggestions made 
in the previous reports (61, 62), the lengths of 17, 21 and 25 nucleotides were chosen for 
this experiment.  
The first analysis, examining the effect of probe length on array reproducibility, showed 
that probes with length of 17 nucleotides are weaker than those with 21 and 25 nucleotide 
in terms of reproducing the same data. Twenty one and 25 nucleotide probes showed a 
similar power in overall array reproducibility. However, in the second experiment, which 
was more dedicated toward reproducibility of probes functioning in different array layouts 
(designs), 25 nucleotide probes clearly showed an advantage to other probes. These 
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experiments provided evidence that probes in length of 25 nucleotides are more stable -in 
terms of performance- and less influenced by potential experimental factors (like sample 
handling) and environmental features such as array composition.     
The third experiment was planed such that cross-hybridization issue could be directly 
analyzed. While some of the detected signals in “condition 1” could originate from non-
specific target binding, all signals obtained in “condition 2” were from specific binding of 
the studied target to the related probes. Hence, the difference observed between data 
produced in these conditions could be referred to the binding of non-specific targets to the 
probes analyzed. This experiment showed that while cross-hybridization can significantly 
influence the performance of 17 nucleotide probes, it can not disturb the functioning of 25 
nucleotide oligos, effectively. Taken together, these analyses suggested 25 nucleotide long 
as the optimum length of the oligonucleotide probes. 
During the array development procedure, it was realized that individual probes with same 
length (e.g. 25 nucleotides) exhibit different abilities in showing the correct methylatin 
levels. Based on this observation, probe calibration and selection were performed. As 
expected, using 25 nucleotide as the probe length, more probes were selected (according to 
the selection criteria), referring to the fact that probes with this length are more able to 
produce reliable data. It is worth noting that vast majority of the probes were able to show 
the correct methylation values for completely unmethylated and fully methylated samples. 
The difference between high and low discriminative probes was revealed when we 
subjected them to the control samples representing partial DNA methylation.  
The complexity and difficulty of adaptation of oligonucleotide arrays to bisfulfite converted 
DNA may reduce when targeting non-CGI CpGs. In contrast to CGIs, CpGs are not densely 
packed together in non-CGI regions. This feature decreases the sequence redundancy 
between these loci, providing a chance to use longer probes in order to increase the 
specificity of binding. Therefore, it seems that oligonucleotide arrays can be implemented 
Discussion 
107 
 
as powerful tools for genome-scale profiling of methylation patterns of non-CGI CpGs. 
Furthermore, the usefulness of this platform to screen CGIs methylation patterns is 
indubitable; however, a careful selection of highly discriminative probes is necessary prior 
to the analysis of actual clinical samples.  
4.1.2 DNA methylation patterns of breast tumors 
Analysis of the DNA methylation profile of samples was directed such that methylation 
markers that can distinguish tumors from control samples could be identified. At first step 
of the analysis, 93 CpGs were identified whose methylation levels significantly separated 
tumors from control samples as depicted in clustering projection in figure 20. These CpG 
sites pertained to CGIs associated with sixteen genes. Additionally, this methylation profile 
divided tumor samples into four subgroups. Due to the lack of complete clinical data (e.g. 
hormone receptor or menopausal status) a detailed analysis on patients of different groups 
was not possible. However, using available data, we did not find a difference in tumor 
staging or lymph nodes status between the four groups. The relative lower DNA 
methylation levels of group B-patients might partially be explained by their ages as they 
are, in average, younger than other patients. The mean of ages of the members was 50.8 ± 
11, 42.8 ± 7.2, 52 ± 11.4 and 56 ± 14 years in groups A, B, C and D, respectively. 
Nevertheless, this does not affect the cancer-association of these methylation markers, 
because they are able to discriminate between tumors from their patient-matched control 
(non-tumor) samples (Fig. 35).  
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Figure 35. Dendrogram clustering of tumors and their corresponding patient-matched 
control samples by the 93 CpGs methylation markers. T: Tumor, N: Normal from same patient. 
In this regard, recent studies have reported on an age-related DNA methylation of CGIs that 
are target of polycomb group proteins (PcGs) (157). This age-dependent DNA methylation 
has been shown to be a hallmark of cancer (158). Intriguingly, among the hypermethylated 
genes identified in our study, SFRP1, SFRP2, SFRP4, SFRP5, HDPR1, HIC1, RASSF1A 
and GHSR are bona fide PcG targets (159-161). 
4.1.3 Genes affected by hypermethylation in tumors 
Wnt signaling inhibitors or associated genes 
Wnt signaling is a pathway that contributes to cell proliferation by transducing mitogenic 
signals from cell membrane to the nucleus. In addition, this pathway helps cells to remain 
in a relatively undifferentiated state. The pathway is activated by binding of Wnt factors to 
the Frizzled receptors on cell surface (2). It has been demonstrated that hyperactivity of 
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Wnt signaling has oncogenic effects on mammary epithelium (162). Interestingly, almost 
half of the hypermethylated genes which were identified in this study produce proteins that 
have an association with Wnt signaling; SFRP1, SFRP2, SFRP3, SFRP4, SFRP5, HDPR1, 
WIF-1, TCF4.  
The first five genes encode members of secreted frizzled-related (SFRP) protein family that 
function as soluble modulator of Wnt signaling. SFRPs contain an N-terminal domain 
homologous to the cysteine-rich domain of Frizzled receptors. This provides them with a 
capacity to inhibit Wnt signaling by competing with Frizzled receptors for Wnt binding or 
by binding directly to Frizzled (163). WIF1 encodes Wnt inhibitory factor-1 (WIF1), a 
secreted protein that binds to Wnt proteins and inhibits their activities (164). HDPR1 
(DACT1) is coding Dapper (Dpr) protein. This protein is a negative regulator of 
Dishevelled (Dvl) protein which acts as a signal transducer in Wnt signaling (165). 
Transcription factor 4 is coded by TCF4 gene. A role for TCF4 as a transcriptional 
repressor of Wnt signaling has been found in breast cells (108). Therefore, products of all 
these genes are implicated in the control of Wnt pathway activation.  
CST6 
Cystatin M (Cystatin E/M), encoded by CST6, is lysosomal cysteine proteinase inhibitor 
that is down-regulated in metastatic breast tumor cells as compared to primary tumor cells 
(166). It regulates the activity of two cysteine proteases, the cathepsins B and L. 
Deregulation of expression and activity of lysosomal cysteine proteases has been 
implicated in cancer progression. In line with this, imbalances between these proteases and 
their inhibitory cystatins can lead to tumor development, invasion and metastasis. This gene 
is silenced in breast cancer due to the DNA hypermethylation (167). 
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C/EBPα  
CCAAT/enhancer binding protein α (C/EBPα) is a member of C/EBP family of 
transcription factors. These proteins are implicated in the regulation of cell proliferation and 
growth arrest in different tissues including mammary gland (168). Down-regulation of 
C/EBPα in both mRNA and protein levels has been reported in primary breast cancer 
samples. As ectopic expression of this protein in breast cancer cell lines results in inhibition 
of cell growth, a tumor suppressor activity has been suggested for this protein (101).  
HIC1 
Hypermethylated in cancer 1 (HIC1) gene was identified as a candidate tumor suppressor 
gene in 1995. The product of this gene is a transcriptional repressor which is ubiquitously 
expressed in normal tissues but down-regulated in tumor cells (169). A role for DNA 
hypermethylation in down-regulation of this gene in breast cancer was reported in 1998 
(121). Recently, based on its ability to inhibit the growth of breast cancer cells, a tumor 
suppressor activity for HIC1 has been suggested (170).  
PAK3  
PAK3 is a member of the p21-activated kinases (PAKs) family. PAK proteins are critical 
effectors that link Rho GTPases to cytoskeleton reorganization and nuclear signaling. In 
mammalian cells, PAKs are one of the targets of Cdc42 and Rac, regulators of formation 
and functions of motile structures in mammalian cells (171). Although involvement of 
PAK1 in cell motility and invasiveness of breast cancer cells has been documented (172), 
no similar effect for PAK3 has been reported so far. PAK3 hypermethylation has been 
reported in esophagus, lung, cervix, head and neck, bladder and breast cancers (110). 
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PTEN 
PTEN is a well-known tumor suppressor that controls the activation of Akt/PKB pathway. 
PTEN is inactivated in variety of human cancers by mutations or DNA methylation. This 
inactivation leads to hyperactivation of Akt/PKB pathway which, in turn, has positive 
effects on cell survival, growth and proliferation (173). Recently aberrant DNA methylation 
of PTEN promoter has been reported in early invasive breast cancers (174). 
RASSF1A 
Ras-associated factor 1 is a member of RASSF family of proteins that mediate some of the 
growth inhibitory functions of Ras proteins. RASSF1A is frequently inactivated in a huge 
variety of cancers by promoter hypermethylation, deletion and rarely by mutation. The 
protein acts as tumor suppressor through various independent pathways including 
apoptosis, the regulation of microtubule dynamics and mitotic arrest via multiple effectors. 
Thus, RASSF1A is involved in the control of both cell growth and migration (175). 
Although hypermethylation of this gene in breast cancer has been known for years, an 
association between this hypermethylation and estrogen receptor-status of the tumor has 
recently been identified (174).  
GSTP1 
Glutathione S-transferase P1 catalyzes intracellular detoxification reactions including 
inactivation of electrophilic carcinogens by conjugating reactive electrophiles to 
glutathione. GSTP1 has been found to be silenced by DNA methylation in different cancers 
and frequent hypermethylation of this gene has been reported in different stages of breast 
carcinomas (176). Recent data show that DNA hypermethylation at GSTP1 locus is more 
frequent in estrogen receptor positive breast tumors (174). 
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GHSR 
GHSR gene encodes a member of the G-protein coupled receptor family called growth 
hormone secretagogue receptor. This protein acts as the receptor for the circulating peptide 
hormone ghrelin which has a stimulatory effect on growth hormone release (177). 
Hypermethylation of GHSR accompanied by its down-regulation has been reported in 
breast cancer (123). The involvement of GHSR in breast cancer formation or inhibition is 
not clear, as no functional study has been done on this protein in breast cancer. However, it 
has been proposed that the deregulation of the gherlin/GHSR axis may play an 
autocrine/paracrine role in hormone-dependent cancers (178). 
To our knowledge, among the genes reviewed above, SFRP3, SFRP4, HDPR1, TCF4 and 
C/EBPα are found with differential DNA methylation between tumor and normal breast 
tissues for the first time in this study. We could examine the effect of DNA methylation 
inhibition on the expression of the three former genes. As re-expression of these genes was 
observed following treatment of breast cancer cells with decitabine, we suggest that DNA 
hyperemethylation is a potential factor involved in down-regulation of these genes in breast 
cancer. Further examinations of possible reactivation of TCF4 and C/EBPα in breast cancer 
cells following treatment with DNA methylation inhibitors will shed light on involvement 
of DNA methylation in their regulation. 
4.1.4 DNA methylator event in breast cancer? 
Further examinations of methylation profiles indicated that a heterogeneous pattern of 
DNA methylation exists within the tumors. For instance, among the 93 identified CpGs, 
hypermethylation were more prevalent for some CpG sites. In addition, a group of patients 
(Group A in Fig. 20) were found affected by a high degree of methylation in almost all of 
these loci, suggesting the existence of a DNA methylator event in these samples. Such a 
concordant methylation of multiple loci has been observed in different tumor entities 
Discussion 
113 
 
including colorectal cancer, ovarian cancer, acute lymphocytice leukemia, liver cancer, 
esophageal cancer, glioblastomas, just to name a few (179). This concept has been studied 
widely in colorectal cancer where it was referred to the “CpG Island Methylator Phenotype 
(CIMP)” for the first time (180). Toyota and colleagues showed that subset of patients 
suffering from colorectal cancer can be distinguished from others by simultaneous 
hypermethylation of several genes in their genome. Majority of patients positive for CIMP 
were also diagnosed with a mutation in BRAF gene and microsatellite instability (MSI) 
(181).  Following the first report on CIMP in colorectal cancer, by Toyota et al., different 
studies have been conducted to investigate the existence and to characterize the CIMP in 
other cancers. It is now accepted that various genes can be the target of methylator event in 
different cancers (179).  
Concomitant DNA methylation between multiple genes has also been reported in breast 
cancer. For instance, a correlation between hypermethylation of RASSF1A and GSTP1 has 
been reported in different studies (e.g. (174, 182) ). In line with the previous reports, these 
genes are among the hypermethylated genes identified in group A-patients in the current 
study. Likewise, we observed a concurrent hypermethylation for genes coding proteins 
known as Wnt antagonist family members. Majority of these genes have been reported as 
being hypermethylated in different cancers including acute lymphoblastic leukemia (ALL) 
(106), acute myeloid leukemia (AML) (183) and medulloblastoma (184). Among Wnt 
antagonist family genes, methylation dependent down-regulation has already been 
confirmed for SFRP1, SFRP2, SFRP5 and WIF1 in breast tumors (102, 104). Our data 
show that SFRP3, SFRP4, HDPR1 and TCF4 are also hypermethylated in breast cancer 
specimens. Strikingly, all these genes –which produce proteins that are functionally related- 
are simultaneously targeted by DNA methylation in group-A patients. The fact that these 
genes are located in different chromosomes but are silenced concomitantly by DNA 
methylation suggests that a connected epigenetic program might underlie their 
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hypermethylation. Such a selective process targeting essential tumor suppressor genes has 
been proposed as a reason for nonrandom distribution of the abnormal promoter CGI 
methylation in breast tumors (185). It is not clear to which extend the proposed methylator 
phenotype in breast cancer is similar to the CIMP phenomenon reported in colorectal 
cancer. Comparisons between mutation spectrums of the “would-be” CIMP-positive and 
CIMP-negative breast tumors will help to verify whether or not this phenomenon shares the 
same genetic background in both breast and colorectal cancers. Moreover, a detailed 
clinical characterization and follow-up data of patients affected by this DNA methylator 
event would help to verify if this event is associated with specific clinical manifestations. 
4.1.5 DNA methylation signature for diagnosis of breast 
cancer  
The study presented here aimed at identification of a DNA methylation signature which 
allows for diagnosis of breast cancer. Primarily, three types of samples were included in the 
analysis: breast tumors (IDC type); patient-matched normal breast tissue specimens from 
some of the patients and normal breast tissue samples from healthy (cancer-free) 
individuals. Among these, the patient-matched normal and healthy breast samples were 
used as controls each from different perspective. The normal breast tissues from patients 
served the purpose of establishing a tumor associated marker by excluding the methylation 
patterns induced mainly by factors such as environmental influences and ageing (186). By 
including samples from cancer-free individuals, we aimed to avoid missing the methylation 
markers that might act as predisposing factors to breast cancer.  
The statistical analysis applied to the microarray data led to discovery of 14 CpG sites 
(pertaining to SFRP2 and GHSR gene CGIs) that possess the most discriminative power 
between tumor and non-tumor samples (exhibiting adjusted P-values ranging between 10-6 
and 10-12). On careful examination of the correspondance analysis plot (Fig. 21) one can 
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observe that three benign samples (samples 49, 55 and 57 coded in pink) have been 
seperated from benign cluster and are among the tumor samples (represented in green). 
Following a request to the clinical partners on re-analysis of their pathology tests, sample 
number 55 was diagnosed with IDC which fits very well with the pathology reports of its 
neighbours in the CA plot. The other two patients (numbers 49 and 57) - which are 
seperated from the core tumor cluster on the plot- were reported to be affected by 
intraductal neoplasia. Therefore, the clinical re-evaluation data supported the ability of the 
identified signature to diagnose invasive ductal carcinoma.   
One important finding of the present study is the observation that the signature CpGs have 
higher levels of DNA methylation in normal samples collected from cancer patients as 
compared to those obtained from healthy donors. Consistent with our data, Yan et al. have 
identified loci hypermethylated in breast tumors that showed no or low methylation in 
normal breast cells of cancer-free individuals. Notably, these loci were frequently 
hypermethylated in normal tissues adjacent to the tumors with hypermethylation in same 
loci (187). Considering these data, it becomes clearer that hypermethylation of DNA in 
normal-appearing tissue of patients affected by cancer is more prevalent than previously 
recognised. This suggests that early cancer-associated methylation patterns might have 
occurred also in these tissues. Being aware of this point is particularly important in marker 
identification when the goal is DNA methylation markers that may be useful for early 
cancer diagnosis and risk assessment. In such a case, using patient-matched normal tissues 
from regions adjacent to the actual tumor as the sole control is probably insufficient. 
Interestingly, the intensities of DNA methylation at signature CpG sites in benign samples 
were higher than those found in healthy controls but lower than observed in tumor samples. 
In line with this observation, Huang and colleagues have shown that genes frequently 
methylated in breast tumors are also methylated in benign breast lesions, albeit at a lower 
level (188). Hypermethylation of tumour suppressor genes has also been reported in women 
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who are not affected by cancer but are at risk to develop breast cancer. This abnormal 
change occurs more frequently in benign breast epithelium of women at high risk for breast 
cancer than in people at low risk (189, 190). Strikingly, abnormally methylated DNA has 
even been identified in mammary epithelial cells with normal morphology in high-risk 
women (191). Combining these data with the possible seminal role of epigenetic 
abnormalities in the earliest steps of cancer initiation (192, 193) suggests a potential cancer 
predisposing role for DNA methylation and support the emerging evidence on an 
involvement of aberrant DNA methylation patterns in the proposed “field defect” (or “field 
cancerization”) concept (194-196). Among the two genes associated with our signature 
CpGs, SFRP2 methylation in normal breast tissues adjacent to tumors has also been noted 
in another recent report (102). As discussed earlier, SFRP2 is involved in modulation of 
Wnt signaling pathway. Wnt signaling is conserved among various adult stem cells and its 
deregulation is associated with oncogenesis (197). In mammary gland, hyperactivity of Wnt 
signaling can result in deregulated self-renewal and can provoke dedifferentiation to a 
stem-like state; a feature of “cancer stem” (or “tumor initiating”) cells (162). Taken 
together, it is conceivable that hypermethylation of genes implicated in regulation of Wnt 
pathway (e.g. SFRP2) is among the early events in breast cancer tumorigenesis which exert 
first predisposing steps toward malignancy. To which extend GHSR might be implicated in 
such a cancer-predisposing event is not clear. Nevertheless, it is plausible that GHSR 
hypermethylation is mediated by the same mechanism which is responsible for 
hypermethylation of SFRP2 as both genes are targeted by PcG proteins (159).    
4.1.6 DNA methylation patterns at signature loci 
Another aspect that was addressed in this study was the pattern of DNA methylation in the 
interesting loci. Substantial evidence has been amassed showing that CGI methylation is a 
step-by-step process which starts initially at certain CpG dinucleotides in a given CGI and 
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then spreads all over the CGI over time (by ageing) (179). It is demonstrated in vitro that 
CGI methylation is acquired gradually over many cell cycles in the benign breast cells 
escaping senescence (198). Moreover, recent studies have indicated that substantial 
differences exist in DNA methylation patterns of different parts of a given CGI (199). 
These findings emphasize on the importance of the position in a given CGI where DNA 
methylation is studied to draw valid conclusion in a studied biological context. By 
analyzing the methylation patterns of the signature loci, we realized that some certain CpG 
sites exhibit an increasing gradient in the load of methylation from healthy samples to the 
tumors, as described in the results. In silico analysis revealed that most of these CpGs lie in 
the annotated binding sites of CTCF protein. CTCF is an important component of the 
epigenetic system regulating the complex interplay between DNA methylation, higher order 
chromatin structure and gene expression. Existing evidence suggests a role of CTCF in 
maintaining the methylation patterns in a cell and protecting the CpG islands from de novo 
methylation (146). CTCF binding to the DNA can be disturbed by DNA methylation, even 
if only one CpG dinucleotide in the binding site is modified by methylation (200, 201). In 
combination, one can speculate that methylation of CpGs located in the binding sites of 
CTCF, and thereby inhibition of CTCF binding, is one of the initial events in the process of 
establishment of abnormal DNA methylation patterns on CGIs associated with CFCT 
binding, such as SFRP2 CGI.  
We observed that some of the signature CpGs located at GHSR CGI are located in the 
annotated binding sites of PAX family transcription factors, particularly PAX5. PAX 
proteins are reported to be very important in the early developmental stages. These 
transcription factors regulate various cellular processes like tissue development and cellular 
differentiation in embryos. They are involved in cellular proliferation, cell-lineage 
specification, migration and survival. Although expression of PAX proteins is attenuated in 
normal conditions after the completion of development (202), a constitutive expression of 
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these proteins has been reported in cancer (203). Interestingly, nuclear accumulation of 
PAX5 has recently been associated with the autocrine growth hormone-induced cell 
proliferation of MCF7 breast cancer cells (204). As an autocrine/paracrine role for GHSR 
in hormone-dependent cancers has been suggested (178), it seems likely that GHSR may be 
involved in PAX5 related cell proliferation. 
Whether CTCF and PAX proteins bind to the SFRP2 and GHSR CGIs could not be 
elucidated in this study. Empirical evidence including data on the effect of DNA 
methylation patterns on binding of these proteins are needed to draw valid conclusions 
about epigenetic regulation of these genes. 
4.2 Identification of miRNAs involved in ERα activation 
Emerging evidences emphasize a fundamental role for miRNAs in different steps of tumor 
formation and progression. In the current study, we demonstrate that miR-375 functions as 
an activator for ER-α signaling in breast cancer cells and its depletion gives rise to an 
attenuated activity of ER-α pathway and reduced cell proliferation. 
We used microarray technology to simultaneously monitor the expression patterns of 
hundreds of miRNAs in human mammary cell line models. Due to its high expression level 
in ERα-positive cancer cells when compared to other cell lines, we identified miR-375 as a 
potential new factor in breast cancer development. Interestingly, miR-375 has not been 
identified as a breast cancer-associated miRNA in previous studies analyzing miRNA 
expression patterns. In some studies, this was due to the fact that miR-375 was not present 
on the microarrays (86, 205). In other reports, the experimental settings and the parameters 
applied in the data analysis did not identify a differential expression of miR-375 between 
breast cancer cell lines (206, 207). Notably, our screening revealed that miR-375 is 
overexpressed specifically in ERα-positive breast cancer cells. To date, only a limited 
number of miRNAs with a regulative connection to the ERα pathway have been discovered. 
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Of these, miR-18a, miR-22, miR-206 and miR-222/221 directly target ERα mRNA and 
reduce ERα expression (92, 93, 208, 209), whereas miR-17-5p attenuates ERα activity - 
and subsequently cell proliferation - by inhibiting AIB1 (an ERα coactivator) translation 
(210). Interestingly, all these miRNAs act as inhibitors of ERα signaling pathways. In 
contrast, miR-375 is the first identified miRNA that has the capacity to enhance ERα 
signaling in breast cells and, thus, to promote cell proliferation. The proliferative activity of 
miR-375 seems to strongly dependent on the cellular context, as its overexpression in 
gastric carcinoma cells led to decreased number of viable cells by induction of apoptosis 
(211). In agreement with the proliferative activity of miR-375, Poy and colleagues showed 
that miR-375 knockout mice have impaired proliferation in pancreatic β-cells in which a 
high endogenous expression of miR-375 is found (212). In another recent study, miRNA 
profiling of patients with Barrett’s-associated adenocarcinoma identified miR-375 as a 
potential marker for cell proliferation (213). Of significance, we also observed 
overexpression of miR-375 in ERα-negative primary tumors. These observations suggest 
that miR-375 might modulate cell proliferation through other mechanisms than ERα 
signaling as well. More work is required to dissect the molecular networks which are 
influenced by miR-375.  
4.2.1 Epigenetic marks at miR-375 locus 
miRNA genes have been previously described to be epigenetically regulated by DNA 
methylation (78). For miR-375, increased DNA methylation in CGI 2 (containing the pre-
miR-375 hairpin sequence) was detected in non-cancerous cell lines, but not in MDA-MB-
231 cells, although low levels of miR-375 are present in all those cells. However, we found 
that DNA methylation patterns in a distal part of CGI 1, which contains potential binding 
sites for the insulator protein CTCF, are crucial for the repression of miR-375. DNA 
demethylation in this region correlated with CTCF binding and low expression of miR-375. 
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As CTCF binds preferentially to unmethylated DNA, we suggest that hypomethylation of 
this region is necessary for CTCF recruitment and subsequent silencing of the miR-375 
locus. CTCF binding also correlated with the repressive mark H3K9me2 which was found 
throughout the locus in cells with a low miR-375 expression. In summary, our data indicate 
the presence of a repressive, CTCF-dependent, chromatin structure at the miRNA locus in 
cells with low miR-375 expression. Such a repressive structure would either directly 
prevent transcription, or inhibit the interaction of the miR-375 promoter region with 
activating factors and enhancer elements (insulation). Additionally, the binding of the 
transcriptional repressor ZEB1 was detected at a region encompassing the putative miR-
375 promoter. This region contains several evolutionary conserved E-boxes, ZEB1-binding 
sites, suggesting that ZEB1 contributes to the repression of miR-375. However, the miR-
375 locus maintains the potential to be reactivated, as indicated by a peak of H3K4me2 on 
the distal part of CGI 1 in cell lines with a silenced locus. In MCF7 cells, we found 
significantly reduced levels of H3K9me2, weak CTCF and ZEB1 interactions with their 
target sites and high abundance of ERα and POLII near the putative promoter of miR-375 
and in its transcribed locus. These findings are in agreement with recent data showing that 
CTCF confines estrogen receptor action on a genome-wide scale (214). Furthermore, the 
CTCF antagonist BORIS, which seems to interact in a methylation-independent way with 
CTCF-binding sites (215), has been found to be aberrantly expressed in breast tumors, 
which correlated in many cases with over-expression of ERα (216). A role of CTCF as 
tumor suppressor has previously been suggested, as CTCF has been found to inhibit cell 
growth and induce cell cycle arrest. CTCF has a repressive role in the regulation of several 
prominent oncogenes and also seems to be important in preventing epigenetic silencing of 
growth suppressor genes (147).  
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4.2.2 Proposed model for RASD1 and miR-375 effects 
on ERα 
Our data show that the modulation of ERα by miR-375 is achieved through the repression 
of negative regulators of the ERα signaling, such as RASD1. RASD1 is known as a guanine 
exchange factor for Gαi/o proteins (217) which is able to inhibit adenylyl cyclase, reducing 
Gsα -induced cAMP production in HEK293T cells (218). Vaidyanathan et al. demonstrated 
that the anti-proliferative effect of RASD1 in MCF7 cells is independent of the activation 
of heterotrimeric G-proteins (152). In this context, Nguyen and Watts have proposed a 
mechanism by which RASD1 could indirectly regulate Gαi/o signaling by negatively 
regulating protein kinase C delta (PKC δ) activity (219). PKC δ is the predominant PKC 
isoform in MCF7 cells (220) and its activation supports proliferation in breast cancer cells 
(221). Interestingly, PKC δ was also reported to be involved in ERα signaling. PKC δ 
overexpression confers estrogen-dependent breast cancer cells a proliferative advantage 
(222) and resistance to tamoxifen (223). Taken together, it seems likely that RASD1 exerts 
its regulatory influence on ERα, at least in part, via inhibition of PKC δ activity in breast 
cells. Nevertheless, considering the rapid induction of RASD1 mRNA by E2, other 
mechanisms of action of RASD1 leading to the destabilization and degradation of ERα 
seem conceivable. More research is warranted to explain the specific mechanisms by which 
RASD1 down-regulate ERα signaling.  
Previous studies have described a negative feedback loop for ERα through several miRNAs 
which are induced and then down-regulate ERα upon estrogenic stimulation (224, 225). 
The present work suggests that, in abnormal conditions such as in cancer, ERα can induce 
aberrant up-regulation of miRNAs that disrupt its natural negative feedback regulation (Fig. 
36). We showed that the up-regulation of miR-375 in MCF7 cells is dependent on the 
presence of ERα and that ERα binds near the putative promoter of miR-375. Because the 
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establishment of abnormal epigenetic patterns is an early event in tumorigenesis, miR-375 
deregulation may prove to be involved in the up-regulation of ERα expression in mammary 
cells in early steps of tumor formation.  
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Figure 36. Proposed model describing miR-375 role in breast cancer development. (A) Under 
normal conditions, ERα activity is controlled through a negative feedback loop by estrogen inducible 
genes, such as RASD1. A low endogenous level of miR-375 is assured by a repressive combination 
of DNA methylation and the binding of the transcriptional repressors CTCF and ZEB1. Under these 
conditions cells grow normally. (B) In cancer, changes in DNA methylation and the consequential 
removal of repressive factors from miR-375 locus give rise to an open chromatin structure which 
attracts transcription factors to the promoter region and induces the transcription of miR-375. High 
amounts of miR-375 destabilize the balance of the negative feedback regulation of ERα by targeting 
RASD1 and increasing ERα activity. As a consequence, ERα can bind to miR-375 promoter and 
activates its expression which, in turn, creates a positive feedback loop leading to aberrant cell 
growth. 
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5 Outlook 
In the first part of the thesis presented here, an oligonucleotide microarray-based analysis was 
applied for the identification of a DNA methylation signature capable of diagnosing breast 
cancer. The signature identified showed a promising potential to be applicable for this 
purpose, as it distinguished actual tumors from both control (normal) and benign samples. 
However, as all tumors included in this study were diagnosed as IDC type, this signature may 
represent an IDC-specific DNA methylation signature. In a new study pursuing the one 
presented here, the identified DNA methylation signature is tested in another set of tumor 
(IDC and non-IDC) and control tissue samples using a quantitative approach. The results of 
this analysis will allow for an evaluation of the robustness of this signature. In addition, 
quantitative data of the new study will be helpful for the analysis of the abnormal DNA 
methylation patterns in patient-matched normal-appearing tissue samples to address the 
possible association of these patterns to the field defect.  
The DNA methylation mapping of the signature loci indicated a potential involvement of 
certain transcription factors in the establishment/maintenance of the aberrant epigenetic 
control of expression of the associated genes. Investigation of the relationship between these 
factors and between them and DNA methylation patterns may be helpful for understanding of 
the mechanisms underlying the establishment of abnormal DNA methylation patterns in 
breast cancer.  
In the second part of this thesis, we reported on miR-375 as the first identified miRNA with a 
capacity to enhance ERα signaling in breast cancer cells. RASD1 was identified as a miR-375 
target that negatively regulates ERα. However, the involvement of other potential molecules 
mediating miR-375 effect on ERα was not excluded. A few known targets of miR-375, which 
have been reported in other tissues, are implicated in signaling pathways that have crosstalk 
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with ERα signaling, such as PDK1 or Cav1. Investigating the potential regulative connection 
between these molecules and the ERα pathway as well as miR-375 in breast cancer cells may 
be helpful to elaborate on the molecular network involved in the positive feedback loop 
between miR-375 and ERα. 
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7 Appendix 
7.1 Supplementary Table S1 
Supplementary Table S1. Clinical information of the patients and control samples used in 
this study. 
Patient Age Diagnosis Grade No. of Lymph nodes 
affected 
Normal 
sample 
IR3 45 IDC III 8 + 
IR4 39 IDC III N/A + 
IR6 74 IDC III N/A + 
IR7 45 IDC III 11 + 
IR9 42 IDC III 9 + 
IR12 49 IDC III 3 + 
IR13 37 ILC III 3 + 
IR14 53 IDC III 14 + 
IR-27 51 IDC III 4 + 
IR5 45 IDC III 3 - 
IR17 38 IDC II 10 - 
IR18 50 IDC III 1 - 
IR19 67 IDC N/A 0 - 
IR20 60 IDC I 1 - 
IR23 40 IDC III 5 - 
IR24 59 ILC I 1 - 
IR-27 51 IDC III 4 - 
IR-28 35 IDC I N/A - 
IR-30 61 IDC I 18 - 
IR-31 53 IDC I 1 - 
IR-32 45 IDC I 3 - 
IR-34 64 IDC III 0 - 
IR-35 45 IDC II 4 - 
IR-36 48 IDC III 1 - 
IR-37 60 IDC II 1 - 
IR-38 47 IDC II 0 - 
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IR-43 33 IDC N/A N/A - 
IR-45 35 IDC N/A N/A - 
IR-46 56 IDC II 2 - 
IR-47 43 IDC III 10 - 
IR-48 56 IDC I 0 - 
IR-49 35 IDC I 0 - 
IR-50 75 IDC II 0 - 
UKR48 36 Adenofibroma - - - 
UKR49 45 Adenofibroma - - - 
UKR 50 35 Adenofibroma - - - 
UKR 51 42 Adenofibroma - - - 
UKR 52 38 Adenofibroma - - - 
UKR 53 48 Adenofibroma - - - 
UKR 54 43 Adenofibroma - - - 
UKR 55 52 Adenofibroma - - - 
UKR 58 58 Adenofibroma - - - 
UKR 59 28 Adenofibroma - - - 
IR-105 29 Healthy - - - 
IR-106 31 Healthy - - - 
UKR5 31 Healthy - - - 
UKR9 22 Healthy - - - 
UKR10 27 Healthy - - - 
UKR13 37 Healthy - - - 
UKR14 40 Healthy - - - 
7.2 Supplementary Table S2 
 The table including the methylation profiling data of all samples can be accessed online 
via: http://www.dkfz.de/funct_genome/Riazalhosseini-thesis-data.html 
7.3 Supplementary Table S3 
The table including miRNA profiling data of the mammary cell lines can be accessed 
online via: http://www.dkfz.de/funct_genome/Riazalhosseini-thesis-data.html 
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7.4 Supplementary Table S4 
Supplementary Table S4. Clinical information of breast cancer specimens used for miR-375 
quantification and target identification. IDC: Invasive ductal carcinoma; AMC: Atypical medullary 
carcinoma; FD: Fibrocystic disease; P: positive; N: Negative; N/A: Not applicable 
# Age Histological subtype ERα  Grade 
Lymph node 
metastasis 
1 45 IDC P III Yes 
2 49 IDC N III Yes 
3 51 IDC P II Yes 
4 46 AMC N III Yes 
5 74 IDC P III Yes 
6 45 IDC N III Yes 
7 63 FD P N/A N/A 
8 42 IDC P III Yes 
9 53 IDC P III Yes 
 
7.5 Supplementary Table S5 
Supplementary Table S5. Transcripts commonly dowregulated in the tumors with 
overexpression of miR-375. 
Symbol Probe ID NCBI Reference Sequence 
Mean Fold-change in 
tumor relative to 
normal 
HBB 5340674 NM_000518 -33.87009985 
HBA1 360554 NM_000558 -33.82576067 
ADH1A 6020441 NM_000667 -25.93859944 
PI16 7560070 NM_153370 -22.17755738 
CLEC3B 4880187 NM_003278 -19.08968666 
GPD1 6290452 NM_005276 -15.06624523 
CFD 5720243 NM_001928 -14.8521602 
DCN 6650196 NM_003467 -11.20582049 
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GPX3 840050 NM_002084 -11.10483516 
FHL1 2320475 NM_001449 -10.57238041 
FABP4 3440477 NM_001442 -10.17169134 
GYG2 5310521 NM_001079855 -9.615858196 
IGFBP6 2230242 NM_002178 -9.613800418 
CD36 4260433 NM_001001548 -9.567190595 
MAOA 6650278 NM_000240 -8.784490748 
DCN 3400682 NM_133503 -8.589691606 
GPC3 3130739 NM_004484 -8.545181193 
CD209 1740300 NM_021155 -8.425745046 
ABCA8 580689 NM_007168 -8.234910062 
CA4 3990296 NM_000717 -8.128796321 
CALB2 6130364 NM_001740 -8.108158855 
CD36 3990167 NM_000072 -7.539840991 
CXCL12 2350482 NM_001033886 -7.397941133 
CIDEC 5490736 NM_022094 -7.252977302 
DPT 1440474 NM_001937 -7.156513683 
PDK4 380400 NM_002612 -7.143417879 
ADM 6650020 NM_001124 -7.047800702 
HSPB6 5310719 NM_144617 -6.855199543 
RDH5 2810609 NM_002905 -6.732952428 
PLAC9 5420184 NM_001012973 -6.636228744 
CCL8 7510360 NM_005623 -6.486231866 
MAMDC2 5260762 NM_153267 -6.267896618 
ABCA6 3520370 NM_080284 -6.101352302 
PLTP 3130154 NM_182676 -6.051027217 
CD163 5570414 NM_203416 -5.94335589 
GPAM 6590301 NM_020918 -5.925120424 
CDO1 730202 NM_001801 -5.846683556 
ALDH1A1 50100 NM_000689 -5.794897295 
CXCL12 4670202 NM_199168 -5.744843023 
SEPP1 6760343 NM_005410 -5.674047839 
ABCA9 5090370 NM_080283 -5.643664088 
F13A1 1300095 NM_000129 -5.549224755 
RNASE1 540670 NM_198232 -5.53853568 
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CXCR7 7050682 NM_020311 -5.480711243 
ACACB 3180139 NM_001093 -5.440757069 
MGST1 3370072 NM_020300 -5.358188051 
LOC221091 5720446 XM_001130636 -5.327153756 
PTGIS 2900722 NM_000961 -5.325847786 
PMP22 3890113 NM_153321 -5.311701041 
RASD1 6180692 NM_016084 -5.153772132 
NMB 770437 NM_205858 -5.153296035 
CYP26B1 2510619 NM_019885 -5.071875192 
AGPAT2 6860039 NM_006412 -5.048047974 
SRPX 3400703 NM_006307 -5.044800086 
VSIG4 4200008 NM_007268 -5.032407928 
CTSG 830619 NM_001911 -4.900024243 
GSN 1510379 NM_198252 -4.89190932 
CAV2 2030195 NM_001233 -4.691028693 
C10orf116 6020017 NM_006829 -4.578504376 
CDKN2C 5690167 NM_078626 -4.401851127 
AOX1 4250291 NM_001159 -4.347345237 
C1R 4220364 NM_001733 -4.23608185 
PPARG 7160711 NM_138711 -4.181030631 
MMD 360671 NM_012329 -4.114168911 
MFAP4 2710167 NM_002404 -4.087520182 
GFPT2 5420053 NM_005110 -3.975438749 
EFEMP1 5820689 NM_001039349 -3.971058827 
ANGPTL4 2630609 NM_139314 -3.964492939 
PMP22 5340630 NM_000304 -3.947155391 
SORBS1 4150343 NM_001034956 -3.830232343 
C1S 1260255 NM_201442 -3.749741705 
MOSC1 1980082 NM_022746 -3.744157261 
CD14 990398 NM_000591 -3.738037941 
FLJ21986 4730064 NM_024913 -3.677525416 
ATOH8 130068 NM_032827 -3.648054215 
EMILIN2 10070 NM_032048 -3.586175202 
EPDR1 5560255 NM_017549 -3.529878588 
GYPC 1580538 NM_002101 -3.528260833 
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RNF150 2340341 NM_020724 -3.476769089 
PNPLA2 5550168 NM_020376 -3.451442902 
PFKFB3 1710273 NM_004566 -3.372097251 
MYOM1 2370477 NM_003803 -3.309374056 
LAMA2 5390373 NM_001079823 -3.293220836 
MT1M 5870398 NM_176870 -3.288630437 
FXYD1 3060767 NM_005031 -3.270451783 
C13orf33 7650468 NM_032849 -3.267193935 
CLDND2 10551 NM_152353 -3.256551554 
CD248 2350292 NM_020404 -3.240887585 
PPP2R1B 3930196 NM_181699 -3.223894069 
FBLN2 2120243 NM_001004019 -3.161848086 
GAS7 6860193 NM_201433 -3.141857829 
MGST1 3940575 NM_145791 -3.12341643 
MSX1 650546 NM_002448 -3.122182544 
CCDC3 4810692 NM_031455 -3.106450045 
MAPK10 240451 NM_138981 -3.09583022 
SMPDL3A 2070411 NM_006714 -3.066785896 
ZBTB16 6040296 NM_006006 -2.979691267 
NID1 670739 NM_002508 -2.928778345 
FCGRT 4540041 NM_004107 -2.89735884 
TYRO3 2450403 NM_006293 -2.889187399 
CGI-38 1400722 NM_015964 -2.874736608 
EBF3 4280482 NM_001005463 -2.852552376 
GSTM5 5570221 NM_000851 -2.840638135 
HSPB2 1580239 NM_001541 -2.804975762 
CDKN1C 3610601 NM_000076 -2.804949084 
TUBB6 1940156 NM_032525 -2.797839665 
HSPB8 5290215 NM_014365 -2.692440056 
MAF 6400369 NM_005360 -2.668694992 
CYP4F12 4390273 NM_023944 -2.603727871 
AVPI1 6840722 NM_021732 -2.568960106 
ANTXR2 240468 NM_058172 -2.538804922 
GAS1 2370762 NM_002048 -2.522079771 
FMOD 3940113 NM_002023 -2.507249207 
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PDE2A 5260102 NM_002599 -2.493511866 
PEMT 2450102 NM_148173 -2.444707749 
BIN1 5890333 NM_139348 -2.441973248 
GLDN 1570615 NM_181789 -2.430553479 
HRH1 5310286 NM_000861 -2.377187947 
TUBB6 1410059 NM_032525 -2.298365414 
CYP4B1 3890767 NM_000779 -2.280069175 
DHRS3 3840170 NM_004753 -2.278422379 
S100A13 4010168 NM_001024212 -2.214367175 
AIFM2 5690070 NM_032797 -2.148792422 
RBPMS2 4230164 NM_194272 -2.012409927 
OLFML2A 2480471 NM_182487 -1.944303204 
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